UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

~~10-Q~~

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, ~~2019~~2020

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______

Commission file number 1-11353

LABORATORY ~~CORP~~CORPORATION OF AMERICA HOLDINGS

(Exact name of registrant as specified in its charter)



Delaware						13-3757370
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

358 South Main Street

Burlington,

North Carolina

27215

(Address of principal executive offices)

(Zip Code)

(Registrant's telephone number, including area code) ~~336~~-~~229-1127~~336-229-1127

Securities registered pursuant to Section 12(b) of the Exchange Act.

Title of Each Class Trading Symbol Name of exchange on which registered

Common Stock, $0.10 par value LH New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (paragraph 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒.

The number of shares outstanding of the issuer's common stock is ~~97.7~~97.4 million shares as of ~~August 6, 2019.~~July 29, 2020.

INDEX

~~INDEX~~

INDEX

PART I. FINANCIAL INFORMATION



Item 1.	Financial Statements (unaudited)

	Condensed Consolidated Balance Sheets	2
	June 30, ~~2019~~2020 and December 31, ~~2018~~2019

	Condensed Consolidated Statements of Operations	3
	Three and six months ended June 30, ~~2019~~2020 and ~~2018~~2019

	Condensed Consolidated Statements of Comprehensive Earnings	4
	Three and six months ended June 30, ~~2019~~2020 and ~~2018~~2019

	Condensed Consolidated Statements of Changes in Shareholders’ Equity	5
	Three and six months ended June 30, ~~2019~~2020 and ~~2018~~2019

	Condensed Consolidated Statements of Cash Flows	6
	Six months ended June 30, ~~2019~~2020 and ~~2018~~2019

	Notes to Unaudited Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2827

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	3938

Item 4.	Controls and Procedures	4039

PART II. OTHER INFORMATION



Item 1.	Legal Proceedings	4240

Item 1A.	Risk Factors	4240

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	42

Item 5.	Other Information	42

Item 6.	Exhibits	42

~~INDEX~~1

INDEX

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements (unaudited)

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions)

(unaudited)


	June 30, 2020		December 31, 2019
ASSETS
Current assets:
Cash and cash equivalents	$	557.0	$	337.5
Accounts receivable, net of allowance for doubtful accounts of $29.1 and $19.0 as of June 30, 2020 and December 31, 2019, respectively	1,661.0		1,543.9
Unbilled services	535.4		481.4
Supplies inventory	342.3		244.7
Prepaid expenses and other	317.5		373.7

Total current assets	3,413.2		2,981.2
Property, plant and equipment, net	2,627.7		2,636.6
Goodwill, net	7,422.7		7,865.0
Intangible assets, net	3,877.2		4,034.5
Joint venture partnerships and equity method investments	72.3		84.9
Deferred income taxes	4.9		8.8
Other assets, net	431.1		435.4

Total assets	$	17,849.1	$	18,046.4

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	534.1	$	632.3
Accrued expenses and other	1,032.7		942.4
Unearned revenue	473.3		451.0
Short-term operating lease liabilities	195.3		206.5
Short-term finance lease liabilities	8.2		8.4
Short-term borrowings and current portion of long-term debt	790.8		415.2

Total current liabilities	3,034.4		2,655.8
Long-term debt, less current portion	5,416.6		5,789.8
Operating lease liabilities	615.5		596.6
Financing lease liabilities	87.5		91.1
Deferred income taxes and other tax liabilities	907.3		942.8
Other liabilities	415.6		383.2

Total liabilities	10,476.9		10,459.3
Commitments and contingent liabilities
Noncontrolling interest	19.5		20.1
Shareholders’ equity:
Common stock, 97.3 and 97.2 shares outstanding at June 30, 2020 and December 31, 2019, respectively	9.0		9.0
Additional paid-in capital	32.1		26.8
Retained earnings	7,760.6		7,903.6

Accumulated other comprehensive loss	(449.0)		(372.4)
Total shareholders’ equity	7,352.7		7,567.0
Total liabilities and shareholders’ equity	$	17,849.1	$	18,046.4

June 30,
2019 December 31,
2018
ASSETS
Current assets:
Cash and cash equivalents $ 265.4
$ 426.8
Accounts receivable 1,576.1
1,467.9
Unbilled services 488.8
394.4
Supplies inventories 219.7
237.3
Prepaid expenses and other 298.6
309.0
Total current assets 2,848.6
2,835.4
Property, plant and equipment, net 2,544.2
1,740.3
Goodwill, net 7,843.7
7,360.3
Intangible assets, net 4,015.9
3,911.1
Joint venture partnerships and equity method investments 86.7
60.5
Deferred income tax assets 1.7
1.7
Other assets, net 403.6
276.0
Total assets $ 17,744.4
$ 16,185.3

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current liabilities:

Accounts payable $ 531.6
$ 634.6
Accrued expenses and other 820.3
870.0
Unearned revenue 404.2
356.4
Short-term operating lease liabilities 229.2
—
Short-term finance lease liabilities 8.2
7.9
Short-term borrowings and current portion of long-term debt 502.3
10.0
Total current liabilities 2,495.8
1,878.9
Long-term debt, less current portion 6,135.0
5,990.9
Operating lease liabilities 586.1
—
Financing lease liabilities 46.2
51.0
Deferred income taxes and other tax liabilities 948.3
940.0
Other liabilities 368.6
334.0
Total liabilities 10,580.0
9,194.8
Commitments and contingent liabilities

Noncontrolling interest 20.0
19.1
Shareholders’ equity:

Common stock, 97.8 and 98.9 shares outstanding at June 30, 2019 and December 31, 2018, respectively 9.1
11.7
Additional paid-in capital 91.4
1,451.1
Retained earnings 7,455.8
7,079.8
Less common stock held in treasury —
(1,108.1 )
Accumulated other comprehensive loss (411.9 ) (463.1 )
Total shareholders’ equity 7,144.4
6,971.4
Total liabilities and shareholders’ equity $ 17,744.4
$ 16,185.3

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

~~INDEX~~2

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share data)

(unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,
	2020		2019		2020		2019
Revenues	$	2,768.8	$	2,881.7	$	5,592.6	$	5,672.9
Cost of revenues	2,008.3		2,056.9		4,104.1		4,058.4

Gross profit	760.5		824.8		1,488.5		1,614.5
Selling, general and administrative expenses	396.3		415.3		791.8		809.1
Amortization of intangibles and other assets	60.1		60.2		122.4		117.3
Goodwill and other asset impairments	—		—		437.4		—
Restructuring and other charges	6.4		13.6		31.8		34.2
Operating income	297.7		335.7		105.1		653.9
Other income (expense):
Interest expense	(52.7)		(59.1)		(107.7)		(115.8)
Equity method income (loss), net	1.8		2.5		(4.8)		5.5
Investment income	2.5		1.4		5.1		2.0
Other, net	47.7		(10.5)		31.6		(20.9)
Earnings before income taxes	297.0		270.0		29.3		524.7
Provision for income taxes	65.4		79.3		114.6		148.1
Net earnings (loss)	231.6		190.7		(85.3)		376.6
Less: Net earnings attributable to the noncontrolling interest	—		(0.3)		(0.3)		(0.6)
Net earnings (loss) attributable to Laboratory Corporation of America Holdings	$	231.6	$	190.4	$	(85.6)	$	376.0

Basic earnings (loss) per common share	$	2.38	$	1.94	$	(0.88)	$	3.82
Diluted earnings (loss) per common share	$	2.37	$	1.93	$	(0.88)	$	3.79

Three Months Ended June 30, Six Months Ended June 30,
2019 2018 2019 2018
Revenues $ 2,881.7
$ 2,866.3
$ 5,672.9
$ 5,714.6
Cost of revenues 2,056.9
2,031.2
4,058.4
4,100.5
Gross profit 824.8
835.1
1,614.5
1,614.1
Selling, general and administrative expenses 415.3
395.2
809.1
792.2
Amortization of intangibles and other assets 60.2
58.5
117.3
120.8
Restructuring and other special charges 13.6
12.2
34.2
26.5
Operating income 335.7
369.2
653.9
674.6
Other income (expenses):

Interest expense (59.1 ) (63.1 ) (115.8 ) (126.6 )
Equity method income, net 2.5
3.0
5.5
5.5
Investment income 1.4
0.8
2.0
1.4
Other, net (10.5 ) 2.8
(20.9 ) (0.7 )
Earnings before income taxes 270.0
312.7
524.7
554.2
Provision for income taxes 79.3
78.6
148.1
147.6
Net earnings 190.7
234.1
376.6
406.6
Less: Net (earnings) loss attributable to the noncontrolling interest (0.3 ) (0.3 ) (0.6 ) 0.4
Net earnings attributable to Laboratory Corporation of America Holdings $ 190.4
$ 233.8
$ 376.0
$ 407.0

Basic earnings per common share $ 1.94
$ 2.29
$ 3.82
$ 3.99
Diluted earnings per common share $ 1.93
$ 2.27
$ 3.79
$ 3.94

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

~~INDEX~~3

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS

(in millions, except per share data)

(unaudited)


	Three Months Ended June 30,						Six Months Ended June 30,

	2020		2019		2020		2019
Net earnings (loss)	$	231.6	$	190.7	$	(85.3)	$	376.6
Foreign currency translation adjustments	66.9		25.6		(80.5)		47.2
Net benefit plan adjustments	2.7		2.8		5.4		5.5

Other comprehensive earnings (loss) before tax	69.6		28.4		(75.1)		52.7
Provision (benefit) for income tax related to items of comprehensive earnings	(0.7)		(0.8)		(1.5)		(1.5)
Other comprehensive earnings (loss), net of tax	68.9		27.6		(76.6)		51.2
Comprehensive earnings (loss)	300.5		218.3		(161.9)		427.8
Less: Net earnings attributable to the noncontrolling interest	—		(0.3)		(0.3)		(0.6)
Comprehensive earnings (loss) attributable to Laboratory Corporation of America Holdings	$	300.5	$	218.0	$	(162.2)	$	427.2

Three Months Ended June 30, Six Months Ended June 30,
2019 2018 2019 2018
Net earnings $ 190.7
$ 234.1
$ 376.6
$ 406.6
Foreign currency translation adjustments 25.6
(121.9 ) 47.2
(82.6 )
Net benefit plan adjustments 2.8
3.3
5.5
6.2
Other comprehensive earnings (loss) before tax 28.4
(118.6 ) 52.7
(76.4 )
(Provision) benefit for income tax related to items of other comprehensive earnings (0.8 ) (7.2 ) (1.5 ) 3.1
Other comprehensive earnings, net of tax 27.6
(125.8 ) 51.2
(73.3 )
Comprehensive earnings 218.3
108.3
427.8
333.3
Less: Net (earnings) loss attributable to the noncontrolling interest (0.3 ) (0.3 ) (0.6 ) 0.4
Comprehensive earnings attributable to Laboratory Corporation of America Holdings $ 218.0
$ 108.0
$ 427.2
$ 333.7

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

~~INDEX~~

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN

SHAREHOLDERS’ EQUITY

(in millions)

(unaudited)


	Common Stock		Additional Paid-in Capital		Retained Earnings		Treasury Stock		Accumulated Other Comprehensive Earnings (Loss)		Total Shareholders’ Equity
BALANCE AT DECEMBER 31, 2018	$	11.7	$	1,451.1	$	7,079.8	$	(1,108.1)	$	(463.1)	$	6,971.4
Net earnings attributable to Laboratory Corporation of America Holdings	—		—		185.6		—		—		185.6
Other comprehensive earnings, net of tax	—		—		—		—		23.6		23.6

Issuance of common stock under employee stock plans	—		24.7		—		—		—		24.7
Net share settlement tax payments from issuance of stock to employees	—		—		—		(19.4)		—		(19.4)

Stock compensation	—		25.5		—		—		—		25.5

Purchase of common stock	(0.1)		(100.0)		—		—		—		(100.1)
BALANCE AT MARCH 31, 2019	$	11.6	$	1,401.3	$	7,265.4	$	(1,127.5)	$	(439.5)	$	7,111.3
Net earnings attributable to Laboratory Corporation of America Holdings	—		—		190.4		—		—		190.4
Other comprehensive earnings, net of tax	—		—		—		—		27.6		27.6
Issuance of common stock under employee stock plans	—		9.2		—		—		—		9.2
Net share settlement tax payments from issuance of stock to employees	—		—		—		(20.7)		—		(20.7)

Stock compensation	—		26.5		—		—		—		26.5
Retirement of treasury stock	(2.4)		(1,145.8)		—		1,148.2		—		—
Purchase of common stock	(0.1)		(199.8)		—		—		—		(199.9)
BALANCE AT JUNE 30, 2019	$	9.1	$	91.4	$	7,455.8	$	—	$	(411.9)	$	7,144.4









BALANCE AT DECEMBER 31, 2019	$	9.0	$	26.8	$	7,903.6	$	—	$	(372.4)	$	7,567.0
Adoption of credit loss accounting standard	—		—		(7.0)		—		—		(7.0)
Net earnings (loss) attributable to Laboratory Corporation of America Holdings	—		—		(317.2)		—		—		(317.2)
Other comprehensive earnings (loss), net of tax	—		—		—		—		(145.5)		(145.5)
Issuance of common stock under employee stock plans	—		26.9		—		—		—		26.9
Net share settlement tax payments from issuance of stock to employees	—		(22.0)		—		—		—		(22.0)

Stock compensation	—		17.9		—		—		—		17.9

Purchase of common stock	—		(49.6)		(50.4)		—		—		(100.0)
BALANCE AT MARCH 31, 2020	$	9.0	$	—	$	7,529.0	$	—	$	(517.9)	$	7,020.1
Net earnings attributable to Laboratory Corporation of America Holdings	—		—		231.6		—		—		231.6
Other comprehensive earnings, net of tax	—		—		—		—		68.9		68.9
Issuance of common stock under employee stock plans	—		1.8		—		—		—		1.8
Net share settlement tax payments from issuance of stock to employees	—		(9.5)		—		—		—		(9.5)

Stock compensation	—		39.8		—		—		—		39.8

Purchase of common stock	—		—		—		—		—		—
BALANCE AT JUNE 30, 2020	$	9.0	$	32.1	$	7,760.6	$	—	$	(449.0)	$	7,352.7

Common
Stock

Additional
Paid-in
Capital

Retained
Earnings

Treasury
Stock

Accumulated
Other
Comprehensive
Loss

Total
Shareholders’
Equity
BALANCE AT DECEMBER 31, 2017 $ 12.0
$ 1,989.8
$ 6,196.1
$ (1,060.1 ) $ (333.7 ) $ 6,804.1
Net earnings attributable to Laboratory Corporation of America Holdings —
—
173.2
—
—
173.2
Other comprehensive earnings, net of tax —
—
—
—
52.5
52.5
Issuance of common stock under employee stock plans —
28.4
—
—
—
28.4
Net share settlement tax payments from issuance of stock to employees —
—
—
(25.0 ) —
(25.0 )
Stock compensation —
25.8
—
—
—
25.8
Purchase of common stock —
(75.0 ) —
—
—
(75.0 )
BALANCE AT MARCH 31, 2018 $ 12.0
$ 1,969.0
$ 6,369.3
$ (1,085.1 ) $ (281.2 ) $ 6,984.0
Net earnings attributable to Laboratory Corporation of America Holdings —
—
233.8
—
—
233.8
Other comprehensive loss, net of tax —
—
—
—
(125.8 ) (125.8 )
Issuance of common stock under employee stock plans —
14.6
—
—
—
14.6
Net share settlement tax payments from issuance of stock to employees —
—
—
(20.1 ) —
(20.1 )
Stock compensation —
26.2
—
—
—
26.2
Purchase of common stock —
(75.0 ) —
—
—
(75.0 )
BALANCE AT JUNE 30, 2018 $ 12.0
$ 1,934.8
$ 6,603.1
$ (1,105.2 ) $ (407.0 ) $ 7,037.7

BALANCE AT DECEMBER 31, 2018 $ 11.7
$ 1,451.1
$ 7,079.8
$ (1,108.1 ) $ (463.1 ) $ 6,971.4
Net earnings attributable to Laboratory Corporation of America Holdings —
—
185.6
—
—
185.6
Other comprehensive earnings, net of tax —
—
—
—
23.6
23.6
Issuance of common stock under employee stock plans —
24.7
—
—
—
24.7
Net share settlement tax payments from issuance of stock to employees —
—
—
(19.4 ) —
(19.4 )
Stock compensation —
25.5
—
—
—
25.5
Purchase of common stock (0.1 ) (100.0 ) —
—
—
(100.1 )
BALANCE AT MARCH 31, 2019 $ 11.6
$ 1,401.3
$ 7,265.4
$ (1,127.5 ) $ (439.5 ) $ 7,111.3
Net earnings attributable to Laboratory Corporation of America Holdings —
—
190.4
—
—
190.4
Other comprehensive earnings, net of tax —
—
—
—
27.6
27.6
Issuance of common stock under employee stock plans —
9.2
—
—
—
9.2
Net share settlement tax payments from issuance of stock to employees —
—
—
(20.7 ) —
(20.7 )
Stock compensation —
26.5
—
—
—
26.5
Retirement of treasury stock (2.4 ) (1,145.8 ) —
1,148.2
—
—
Purchase of common stock (0.1 ) (199.8 ) —
—
—
(199.9 )
BALANCE AT JUNE 30, 2019 $ 9.1
$ 91.4
$ 7,455.8
$ —
$ (411.9 ) $ 7,144.4

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

~~INDEX~~5

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)

(unaudited)


								Six Months Ended June 30,
								2020		2019
CASH FLOWS FROM OPERATING ACTIVITIES:							CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings (loss)							Net earnings (loss)	$	(85.3)	$	376.6
Adjustments to reconcile net earnings (loss) to net cash provided by operating activities:							Adjustments to reconcile net earnings (loss) to net cash provided by operating activities:
Depreciation and amortization							Depreciation and amortization	288.5		277.1
Stock compensation							Stock compensation	57.7		52.0

	Six Months Ended June 30,
	2019			2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings	$	376.6		$	406.6
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	277.1			281.3
Stock compensation	52.0			52.0
Loss (gain) on sale of assets	4.5			(0.3		)
Loss on sale of business	8.8			—
Accreted interest on zero-coupon subordinated notes	—			0.1
Operating lease right-of-use asset expense	94.0			—			Operating lease right-of-use asset expense	103.9		94.0
Earnings less distributions (excess)/deficit from equity method investments	8.0			(1.3		)
Asset impairment	—			2.3

Goodwill and other asset impairments							Goodwill and other asset impairments	437.4		—
Deferred income taxes	15.2			36.0			Deferred income taxes	(29.4)		15.2
Change in assets and liabilities (net of effects of acquisitions):
(Increase) decrease in accounts receivable	(91.1		)	13.2
Other							Other	55.4		21.3
Change in assets and liabilities (net of effects of acquisitions and divestitures):							Change in assets and liabilities (net of effects of acquisitions and divestitures):
Increase in accounts receivable							Increase in accounts receivable	(124.2)		(91.1)
Increase in unbilled services	(67.4		)	(36.5		)	Increase in unbilled services	(58.9)		(67.4)
Increase in inventories	(1.7		)	(4.7		)
Decrease (increase) in prepaid expenses and other	16.1			(27.2		)
Increase in supplies inventory							Increase in supplies inventory	(98.4)		(1.7)
(Increase) decrease in prepaid expenses and other							(Increase) decrease in prepaid expenses and other	33.1		16.1
Decrease in accounts payable	(109.0		)	(91.3		)	Decrease in accounts payable	(88.9)		(109.0)
(Decrease) increase in unearned revenue	(5.0		)	8.3			(Decrease) increase in unearned revenue	28.9		(5.0)
Decrease in accrued expenses and other	(158.8		)	(71.4		)

Decrease (increase) in accrued expenses and other							Decrease (increase) in accrued expenses and other	54.7		(158.8)
Net cash provided by operating activities	419.3			567.1			Net cash provided by operating activities	574.5		419.3
CASH FLOWS FROM INVESTING ACTIVITIES:							CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	(179.4		)	(159.7		)	Capital expenditures	(205.1)		(179.4)
Proceeds from sale of assets	4.2			0.7			Proceeds from sale of assets	7.2		4.2
Proceeds from sale of investment	3.4			—
Net proceeds from sale of held for sale assets	—			49.1
Proceeds from sale or distribution of investments							Proceeds from sale or distribution of investments	1.0		3.4

Investments in equity affiliates	(15.8		)	(7.3		)	Investments in equity affiliates	(21.8)		(15.8)
Acquisition of businesses, net of cash acquired	(703.7		)	(79.1		)	Acquisition of businesses, net of cash acquired	(11.3)		(703.7)
Net cash used for investing activities	(891.3		)	(196.3		)	Net cash used for investing activities	(230.0)		(891.3)
CASH FLOWS FROM FINANCING ACTIVITIES:							CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from term loan	850.0			—			Proceeds from term loan	—		850.0
Payments on term loan	(250.0		)	(295.0		)	Payments on term loan	—		(250.0)
Proceeds from revolving credit facilities	419.5			394.7			Proceeds from revolving credit facilities	151.7		419.5
Payments on revolving credit facilities	(384.5		)	(394.7		)	Payments on revolving credit facilities	(151.7)		(384.5)
Payments on zero-coupon subordinated notes	(5.2		)	—
Noncontrolling interest distributions	(0.5		)	(5.9		)
Deferred payments on acquisitions	(4.7		)	—
Payments on other long-term obligations	(6.7		)	(5.1		)

Net share settlement tax payments from issuance of stock to employees	(40.1		)	(45.1		)	Net share settlement tax payments from issuance of stock to employees	(31.5)		(40.1)
Net proceeds from issuance of stock to employees	33.9			43.0			Net proceeds from issuance of stock to employees	28.8		33.9
Purchase of common stock	(300.0		)	(150.0		)	Purchase of common stock	(100.0)		(300.0)
Net cash provided by (used for) financing activities	311.7			(458.1		)
Other							Other	(17.0)		(17.1)
Net cash used for financing activities							Net cash used for financing activities	(119.7)		311.7
Effect of exchange rate changes on cash and cash equivalents	(1.1		)	(7.9		)	Effect of exchange rate changes on cash and cash equivalents	(5.3)		(1.1)
Net decrease in cash and cash equivalents	(161.4		)	(95.2		)
Net increase (decrease) in cash and cash equivalents							Net increase (decrease) in cash and cash equivalents	219.5		(161.4)
Cash and cash equivalents at beginning of period	426.8			316.6			Cash and cash equivalents at beginning of period	337.5		426.8

Cash and cash equivalents at end of period	$	265.4		$	221.4		Cash and cash equivalents at end of period	$	557.0	$	265.4

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

1. BASIS OF FINANCIAL STATEMENT PRESENTATION


1.	~~BASIS OF FINANCIAL STATEMENT PRESENTATION~~

Laboratory Corporation of America^® Holdings together with its subsidiaries (the Company) is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. The Company’s mission is to improve health and improve lives by delivering world-class diagnostic solutions, bringing innovative medicines to patients faster and using technology to provide better care. The Company serves a broad range of customers, including managed care organizations (MCOs), biopharmaceutical companies, ~~medical device companies,~~ governmental agencies, physicians and other healthcare providers (e.g., physician assistants and nurse practitioners, generally referred to herein as physicians), hospitals and health systems, employers, patients and consumers, contract research organizations (CROs), and independent clinical laboratories. ~~The Company believes that it generated more revenue from laboratory testing than any other company in the world in 2018.~~

The Company reports its business in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). For further financial information about these segments, see Note 16 ~~(Business~~Business Segment ~~Information).~~Information to the Condensed Consolidated Financial Statements. During the three months ended June 30, ~~2019,~~2020, LCD and CDD contributed approximately 61% and 39%, respectively, of revenues to the Company. During the six months ended June 30, ~~2019,~~2020, LCD and CDD contributed approximately ~~61%~~60% and ~~39%~~40%, respectively, of revenues to the Company.

The condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries for which it exercises control. Long-term investments in affiliated companies in which the Company exercises significant influence, but which it does not control, are accounted for using the equity method. Investments in which the Company does not exercise significant influence (generally, when the Company has an investment of less than 20.0%) and no representation on the investee's board of directors) are accounted for at fair value or at cost minus impairment adjusted for observable price changes in orderly transactions for an identical or similar investment of the same issuer for those investments that do not have readily determinable fair values. All significant inter-company transactions and accounts have been eliminated. The Company does not have any significant variable interest entities or special purpose entities whose financial results are not included in the condensed consolidated financial statements.

The financial statements of the Company's operating foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated at exchange rates as of the balance sheet date. Revenues and expenses are translated at average monthly exchange rates prevailing during the period. Resulting translation adjustments are included in “Accumulated other comprehensive income.”

The accompanying condensed consolidated financial statements of the Company are unaudited. In the opinion of management, all adjustments necessary for a fair statement of results of operations, cash flows, and financial position have been made. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for a full year. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by generally accepted accounting principles.

The condensed consolidated financial statements and notes are presented in accordance with the rules and regulations of the United States (U.S.) Securities and Exchange Commission (SEC) and do not contain certain information included in the Company’s ~~2018~~2019 Annual Report on Form ~~10-K.~~10-K (Annual Report). Therefore, these interim statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report.

Recently Adopted Guidance

~~Leases~~

In February 2016, the Financial Accounting Standards Board (FASB) issued a new accounting standard that sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e., lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. The Company has elected to utilize the short-term lease exemption and not record leases with initial terms of 12 months or less on the balance sheet. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases and direct financing leases.

The Company adopted the standard on January 1, 2019, using the modified retrospective method. Comparative periods were not adjusted and are presented in accordance with lease guidance in effect for that period. The Company elected the package of practical expedients, which includes not reassessing whether existing contracts contain leases under the new definition of a lease, reassessing the classification of existing leases, and reassessing whether previously capitalized initial direct costs qualify for

~~INDEX~~

~~LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(dollars and shares in millions, except per share data)~~

capitalization under the new standard. Leases with an initial term of 12 months or less are not recorded on the Condensed Consolidated Balance Sheets. Operating lease expense is recognized on a straight-line basis over the lease term.

Operating lease assets and liabilities are recognized at the commencement date, based on the present value of the future minimum lease payments over the lease term. A certain number of these leases contain rent escalation clauses either fixed or adjusted periodically for inflation or market rates that are factored into the Company's determination of lease payments. The Company also has variable lease payments that do not depend on a rate or index, for items such as volume purchase commitments, which are recorded as variable cost when incurred. As most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date to discount payments to the present value. Some operating leases contain renewal options, some of which also include options to early terminate the leases. The exercise of these options is at the Company's discretion. The Company determined that all renewal options within leases for main laboratories, STAT laboratories, branches or combination sites were reasonably possible to be exercised and therefore are included in the accounting lease term.

The standard had a material impact in the consolidated balance sheets, but no material impact in the consolidated income statements. The most significant impact was the recognition of right-of-use (ROU) assets and lease liabilities for operating leases, while the accounting for finance leases remained unchanged.

~~New Accounting Pronouncements~~

In June 2016, the FASB issued a new accounting standard intended to provide financial statement users with more decision-useful information about expected credit losses and other commitments to extend credit held by the reporting entity. The standard replaces the incurred loss impairment methodology in current ~~GAAP~~generally accepted accounting principles(GAAP) with one that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The ~~update is effective~~Company recorded an opening retained earnings adjustment of $7.0 with the adoption of this standard on January 1, ~~2020, with early adoption permitted. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements.~~2020.

In August 2018, the FASB issued a new accounting standard to reduce, modify, and add to the disclosure requirements on fair value measurements. The Company adopted this standard is effective on January 1, ~~2020, with early~~2020. The adoption ~~permitted. The Company is currently evaluating the~~of this standard did not have a material impact ~~this new standard will have~~ on the consolidated financial statements.

In August 2018, the FASB issued a new accounting standard to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

to develop or obtain internal-use software. The Company adopted this standard effective January 1, 2020. The adoption of this standard did not have a material impact on the consolidated financial statements.

New Accounting Pronouncements

In August 2018, the FASB issued a new accounting standard to reduce, modify, and add to the disclosure requirements on defined benefit pension and other postretirement plans. The standard is effective on January 1, 2021, with early adoption permitted. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements.

In ~~August 2018,~~December 2019, the FASB issued a new accounting standard to ~~align~~simplify accounting for income taxes and remove, modify, and add to the disclosure requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software.of income taxes. The standard is effective on January 1, ~~2020,~~2021, with early adoption permitted. The Company is currently evaluating the impact this new standard will have on the consolidated financial statements.

~~Reclassifications~~In January 2020, the FASB issued a new accounting standard to clarify the interaction of the accounting for equity securities and ~~Revisions~~

investments accounted for under the equity method of accounting and the accounting for certain forward contracts and purchased options. The standard is effective January 1, 2021. The Company ~~adopted Accounting Standard Update 2016-09~~ ~~Compensation - Stock Compensation (Topic 718)~~ ~~during 2016~~is currently evaluating the impact this new standard will have on the consolidated financial statements.

In March 2020, the FASB issued a new accounting standard to provide optional expedients and ~~incorrectly classified payments made~~exceptions if certain conditions are met for applying GAAP to ~~tax authorities~~contracts, hedging relationships, and other transactions affected by reference rate reform. The expedients and exceptions in the standard are effective between March 12, 2020 and December 31, 2022. The Company did not elect to apply any of the expedients or exceptions for ~~withheld shares~~the period ended June 30, 2020 and is currently evaluating the impact this new standard will have on the consolidated financial statements.

Novel Coronavirus (COVID-19) Financial Statement Impact

In March 2020, COVID-19 was declared a pandemic. COVID-19 has had and continues to have an extensive impact on the global health and economic environment. Given the continued unpredictability of the COVID-19 pandemic and the corresponding government restrictions and customer behavior, there are a wide-range of feasible financial results for 2020. While the Company's Base Business continues to be negatively impacted by the COVID-19 pandemic, the Company's outlook has improved across the enterprise. Base Business includes the Company's business operations except for molecular and serology COVID-19 testing (COVID-19 Testing).

In LCD, demand for its Base Business continues to be below the Company's historical levels; however, the Company's Base Business has been steadily recovering from ~~an employee’s equity award~~its trough in April, while at the same time COVID-19 Testing continues to grow and the Company continues to increase capacity for its COVID-19 molecular and antibody tests.

In CDD, while the pandemic is expected to continue to negatively impact its business, this impact is expected to subside throughout the year as ~~cash flows~~CDD continues to work on projects supporting global vaccine and treatment development, with additional support from ~~operating activities versus cash flows from financing activities.~~ COVID-19 Testing.

As a result of the ~~Company has revised~~impact of the ~~consolidated statement of cash flows for these tax payments of $45.1 for~~COVID-19 pandemic, during the six months ended June 30, ~~2018, from operating activities to financing activities.~~2020, the Company recorded goodwill and other asset impairment charges of $437.4: $426.4 within CDD and $11.0 within LCD, all of which were recorded in the three months ended March 31, 2020. See Note 6 Goodwill and Intangible Assets for discussion of goodwill and intangible asset impairment and Note 2 Revenue for the discussion of credit losses and additional price concessions. The Company ~~concluded that these errors were not material individually~~also wrote-off or wrote down certain of the Company's investments by $25.4 due to the impact of COVID-19, $7.1 included in Equity method earnings (loss), net (recorded in the ~~aggregate~~three months ended March 31, 2020), and $18.3 included in Other, net ($13.1 recorded during the three months ended March 31, 2020 and $5.2 recorded during the three months ended June 30, 2020).

~~In conjunction~~Coronavirus Aid, Relief, and Economic Security Act (CARES Act). Upon receiving and satisfying the terms and conditions associated with the ~~adoption of the new lease standard,~~distributed funds, the Company ~~reclassified~~accounted for the ~~capital lease asset balance~~transaction by applying the guidance in ASC 450-30 Gain Contingencies, andrecorded these funds in Other, net non-operating income in the Consolidated Statement of ~~$44.4 at December 31, 2018,~~Operations as of June 30, 2020.

The Company instituted numerous actions to help mitigate the financial impact from ~~Property, plant~~the COVID-19 pandemic, which included furloughs, reduced hours, and ~~equipment, net to Other assets.~~

the suspension of discretionary merit adjustments and 401(k) plan contributions in the

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

United States (U.S.). In response to its improved business operations, the Company has been rapidly resuming regular work schedules and is proceeding with merit adjustments and will retroactively reinstate 401(k) plan contributions in the U.S.

Use of Estimates

The extent to which the COVID-19 pandemic has and will impact the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the COVID-19 pandemic, the extent to which it will impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business reactions to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2020 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s implicit price concessions and credit losses, equity investments, notes receivable and the carrying value of goodwill and other long-lived assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in additional material impacts to the Company’s consolidated financial statements in future reporting periods.


2.	~~REVENUES~~

2. REVENUES

The Company's revenues by segment payers/customer groups for the three and six months ended June 30, 2020, and 2019, ~~and 2018, is~~were as follows:


	For the Three Months Ended June 30, 2020
	U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	20	%	1	%	—	%	—	%	—	%	—	%	21	%
Patients	7	%	—	%	—	%	—	%	—	%	—	%	7	%
�� Medicare and Medicaid	7	%	—	%	—	%	—	%	—	%	—	%	7	%
Third-party	25	%	1	%	—	%	—	%	—	%	—	%	26	%
Total LCD revenues by payer	59	%	2	%	—	%	—	%	—	%	—	%	61	%

CDD
Biopharmaceutical and medical device companies	18	%	—	%	5	%	4	%	3	%	9	%	39	%

Total revenues	77	%	2	%	5	%	4	%	3	%	9	%	100	%


	For the Three Months Ended June 30, 2019															For the Three Months Ended June 30, 2019
	U.S.		Canada		U.K.		Switzerland		Other Europe		Other		Total			U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer															Payer/Customer
LCD															LCD
Clients	16	%	1	%	—	%	—	%	—	%	—	%	17	%	Clients	16	%	1	%	—	%	—	%	—	%	—	%	17	%
Patients	8	%	—	%	—	%	—	%	—	%	—	%	8	%	Patients	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Medicare and Medicaid	8	%	—	%	—	%	—	%	—	%	—	%	8	%	Medicare and Medicaid	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Third-party	26	%	2	%	—	%	—	%	—	%	—	%	28	%	Third-party	26	%	2	%	—	%	—	%	—	%	—	%	28	%
Total LCD revenues by payer	58	%	3	%	—	%	—	%	—	%	—	%	61	%	Total LCD revenues by payer	58	%	3	%	—	%	—	%	—	%	—	%	61	%

CDD															CDD
Biopharmaceutical and medical device companies	20	%	—	%	4	%	5	%	3	%	7	%	39	%	Biopharmaceutical and medical device companies	20	%	—	%	4	%	5	%	3	%	7	%	39	%

Total revenues	78	%	3	%	4	%	5	%	3	%	7	%	100	%	Total revenues	78	%	3	%	4	%	5	%	3	%	7	%	100	%

For the Three Months Ended June 30, 2018
U.S. Canada U.K. Switzerland Other Europe Other Total
Payer/Customer
LCD
   Clients 18 % 1 % — % — % — % — % 19 %
   Patients 7 % — % — % — % — % — % 7 %
   Medicare and Medicaid 10 % — % — % — % — % — % 10 %
   Third-party 25 % 2 % — % — % — % — % 27 %
Total LCD revenues by payer 60 % 3 % — % — % — % — % 63 %

CDD
   Biopharmaceutical and medical
device companies 20 % — % 2 % 5 % 3 % 7 % 37 %

Total revenues 80 % 3 % 2 % 5 % 3 % 7 % 100 %

For the Six Months Ended June 30, 2019
U.S. Canada U.K. Switzerland Other Europe Other Total
Payer/Customer
LCD
   Clients 16 % 1 % — % — % — % — % 17 %
   Patients 8 % — % — % — % — % — % 8 %
   Medicare and Medicaid 8 % — % — % — % — % — % 8 %
   Third-party 26 % 2 % — % — % — % — % 28 %
Total LCD revenues by payer 58 % 3 % — % — % — % — % 61 %

CDD
   Biopharmaceutical and medical
device companies 20 % — % 4 % 5 % 3 % 7 % 39 %

Total revenues 78 % 3 % 4 % 5 % 3 % 7 % 100 %

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)


	For the Six Months Ended June 30, 2020
	U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	18	%	1	%	—	%	—	%	—	%	—	%	19	%
Patients	7	%	—	%	—	%	—	%	—	%	—	%	7	%
Medicare and Medicaid	7	%	—	%	—	%	—	%	—	%	—	%	7	%
Third-party	25	%	2	%	—	%	—	%	—	%	—	%	27	%
Total LCD revenues by payer	57	%	3	%	—	%	—	%	—	%	—	%	60	%

CDD
Biopharmaceutical and medical device companies	19	%	—	%	5	%	5	%	3	%	8	%	40	%

Total revenues	76	%	3	%	5	%	5	%	3	%	8	%	100	%

For the Six Months Ended June 30, 2018
U.S. Canada U.K. Switzerland Other Europe Other Total
Payer/Customer
LCD
   Clients 18 % 1 % — % — % — % — % 19 %
   Patients 7 % — % — % — % — % — % 7 %
   Medicare and Medicaid 9 % — % — % — % — % — % 9 %
   Third-party 25 % 2 % — % — % — % — % 27 %
Total LCD revenues by payer 59 % 3 % — % — % — % — % 62 %

CDD
   Biopharmaceutical and medical
device companies 20 % — % 2 % 5 % 4 % 7 % 38 %

Total revenues 79 % 3 % 2 % 5 % 4 % 7 % 100 %


	For the Six Months Ended June 30, 2019
	U.S.		Canada		United Kingdom		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	16	%	1	%	—	%	—	%	—	%	—	%	17	%
Patients	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Medicare and Medicaid	8	%	—	%	—	%	—	%	—	%	—	%	8	%
Third-party	26	%	2	%	—	%	—	%	—	%	—	%	28	%
Total LCD revenues by payer	58	%	3	%	—	%	—	%	—	%	—	%	61	%

CDD
Biopharmaceutical and medical device companies	20	%	—	%	4	%	5	%	3	%	7	%	39	%

Total revenues	78	%	3	%	4	%	5	%	3	%	7	%	100	%

Contract costs

CDD incurs sales commissions in the process of obtaining contracts with customers, which are recoverable through the service fees in the contract. Sales commissions that are payable upon contract award are recognized as assets and amortized over the expected contract term, along with related payroll tax expense. The amortization of commission expense is based on the weighted average contract duration for all commissionable awards in the respective business in which the commission expense is paid, which approximates the period over which goods and services are transferred to the customer. The amortization period of sales commissions ranges from approximately ~~12 months~~1 to ~~57 months,~~5 years, depending on the business. For businesses that enter into primarily short-term contracts, the Company applies the practical expedient, which allows costs to obtain a contract to be expensed when incurred if the amortization period of the assets that would otherwise have been recognized is one year or less. Amortization of assets from sales commissions is included in selling, general, and administrative expense.

CDD incurs costs to fulfill contracts with customers, which are recoverable through the service fees in the contract. Contract fulfillment costs include software implementation costs and setup costs for certain ~~endpoint and~~ market access solutions. These costs are recognized as assets and amortized over the expected term of the contract to which the implementation relates, which is the period over which services are expected to be provided to the customer. This period typically ranges from ~~24-60 months.~~2 to 5 years. Amortization of deferred contract fulfillment costs is included in cost of goods sold.


	June 30, 2020		December 31, 2019
Sales commission assets	$	32.0	$	28.6
Deferred contract fulfillment costs	13.3		14.9
Total	$	45.3	$	43.5

June 30, 2019 December 31, 2018
Sales commission assets $ 27.4
$ 24.2
Deferred contract fulfillment costs 14.2
12.9
Total $ 41.6
$ 37.1

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

Amortization related to sales commission assets and associated payroll taxes for the ~~three-month~~three months ended June 30, 2020, and 2019, was $5.5 and $5.1, respectively and for the six month periods ended June 30, 2020, and 2019, was $10.8 and ~~2018, was $5.1 and $4.4, respectively, and for the six-month periods ended June 30, 2019, and 2018, was~~ $9.5, ~~and $8.6,~~ respectively. Amortization related to deferred contract fulfillment costs for the ~~three-month periods~~three months ended June 30, 2020, and 2019, ~~and 2018,~~ was ~~$1.9~~$2.3 and $1.9, respectively, and was ~~$3.8~~$5.3 and ~~$2.5,~~$3.8, respectively, for the ~~six-month~~six month periods ended June 30, ~~2019,~~2020, and ~~2018. Impairment expense related to contract costs was immaterial to the Company’s consolidated statement of operations.~~2019.

Receivables, Unbilled Services and Unearned Revenue

~~The following table provides information about receivables, unbilled services, and unearned revenue (contract liabilities) from contracts with customers for the CDD segment.~~ Unbilled services are comprised primarily of unbilled receivables, but also include contract assets. A contract asset is recorded when a right to payment has been earned for work performed, but billing and payment for that work is determined by certain contractual milestones, whereas unbilled receivables are billable upon the passage of time. While CDD attempts to negotiate terms that provide for billing and payment of services prior or in close proximity to the provision of services, this is not always possible and there are fluctuations in the level of unbilled services and unearned revenue from period to period. The following table provides information about receivables, unbilled services, and unearned revenue (contract liabilities) from contracts with customers for CDD.

June 30, 2019 December 31, 2018
Receivables, which are included in Accounts Receivable, net $ 735.4
$ 693.6
Unbilled services 491.5
396.9
Unearned revenue 402.2
354.1

~~INDEX~~

~~LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(dollars and shares in millions, except per share data)~~


	June 30, 2020		December 31, 2019
Receivables, which are included in accounts receivable	$	730.5	$	771.1
Unbilled services	539.7		483.7
Unearned revenue	471.4		449.2

Revenues recognized during the period, ~~which was~~that were included in the unearned revenue balance at the beginning of the period for the ~~six-month periods~~six months ended June 30, ~~2019,~~2020, and June 30, ~~2018, was~~2019, were $102.2 and $161.6, respectively.

Credit Loss Rollforward

With the adoption of current expected credit loss standard in 2020, the Company estimates future expected losses on accounts receivable, unbilled services and ~~$135.6, respectively. Bad debt expense on receivables~~notes receivable over the remaining collection period of the instrument. The rollforward for the ~~six-month periods~~allowance for credit losses for the six months ended June 30, ~~2019, and 2018, was immaterial to~~2020, is as follows:


	For the Six Months Ended June 30, 2020
	Accounts Receivable		Unbilled Services		Note Receivable		Total
Allowance for credit losses as of December 31, 2019	$	19.0	$	2.3	$	—	$	21.3
Current expected credit losses opening balance impact on retained earnings	1.9		0.2		5.0		7.1
Plus, credit loss expense	9.1		1.9		5.0		16.0
Less, write offs	0.9		0.1		—		1.0
Ending allowance for credit losses	$	29.1	$	4.3	$	10.0	$	43.4

The note receivable is the ~~Company’s consolidated statement~~floating note receivable due 2022 from the Envigo transaction which is recorded in Other assets, net.

During the six months ended June 30, 2020, the Company also recorded $23.3 of ~~operations.~~additional implicit price concessions as a result of anticipated collection challenges from the economic decline.

Performance Obligations Under Long-Term Contracts

Long-term contracts at the Company consist primarily of fully managed clinical studies within ~~the CDD segment.~~CDD. The amount of existing performance obligations under such long-term contracts unsatisfied as of June 30, ~~2019,~~2020, was ~~$4,138.0.~~$4,498.8. The Company expects to recognize approximately ~~34%~~31% of the remaining performance obligations as ~~revenues~~of June 30, 2020, as revenue over the next 12 months, and the balance thereafter. The Company's long-term contracts generally range from 1 to 8 years.

Within CDD, ~~revenue~~revenues of $13.7 and $48.4 ~~and $(12.5) was~~were recognized during the six months ended June 30, ~~2019,~~2020, and ~~2018,~~2019, respectively, from performance obligations that were satisfied in previous periods. This revenue comes from adjustments related to changes in scope and estimates in full service clinical studies.


3.	~~BUSINESS ACQUISITIONS AND DISPOSITIONS~~

3. BUSINESS ACQUISITIONS AND DISPOSITIONS

On June 3, 2019, ~~the Company's~~ CDD ~~segment completed the acquisition of~~acquired Envigo's nonclinical contract research services business, expanding CDD's global nonclinical drug development capabilities with additional locations and resources. ~~Envigo also completed~~Additionally, the ~~acquisition of~~Company divested the Covance Research Products (CRP) business, which was a part of ~~the~~ CDD, ~~segment. The two companies will continue~~ to ~~collaborate through~~Envigo. As part of this sale, CDD entered into a multi-year, renewable supply ~~agreement.~~agreement with Envigo. The Company paid cash consideration of $601.0, received a floating rate ~~secured note of $110.0, and recorded a loss on sale of CRP of $8.8. The Company funded the transaction through a new term loan facility.~~

~~The preliminary valuation of acquired assets and assumed liabilities as of June 3, 2019, include the following:~~

Consideration Transferred
Cash consideration $ 601.0
Fair value of CRP 110.0
Total $ 711.0

Preliminary
Net Assets Acquired
Cash and cash equivalents $ 15.1
Accounts receivable 16.5
Unbilled services 26.5
Inventories 4.5
Prepaid expenses and other 3.5
Property, plant and equipment (including ROU operating lease assets) 99.1
Deferred tax asset 25.5
Goodwill 432.2
Customer relationships 125.8
Trade name and trademarks 0.6
Other assets 9.9
Total assets acquired 759.2
Accounts payable 15.4
Accrued expenses and other 11.6
Unearned revenue 49.9
Operating lease liabilities 15.0
Other liabilities 66.3
Total liabilities acquired 158.2
Net Envigo assets acquired 601.0
Floating rate secured note receivable due 2022 110.0
Total $ 711.0

INDEX~~The amortization periods for intangible assets acquired are 11 years for customer relationships.~~

~~The Envigo transaction contributed $16.5 and $0.7 of revenues and operating income, respectively, during the three and six months ended June 30, 2019.~~

~~INDEX~~

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

secured note of $110.0, and recorded a loss on the sale of CRP of $12.2. The Company funded the transaction through a new term loan facility.

The final valuation of acquired assets and assumed liabilities in the transaction as of June 3, 2019, include the following:


Consideration Transferred
Cash consideration	$	601.0
Fair value of CRP	110.0
Total	$	711.0

	Preliminary June 30, 2019		Measurement Period Adjustments		Final June 30, 2020
Net Assets Acquired
Cash and cash equivalents	$	15.1	$	(3.8)	$	11.3
Accounts receivable	16.5		(4.4)		12.1
Unbilled services	26.5		(0.9)		25.6
Inventories	4.5		—		4.5
Prepaid expenses and other	3.5		7.3		10.8
Property, plant and equipment (including ROU operating lease assets)	99.1		29.3		128.4
Deferred income taxes	25.5		(0.3)		25.2
Goodwill	432.2		(55.6)		376.6
Customer relationships	125.8		15.0		140.8
Trade name and trademarks	0.6		—		0.6
Other assets	9.9		—		9.9
Total assets acquired	759.2		(13.4)		745.8
Accounts payable	15.4		(0.2)		15.2
Accrued expenses and other	11.6		(1.2)		10.4
Unearned revenue	49.9		—		49.9

Operating lease liabilities	15.0		(15.0)		—
Other liabilities	66.3		3		69.3
Total liabilities acquired	158.2		(13.4)		144.8
Net Envigo assets acquired	601.0		$	—	$	601.0
Floating rate secured note receivable due 2022	110.0
Total	$	711.0

The final purchase ~~price allocation~~consideration for Envigo has been allocated to the estimated fair market value of the net assets acquired, including approximately $141.4 in identifiable intangible assets and a residual amount of non-tax-deductible goodwill of approximately $376.6. The amortization period for intangible assets acquired is 11 years for customer relationships.

During the six months ended June 30, 2020, the Company recorded a $5.0 charge for the ~~Envigo transaction is still preliminary~~estimated credit loss related to the CDD floating rate secured note receivable due 2022 from Envigo.

During the six months ended June 30, 2020, the Company acquired a business and ~~subject~~related assets for approximately $17.3 in cash (including contingent consideration of $6.0 and net of cash acquired). The purchase consideration for this acquisition has been allocated to ~~change. The areas~~the estimated fair market value of the ~~purchase price allocation that are not yet finalized relate~~net assets acquired, including approximately $9.2 in identifiable intangible assets and a residual amount of non-tax deductible goodwill of approximately $8.1. This acquisition was made primarily to intangible assets, goodwill, fixed assets and the impact of finalizing deferred taxes. Accordingly, adjustments may be made as additional information is obtained about the facts and circumstances that existed as of the valuation date. The Company expects these purchase price allocations to be finalized by the second quarter of 2020. Any adjustments will be recorded in the period in which they are identified.expand its specialty testing.

During the six months ended June 30, 2019, the Company ~~also~~ acquired various businesses and related assets for approximately $117.7 in cash (net of cash acquired). The purchase consideration for all acquisitions ~~year to date~~in the six months ended June 30, 2019, has been allocated to the estimated fair market value of the net assets acquired, including approximately $90.7 in identifiable intangible assets and a residual amount of non-tax deductible goodwill offor approximately $53.8. The amortization periods for intangible assets acquired from these businesses range from 11 to 15 years for customer relationships. These acquisitions were made primarily to extend the Company's geographic reach in important market areas, enhance the Company's scientific differentiation and to expand the breadth and scope of the Company's CRO services. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill.The goodwill reflects the Company's expectations to utilize the acquired ~~businesses’~~businesses' workforce and established relationships and the benefits of being able to leverage operational efficiencies with favorable growth opportunities in these markets.

INDEX

~~Additionally,~~LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

Unaudited Pro Forma Information

Had the ~~Company divested its food solutions~~Company's total 2019 and ~~forensic testing services business in~~2020 acquisitions been completed as of January 1, 2019, the ~~United Kingdom (U.K) and the U.S. in 2018. Total operating income for the three divested businesses was $3.4 and $5.4 for the three and six months ended June 30, 2018, respectively.~~Company's pro forma results would have been as follows:


	Three Months Ended June 30,						Six Months Ended June 30,
	2020		2019		2020		2019
Revenues	$	2,770.7	$	2,941.0	$	5,596.7	$	5,775.9
Net earnings attributable to Laboratory Corporation of America Holdings	$	231.8	$	194.3	$	(84.9)	$	382.6


4.	~~EARNINGS PER SHARE~~

4. EARNINGS (LOSS) PER SHARE

Basic earnings (loss) per share is computed by dividing net earnings attributable to Laboratory Corporation of America Holdings by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net earnings including the impact of dilutive adjustments by the weighted average number of common shares outstanding plus potentially dilutive shares, as if they had been issued at the earlier of the date of issuance or the beginning of the period presented. Potentially dilutive common shares result primarily from the Company’s outstanding stock options, restricted stock awards, restricted stock units, and performance share ~~awards, and shares issuable upon conversion of zero-coupon subordinated notes.~~awards.

The following represents a reconciliation of basic earnings (loss) per share to diluted earnings (loss) per share:


	Three Months Ended June 30,																		Six Months Ended June 30,
	2020								2019									2020			2019
	Earnings		Shares	Per Share Amount		Earnings		Shares	Per Share Amount		Earnings (Loss)		Shares	Per Share Amount		Earnings		Shares	Per Share Amount
Basic earnings (loss) per share:
Net earnings (loss)	$	231.6	97.3	$	2.38	$	190.4	98.1	$	1.94	$	(85.6)	97.2	$	(0.88)	$	376.0	98.4	$	3.82
Dilutive effect of employee stock options and awards	—		0.4			—		0.7			—		—			—		0.7


Net earnings (loss) including impact of dilutive adjustments ^(a)	$	231.6	97.7	$	2.37	$	190.4	98.8	$	1.93	$	(85.6)	97.2	$	(0.88)	$	376.0	99.1	$	3.79

Three Months Ended June 30, Six Months Ended June 30,
2019 2018 2019 2018
Earnings Shares
Per
Share
Amount
Earnings Shares
Per
Share
Amount
Earnings Shares
Per
Share
Amount
Earnings Shares
Per
Share
Amount
Basic earnings per share:
Net earnings $ 190.4
98.1
$ 1.94
$ 233.8
101.9
$ 2.29
$ 376.0
98.4
$ 3.82
$ 407.0
101.9
$ 3.99
Dilutive effect of employee stock options and awards —
0.7

—
1.0

—
0.7

—
1.3

Net earnings including impact of dilutive adjustments $ 190.4
98.8
$ 1.93
$ 233.8
103.0
$ 2.27
$ 376.0
99.1
$ 3.79
$ 407.0
103.3
$ 3.94

^(a)
Due to the Company's net loss for the six months ended June 30, 2020, diluted earnings (loss) per share is the same as basic earnings (loss) per share.

Diluted earnings per share represent the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. These potential shares include dilutive stock options and unissued restricted stock awards. The following table summarizes the potential common shares not included in the computation of diluted earnings per share because their impact would have been antidilutive:

Three Months Ended June 30, Six Months Ended June 30,
2019 2018 2019 2018
Stock options 0.2
0.1
0.2
0.1


	Three Months Ended June 30,			Six Months Ended June 30,
	2020	2019	2020	2019
Employee stock options and awards	0.8	0.2	1.3	0.2


5.	~~RESTRUCTURING AND OTHER SPECIAL CHARGES~~

5. RESTRUCTURING AND OTHER CHARGES

During the six months ended June 30, 2020, the Company recorded net restructuring and other charges of $31.8: $11.8 within LCD and $20.0 within CDD. The charges were comprised of $10.5 related to severance and other personnel costs, $8.0 for a CDD lab facility and equipment impairments, and $20.0 in facility closures, impairment of operating lease right-of use assets and general integration activities. The charges were offset by the reversal of previously established liability of $1.0 and $5.7 in unused severance costs and facility-related costs, respectively.

During the six months ended June 30, 2019, the Company recorded net restructuring and other ~~special~~ charges of $34.2: $16.1 within LCD and $18.1 within CDD. The charges were comprised of $20.3 related to severance and other personnel costs and $13.5 in costs associated with facility closures, impairment of operating lease right-of-use assets and general integration initiatives. The charges were increased by the adjustment of previously established reserves of $0.4 in severance reserves.

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

During the six months ended June 30, 2018, the Company recorded net restructuring and other special charges of $26.5: $9.1 within LCD and $17.4 within CDD. The charges were comprised of $23.1 related to severance and other personnel costs, $2.5 in costs associated with facility closures and general integration initiatives, and $2.3 in impairment to land held for sale. The Company reversed previously established reserves of $0.9 and $0.5 in unused facility reserves and unused severance reserves, respectively.

The following represents the Company’s restructuring reserve activities for the period indicated:

LCD CDD

Severance and Other
Employee Costs

Facility Costs

Severance and Other
Employee Costs

Facility Costs
Total
Balance as of December 31, 2018 $ 2.1
$ 7.4
$ 6.5
$ 27.6
$ 43.6
Reclassification for ASC 842 adoption —
(5.7 ) —
(27.1 ) (32.8 )
Restructuring charges 11.9
1.0
8.4
1.7
23.0
Adjustments to prior restructuring accruals (0.1 ) —
0.5
—
0.4
Impairment of operating lease right-of-use asset —
3.3
—
7.5
10.8
Cash payments and other adjustments (13.6 ) (3.1 ) (8.5 ) (7.2 ) (32.4 )
Balance as of June 30, 2019 $ 0.3
$ 2.9
$ 6.9
$ 2.5
$ 12.6
Current

$ 10.4
Non-current

2.2

$ 12.6


	LCD						CDD
	Severance and Other Employee Costs		Facility Costs		Severance and Other Employee Costs		Facility Costs		Total
Balance as of December 31, 2019	$	0.5	$	2.7	$	5.5	$	4.7	$	13.4

Restructuring charges	2.7		3.5		7.8		6.4		20.4
Adjustments to prior restructuring accruals	(0.1)		(0.4)		(0.9)		(5.3)		(6.7)
Impairment of lab facility and equipment	—		—		—		8.0		8.0
Impairment of operating lease right-of-use asset	—		6.1		—		4.0		10.1
Cash payments and other adjustments	(3.0)		(9.9)		(3.8)		(15.5)		(32.2)
Balance as of June 30, 2020	$	0.1	$	2.0	$	8.6	$	2.3	$	13.0
Current									$	9.4
Non-current									3.6
									$	13.0


6.	~~GOODWILL AND INTANGIBLE ASSETS~~

6. GOODWILL AND INTANGIBLE ASSETS

The changes in the carrying amount of goodwill for the ~~three-month period~~six months ended June 30, ~~2019,~~2020, are as follows:

LCD CDD Total
Balance as of January 1, 2019 $ 3,638.8
$ 3,721.5
$ 7,360.3
Goodwill acquired during the period 22.3
468.2
490.5
Dispositions —
(12.6 ) (12.6 )
Adjustments to goodwill 1.9
3.6
5.5
Balance at June 30, 2019 $ 3,663.0
$ 4,180.7
$ 7,843.7



	LCD		CDD		Total

Balance as of January 1, 2020	$	3,721.5	$	4,143.5	$	7,865.0
Goodwill acquired during the period	8.1		—		8.1


Impairment	(3.7)		(418.7)		(422.4)
Foreign currency impact and other adjustments to goodwill	6.4		(34.4)		(28.0)
Balance as of June 30, 2020	$	3,732.3	$	3,690.4	$	7,422.7

The ~~components of identifiable intangible assets are as follows:~~

June 30, 2019 December 31, 2018

Gross
Carrying
Amount

Accumulated
Amortization
Net
Gross
Carrying
Amount

Accumulated
Amortization
Net
Customer relationships $ 4,307.9
$ (1,233.0 ) $ 3,074.9
$ 4,119.4
$ (1,146.7 ) $ 2,972.7
Patents, licenses and technology 452.3
(224.1 ) 228.2
447.3
(211.2 ) 236.1
Non-compete agreements 82.5
(57.2 ) 25.3
76.8
(53.7 ) 23.1
Trade names 407.7
(202.9 ) 204.8
404.0
(189.1 ) 214.9
Land use right 11.1
(4.9 ) 6.2
10.8
(4.1 ) 6.7
Canadian licenses 476.5
—
476.5
457.6
—
457.6
$ 5,738.0
$ (1,722.1 ) $ 4,015.9
$ 5,515.9
$ (1,604.8 ) $ 3,911.1

~~Amortization of intangible assets~~Company assesses goodwill and indefinite-lived intangibles for impairment at least annually or whenever events or changes in circumstances indicate that the three-month periods ended June 30, 2019, and 2018, was $60.2 and $58.5, respectively and for the six-month periods ended June 30, 2019, and 2018, was $117.3 and $120.8, respectively. Amortization expense for the net carrying amount of ~~intangible~~such assets ~~is estimated to~~may not be ~~$119.1~~recoverable. Based upon the revised forecasted revenues and operating income following the declaration of the COVID-19 global pandemic, management concluded there was a triggering event and updated its annual 2019 goodwill impairment testing as of March 31, 2020, for its CDD reporting units, including one where the 2019 fair value exceeded carrying value by approximately 10%, and its LCD reporting units. Based on the quantitative impairment assessment, the Company concluded that the fair value was less than carrying value for two of its reporting units and recorded a goodwill impairment of $418.7 for the ~~remainder of fiscal 2019, $232.0 in fiscal 2020, $225.2 in fiscal 2021, $219.3 in fiscal 2022, $215.6 in fiscal 2023~~CDD segment and ~~$2,528.2 thereafter.~~

~~7. LEASES~~

$3.7 for LCD segment.

The Company ~~has operating~~utilized a combination of income and ~~finance leases for patient service centers, laboratories and testing facilities, general office spaces, vehicles, and certain equipment. Leases have remaining lease terms~~market approaches to determine the fair value of the CDD reporting units. Based upon the results of the quantitative assessments, the Company concluded that the fair value was less than its carrying value for one of the CDD reporting units. A non-cash charge of $418.7 was recognized and included in goodwill and other asset impairments on the Consolidated Statement of Operations to reduce the carrying amount of goodwill for the CDD reporting unit to fair value. Following the impairment charge, the carrying value of goodwill for this reporting unit is $1,560.5. The other CDD reporting unit evaluated indicated a ~~year~~fair value that exceeded carrying value by less than 10%. Management notes that a 1% change in the discount rate in the March 31, 2020, analysis would reduce the headroom to ~~15 years, some~~approximately 2.0%. Goodwill for this reporting unit as of June 30, 2020 is $628.5.

The Company utilized the income approach to determine the fair value of the LCD reporting units. Based upon the results of the quantitative assessments, the Company concluded the fair value of one of the reporting units was less than its carrying value. A non-cash charge of $3.7 was recognized and included in goodwill and other asset impairments on the Consolidated Statement of Operations to reduce the carrying amount of goodwill for this LCD reporting unit to zero. The other LCD reporting unit evaluated indicated a fair value that exceeded carrying value by less than 10.0%. Management notes that a 1% change in the discount rate in the March 31, 2020, analysis would cause the fair value to be less than carrying value and would result in an impairment of approximately $40.0. Goodwill and indefinite-lived intangibles of Canadian licenses for this reporting unit as of June 30, 2020 were $84.4 and $459.7, respectively.

Although the Company believes that the current assumptions and estimates used in its goodwill analysis are reasonable, supportable, and appropriate, continued efforts to maintain or improve the performance of this business could be impacted by unfavorable or unforeseen changes which ~~include options to extend~~could impact the ~~leases for up to 15 years.~~

existing assumptions used in the impairment analysis. Various

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

factors could reasonably be expected to unfavorably impact existing assumptions: primarily delays in new customer bookings and the related delay in revenue from new customers, increases in customer termination activity or increases in operating costs. In addition, given the ongoing and rapidly changing nature of the COVID-19 pandemic, there is significant uncertainty regarding the duration and severity of the pandemic as well as any future government restrictions, which may unfavorably impact existing assumptions. Accordingly, there can be no assurance that the estimates and assumptions made for the purposes of the goodwill impairment analysis will prove to be accurate predictions of future performance.

The Company will continue to monitor the financial performance of and assumptions for its reporting units. Management's impairment analysis utilizes significant judgments and assumptions related to the market comparable method analysis, such as selected market multiples, and those related to cash flow projections, such as revenue and terminal growth rates, projected operating margin, and the discount rate. A significant increase in the discount rate, decrease in the revenue and terminal growth rates, decreased operating margin, or substantial reductions in end markets and volume assumptions, could have a negative impact on the estimated fair value of the reporting units. A future impairment charge for goodwill or intangible assets could have a material effect on the Company's consolidated financial position and results of operations.

The components of ~~lease expense were~~identifiable intangible assets are as follows:


	June 30, 2020										December 31, 2019
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Customer relationships	$	4,424.3	$	(1,419.9)	$	3,004.4	$	4,441.7	$	(1,329.5)	$	3,112.2
Patents, licenses and technology	449.0		(245.5)		203.5		453.6		(235.7)		217.9
Non-compete agreements	96.2		(65.0)		31.2		90.9		(60.5)		30.4
Trade name	408.1		(234.3)		173.8		408.2		(219.9)		188.3
Land use right	10.8		(6.2)		4.6		10.9		(5.5)		5.4
Canadian licenses	459.7		—		459.7		480.3		—		480.3
	$	5,848.1	$	(1,970.9)	$	3,877.2	$	5,885.6	$	(1,851.1)	$	4,034.5

Three Months Ended June 30, 2019 Six Months Ended June 30, 2019
Operating lease cost $ 59.9
$ 110.8

Finance lease cost:

Amortization of ROU assets $ 1.5
$ 2.9
Interest on lease liabilities 0.4
1.2
Total finance lease cost $ 1.9
$ 4.1
The Company recorded a non-cash charge of $2.7 for the impairment of a CDD tradename during the six months ended June 30, 2020.

Amortization of intangible assets for the three months ended June 30, 2020 and 2019, was $60.1 and $60.2, respectively and for the six months ended June 30, 2020 and 2019 was $122.4 and $117.3, respectively. Amortization expense for the net carrying amount of intangible assets is estimated to be $118.2 for the remainder of fiscal 2020, $235.6 in fiscal 2021, $229.6 in fiscal 2022, $224.2 in fiscal 2023, $219.2 in fiscal 2024, and $2,311.1 thereafter.

7. DEBT

Short-term borrowings and the current portion of long-term debt at June 30, 2020, and December 31, 2019, consisted of the following:


	June 30, 2020		December 31, 2019

4.625% senior notes due 2020	$	414.6	$	413.7
2019 Term Loan	375.0		—
Debt issuance costs	(1.0)		(0.7)
Current portion of note payable	2.2		2.2
Total short-term borrowings and current portion of long-term debt	$	790.8	$	415.2

~~Supplemental cash flow information related to leases was as follows:~~

Six Months Ended June 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases $ (115.2 )
Operating cash flows from finance leases (0.9 )
Financing cash flows from finance leases (4.8 )

ROU assets obtained in exchange for lease obligations:
Operating leases $ 43.7
Finance leases 0.2

~~Supplemental balance sheet information related to leases was as follows:~~

June 30, 2019
Operating Leases
Operating lease ROU assets (included in Property, plant and equipment, net) $ 770.3

Short-term operating lease liabilities 229.2
Operating lease liabilities 586.1
Total operating lease liabilities $ 815.3

June 30, 2019
Finance Leases
Finance lease ROU assets (included in Other assets) $ 85.4

Short-term finance lease liabilities $ 8.2
Finance lease liabilities 46.2
Total finance lease liabilities $ 54.4

Weighted Average Remaining Lease Term
Operating leases 5.8
Finance leases 6.5

Weighted Average Discount Rate
Operating leases 4.2 %
Finance leases 4.8 %

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

~~Maturities of lease liabilities are as follows:~~

Six Months Ended June 30, 2019 Operating Leases Finance Leases

2019 $ 254.1
$ 7.1
2020 274.7
13.8
2021 174.6
12.0
2022 69.3
10.8
2023 45.1
10.7
Thereafter 153.1
34.5
Total lease payments 970.9
88.9
Less imputed interest (155.6 ) (34.5 )
Total $ 815.3
$ 54.4

~~Rental expense for short term leases with a term less than one year for the three and six months ended~~Long-term debt at June 30, ~~2019, amounted to $2.6~~2020, and $5.9, respectively. The Company has variable lease payments that do not depend on a rate or index, primarily for purchase volume commitments, which are recorded as variable cost when incurred. Total variable payments for the three and six months ended June 30, 2019, were $4.7 and $9.2, respectively. As of June 30, 2019, the Company has entered into approximately 50 additional operating leases, primarily for patient service centers, that have not yet commenced and are not significant to the overall lease portfolio. These operating leases will commence later in 2019 with lease terms ranging from less than a year to 11 years.

~~The Company leases various facilities and equipment under non-cancelable lease arrangements. Future minimum rental commitments for leases with non-cancelable terms of one year or more at~~ December 31, ~~2018, under Accounting Standards Codification 840 are as follows:~~

Year Ended December 31, Operating Leases Finance Leases

2019 $ 191.1
$ 8.6
2020 145.4
8.0
2021 107.0
6.7
2022 80.9
6.0
2023 61.5
6.5
Thereafter 155.6
23.1

~~Rental expense, which includes rent for real estate, equipment and automobiles under operating leases, amounted to $85.1 and $167.5, respectively, for the three and six months ended June 30, 2019.~~


8.	~~DEBT~~

~~Short-term borrowings and the current portion of long-term debt at~~ ~~June 30,~~ 2019,~~, and~~ ~~December 31, 2018~~, consisted of the following:

June 30,
2019 December 31, 2018
Zero-coupon convertible subordinated notes $ 1.4
$ 8.7
2.625% senior notes due 2020 500.0
—
Debt issuance costs (1.0 ) (0.5 )
Current portion of note payable 1.9
1.8
Total short-term borrowings and current portion of long-term debt $ 502.3
$ 10.0

~~INDEX~~

~~LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(dollars and shares in millions, except per share data)~~

~~Long-term debt at~~ ~~June 30, 2019, and~~ ~~December 31, 2018, consisted of the following:~~

June 30,
2019 December 31, 2018
2.625% senior notes due 2020 $ —
$ 500.0
4.625% senior notes due 2020 603.7
596.9
3.20% senior notes due 2022 500.0
500.0
3.75% senior notes due 2022 500.0
500.0
4.00% senior notes due 2023 300.0
300.0
3.25% senior notes due 2024 600.0
600.0
3.60% senior notes due 2025 1,000.0
1,000.0
3.60% senior notes due 2027 600.0
600.0
4.70% senior notes due 2045 900.0
900.0
Revolving credit facility 35.0
—
2019 Term loan 850.0
—
2017 Term loan 277.0
527.0
Debt issuance costs (37.1 ) (40.2 )
Note payable 6.4
7.2
Total long-term debt $ 6,135.0
$ 5,990.9

~~Senior Notes~~

During the third quarter of 2013, the Company entered into two fixed-to-variable interest rate swap agreements for its 4.625% senior notes due 2020 with an aggregate notional amount of $600.0 and variable interest rates based on one-month LIBOR plus 2.298% to hedge against changes in the fair value of a portion of the Company's long-term debt. These derivative financial instruments are accounted for as fair value hedges of the senior notes due 2020. These interest rate swaps are included in other long-term assets or other long-term liabilities, as applicable, and added to or subtracted from the value of the senior notes, with an aggregate fair value asset of $~~3.7~~ at ~~June 30, 2019, and an aggregate fair value liability of~~ ~~$3.1~~ at ~~December 31, 2018~~.

~~Zero-Coupon Subordinated Notes~~

On March 11, 2019, the Company announced that for the period from March 11, 2019, to September 10, 2019, the zero-coupon subordinated notes will accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a zero-coupon subordinated note for the five trading days ended August 27, 2019, in addition to the continued accrual of the original issue discount.

During the six months ended June 30, 2019, the Company settled notices to convert $7.7 aggregate principal amount of its zero-coupon subordinated notes with a conversion value of $14.5. The total cash used for these settlements was $7.3. As a result of these conversions, the Company also reversed deferred tax liabilities of $1.7.

On July 1, 2019, the Company announced that its zero-coupon subordinated notes may be converted into cash and common stock at the conversion rate of 13.4108 per $1,000.0 principal amount at maturity of the notes, subject to the terms of the zero-coupon subordinated notes and the Indenture, dated as of October 24, 2006, between the Company and The Bank of New York Mellon, as trustee and the conversion agent. In order to exercise the option to convert all or a portion of the zero-coupon subordinated notes, holders are required to validly surrender their zero-coupon subordinated notes at any time during the calendar quarter beginning July 1, 2019, through the close of business on the last business day of the calendar quarter, which is 5:00 p.m., New York City time, on Monday, September 30, 2019. If notices of conversion are received, the Company plans to settle the cash portion of the conversion obligation with cash on hand and/or borrowings under its revolving credit facility.


	June 30, 2020		December 31, 2019



3.20% senior notes due 2022	$	500.0	$	500.0
3.75% senior notes due 2022	500.0		500.0
4.00% senior notes due 2023	300.0		300.0
3.25% senior notes due 2024	600.0		600.0
3.60% senior notes due 2025	1,000.0		1,000.0
3.60% senior notes due 2027	600.0		600.0
4.70% senior notes due 2045	900.0		900.0
2.30% senior notes due 2024	400.0		400.0
2.95% senior notes due 2029	650.0		650.0

2019 Term Loan	—		375.0

Debt issuance costs	(39.8)		(42.2)

Note payable	6.4		7.0
Total long-term debt	$	5,416.6	$	5,789.8

Credit Facilities

On June 3, 2019, the Company entered into a new $850.0 ~~term loan facility in addition to its $750.02017 term loan facility.The~~ 2019 term loan facility ~~will mature~~that matures on June 3, 2021. Proceeds of the 2019 term loan facility were used for general corporate purposes, including to repay approximately $250.0 of the 2017 term loan facility and in connection with the acquisition of Envigo's nonclinical research services business. This net change of $600.0 represents the only contractual obligation as of June 30, 2019, that materially changed from December 31, 2018.

The 2019 term loan facility accrues interest at a per annum rate equal to, at the Company's election, either a LIBOR rate plus a margin ranging from 0.55% to 1.175%, or a base rate determined according to a prime rate or federal funds rate plus a margin ranging from 0.0% to 0.175%. The 2019 term loan balance at June 30, 2020 and December 31, 2019, was ~~$850.0.~~$375.0 and $375.0, respectively. As of June 30, ~~2019,~~2020, the effective interest rate on the 2019 term loan was ~~3.24%~~0.98%.

~~INDEX~~

~~LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(dollars and shares in millions, except per share data)~~

On September 15, 2017, the Company entered into a $750.0 term loan facility in addition to its then existing $1,000.0 term loan entered into in December 2014. The 2017 term loan facility will mature on September 15, 2022. The Company paid off the 2014 term loan during the second quarter of 2018.

The 2017 term loan facility accrues interest at a per annum rate equal to, at the Company's election, either a LIBOR rate plus a margin ranging from 0.875% to 1.50%, or a base rate determined according to a prime rate or federal funds rate plus a margin ranging from 0.0% to 0.50%. The 2017 term loan balance at June 30, 2019, was $277.0 and at December 31, 2018, was $527.0. As of June 30, 2019, the effective interest rate on the 2017 term loan was 3.56%.

The Company ~~entered into~~also maintains a senior ~~unsecured~~ revolving credit facility on December 21, 2011, which was amended and restated on December 19, 2014, further amended on July 13, 2016, and further amended and restated on September 15, 2017. The revolving credit facility consistsconsisting of a five-year ~~revolving~~ facility in the principal amount of up to $1,000.0, with the option of increasing the facility by up to an additional $350.0, subject to the agreement of one or more new or existing lenders to provide such additional amounts and certain other customary conditions. The revolving credit facility also provides for a subfacility of up to $100.0 for swing line borrowings and a subfacility of up to $150.0 for issuances of letters of credit. The Company is required to pay a facility fee on the aggregate commitments under the revolving credit facility, at a per annum rate ranging from 0.00% to 0.25%. The revolving credit facility is permitted to be used for general corporate purposes, including working capital, capital expenditures, funding of share repurchases and certain other payments, ~~and~~ acquisitions and other investments. ~~The Company had $35.0~~There were no balances outstanding on ~~its~~the Company's current revolving credit facility at June 30, ~~2019,~~2020, and ~~no outstanding balance on~~ December 31, ~~2018.~~

~~Advances under~~2019. As of June 30, 2020, the effective interest rate on the revolving credit facility will accrue interest at a per annum rate equal to, at the Company’s election, either a LIBOR rate plus a margin ranging from 0.775% to 1.25%, or a base rate determined according to a prime rate or federal funds rate plus a margin ranging from 0.00% to 0.25%was 1.14%. ~~Fees are payable on outstanding letters of credit under the revolving~~The credit facility ~~at a per annum rate equal to the applicable margin for LIBOR loans, and the Company is required to pay a facility fee~~expires on ~~the aggregate commitments under the revolving credit facility, at a per annum rate ranging from 0.10% to 0.25%.~~

The interest margin applicable to the term loan and credit facilities, and the facility fee and letter of credit fees payable under the revolving credit facility, are based on the Company’s senior credit ratings as determined by Standard & Poor’s and Moody’s.September 15, 2022.

Under the term loan ~~facilities~~facility and the revolving credit facility, the Company is subject to negative covenants limiting subsidiary indebtedness and certain other covenants typical for investment grade-rated borrowers, and the Company is required to maintain certain leverage ratios. In May 2020, the Company entered into amendments to its term loan facility and its revolving credit facility, in each case to, among other things, increase the maximum leverage ratio covenant to 5.0x debt to last twelve months EBITDA for each of the three periods ended June 30, September 30, and December 31, 2020, 4.5x for period ended March 31, 2021 and then reverts back to 4.0x. The Company was in compliance with all covenants in the term loan ~~facilities~~facility and the revolving credit facility at June 30, ~~2019. As of June 30, 2019,~~2020 and expects that it will remain in compliance with its existing debt covenants for the ~~ratio of total debt to consolidated proforma trailing 12 month EBITDA was 3.4 to 1.0.~~next twelve months.

~~As of June 30, 2019, the Company had provided letters of credit aggregating approximately $72.2, primarily in connection with certain insurance programs.~~ The Company's availability of ~~$892.8~~$997.0 at June 30, ~~2019,~~2020, under its revolving credit facility ~~is reduced by~~reflects a reduction equivalent to the amount of ~~these~~the Company's outstanding letters of credit.

Liquidity

~~9. PREFERRED STOCK AND COMMON SHAREHOLDERS’ EQUITY~~

During the fourth quarter of 2020, $412.2 of the Company's senior notes mature. The Company ~~is authorized~~has elected to ~~issue up to~~ ~~265.0~~ ~~shares of common stock,~~redeem these notes in August 2020 at par ~~value~~ ~~$0.10~~ ~~per share. The Company’s treasury shares were recorded at aggregate cost~~using from available cash on hand and ~~were retired during the second quarter of 2019. The Company is authorized to issue up to~~ ~~30.0~~ ~~shares of preferred stock, par value~~ ~~$0.10~~ ~~per share. There were~~ no ~~preferred shares outstanding as of~~ borrowings under its revolving credit facility.

At June 30, ~~2019~~,2020, the Company had $557.0 of cash and $997.0 of available borrowings under its revolving credit facility, which does not mature until 2022, and the Company was in compliance with all of its debt covenants. In May 2020, in order to obtain increased financial covenant flexibility, the Company and its lenders entered into amendments to the term loan facility and the revolving credit facility to increase the maximum leverage ratio to 5.0x debt to last twelve months EBITDA for the three month periods ending June 30, September 30 and December 31, ~~2018.~~

2020 and 4.5x for the period ended March 31, 2021. The ~~changes~~amendments also provide that during any period in ~~common shares issued and held in treasury are summarized below:~~

Issued Held in Treasury Outstanding
Common shares at December 31, 2018 122.4
(23.5 ) 98.9
Common stock issued under employee stock plans 1.0
—
1.0
Surrender of restricted stock and performance share awards —
(0.1 ) (0.1 )
Retirement of common stock (2.0 ) —
(2.0 )
Retirement of treasury stock (23.6 ) 23.6
—
Common shares at June 30, 2019 97.8
—
97.8

~~Share Repurchase Program~~

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

EBITDA (i) the Company will be prohibited from consummating share repurchases, subject to limited exceptions, (ii) borrowings under the revolving credit facility will accrue interest at a per annum rate equal to, at the Company's election, either a LIBOR rate plus a margin of 1.25% or a base rate plus a margin of 0.25%, (iii) the facility fee that the Company is required to pay on the aggregate commitments under the revolving credit facility will be 0.25% per annum, and (iv) borrowings under the term loan facility will accrue interest at a per annum rate equal to, at the Company's election, either a LIBOR rate plus a margin of 1.175% or a base rate plus a margin of 0.175%.

~~has no expiration.~~The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business and the effects such impacts will have on the Company's liquidity.The significance of the impact on the Company’s business is not yet certain and depends on numerous evolving factors that the Company may not be able to accurately predict.

8. PREFERRED STOCK AND COMMON SHAREHOLDERS’ EQUITY

The Company is authorized to issue up to 265.0 shares of common stock, par value $0.10 per share. The Company is authorized to issue up to 30.0 shares of preferred stock, par value $0.10 per share. There were 0 preferred shares outstanding as of June 30, 2020 and December 31, 2019.

The changes in common shares issued are summarized below:


			Issued and Outstanding
Common shares at December 31, 2019			97.2
Common stock issued under employee stock plans			0.6


Retirement of common stock			(0.5)

Common shares at June 30, 2020			97.3

Share Repurchase Program

At the end of 2019, the Company had outstanding authorization from the board of directors to purchase $900.0 of Company common stock. During ~~the~~ three months ended ~~June 30, 2019,~~March 31, 2020, the Company purchased ~~1.3~~0.6 shares of its common ~~stock at an average price~~stock. When the Company repurchases shares, the amount paid to repurchase the shares in excess of ~~$159.13 for~~the par or stated value is allocated to additional paid-in-capital unless subject to limitation or the balance in additional paid-in-capital is exhausted. Remaining amounts are recognized as a ~~total cost of $199.9.~~reduction in retained earnings. As of June 30, ~~2019,~~2020, the Company had outstanding authorization from the board of directors to purchase up to ~~$1.05 billion~~$800.0 of the Company's common stock. The repurchase authorization has no expiration date; however, the Company temporarily suspended stock repurchases beginning in March 2020 due to the impact of the COVID-19 pandemic.

Accumulated Other Comprehensive Earnings

The components of accumulated other comprehensive earnings (loss) are as follows:

Foreign Currency
Translation
Adjustments

Net Benefit
Plan Adjustments

Accumulated Other
Comprehensive
Earnings (Loss)
Balance at December 31, 2018 $ (389.8 ) $ (73.3 ) $ (463.1 )
Other comprehensive earnings before reclassifications 47.2
5.5
52.7
Tax effect of adjustments —
(1.5 ) (1.5 )
Balance at June 30, 2019 $ (342.6 ) $ (69.3 ) $ (411.9 )


	Foreign Currency Translation Adjustments		Net Benefit Plan Adjustments		Accumulated Other Comprehensive Earnings (Loss)
Balance as of December 31, 2019	$	(285.4)	$	(87.0)	$	(372.4)
Current year adjustments	(80.5)		5.4		(75.1)

Tax effect of adjustments	—		(1.5)		(1.5)
Balance as of June 30, 2020	$	(365.9)	$	(83.1)	$	(449.0)


~~10.~~	~~INCOME TAXES~~

9. INCOME TAXES

The Company does not recognize a tax benefit unless ~~the Company~~it concludes that it is more likely than not that the benefit will be sustained on audit by the taxing authority based solely on the technical merits of the associated tax position. If the recognition threshold is met, the Company recognizes a tax benefit measured at the largest amount of the tax benefit that ~~the Company~~it believes is greater than 50% likely to be realized.

The gross unrecognized income tax benefits were ~~$25.6~~$40.4 and ~~$18.0~~$31.7 at June 30, ~~2019,~~2020 and December 31, ~~2018,~~2019, respectively. It is anticipated that the amount of the unrecognized income tax benefits will change within the next 12 months; however, these changes are not expected to have a significant impact on the results of operations, cash flows or the financial position of the Company.

As of June 30, ~~2019,~~2020 and December 31, ~~2018, $25.6~~2019, $40.4 and ~~$18.0,~~$31.7, respectively, are the approximate amounts of gross unrecognized income tax benefits that, if recognized, would favorably affect the effective income tax rate in future periods.

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

The Company recognizes interest and penalties related to unrecognized income tax benefits in income tax expense. Accrued interest and penalties related to uncertain tax positions totaled ~~$10.3~~$8.2 and ~~$8.7~~$5.5 as of June 30, ~~2019,~~2020 and December 31, ~~2018,~~2019, respectively.

The Company has substantially concluded all U.S. federal income tax matters for years through ~~2014.~~2015. Substantially all material state and local and foreign income tax matters have been concluded through ~~2013~~2014 and ~~2014,~~2010, respectively.

~~The IRS has not initiated a new examination of any of the Company's federal income tax returns.~~ The Company has various state and foreign income tax examinations ongoing throughout the year. The Company believes adequate provisions have been recorded related to all open tax years.


~~11.~~	~~COMMITMENTS AND CONTINGENCIES~~

10. COMMITMENTS AND CONTINGENCIES

The Company is involved from time to time in various claims and legal actions, including arbitrations, class actions, and other litigation (including those described in more detail below), arising in the ordinary course of business. Some of these actions involve claims that are substantial in amount. These matters include, but are not limited to, intellectual property disputes; commercial and contract disputes; professional liability claims; employee-related matters; and inquiries, including subpoenas and other civil investigative demands, from governmental agencies, Medicare or Medicaid payers and MCOs reviewing billing practices or requesting comment on allegations of billing irregularities that are brought to their attention through billing audits or third parties. The Company receives civil investigative demands or other inquiries from various governmental bodies in the ordinary course of its business. Such inquiries can relate to the Company or other parties, including physicians and other health care providers. The Company works cooperatively to respond to appropriate requests for information.

The Company also is named from time to time in suits brought under the qui tam provisions of the False Claims Act and comparable state laws. These suits typically allege that the Company has made false statements and/or certifications in connection with claims for payment from U.S. federal or state healthcare programs. The suits may remain under seal (hence, unknown to the Company) for some time while the government decides whether to intervene on behalf of the qui tam plaintiff. Such claims are an inevitable part of doing business in the healthcare field today.

~~INDEX~~

~~LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(dollars and shares in millions, except per share data)~~

The Company believes that it is in compliance in all material respects with all statutes, regulations, and other requirements applicable to its commercial laboratory operations and drug development support services. The healthcare diagnostics and drug development industries are, however, subject to extensive regulation, and the courts have not interpreted many of the applicable statutes and regulations. Therefore, the applicable statutes and regulations could be interpreted or applied by a prosecutorial, regulatory, or judicial authority in a manner that would adversely affect the Company. Potential sanctions for violation of these statutes and regulations include significant civil and criminal penalties, fines, the loss of various licenses, certificates and authorizations, additional liabilities from third-party claims, and/or exclusion from participation in government programs.

Many of the current claims and legal actions against the Company are in preliminary stages, and many of these cases seek an indeterminate amount of damages. The Company records an aggregate legal reserve, which is determined using calculations based on historical loss rates and assessment of trends experienced in settlements and defense costs. In accordance with FASB Accounting Standards Codification Topic 450 “Contingencies,” the Company establishes reserves for judicial, regulatory, and arbitration matters outside the aggregate legal reserve if and when those matters present loss contingencies that are both probable and estimable and would exceed the aggregate legal reserve. When loss contingencies are not both probable and estimable, the Company does not establish separate reserves.

The Company is unable to estimate a range of reasonably probable loss for the proceedings described in more detail below in which damages either have not been specified or, in the Company's judgment, are unsupported and/or exaggerated and (i) the proceedings are in early stages; (ii) there is uncertainty as to the outcome of pending appeals or motions; (iii) there are significant factual issues to be resolved; and/or (iv) there are novel legal issues to be presented. For these proceedings, however, the Company does not believe, based on currently available information, that the outcomes will have a material adverse effect on the Company's financial condition, though the outcomes could be material to the Company's operating results for any particular period, depending, in part, upon the operating results for such period.

As previously reported, the Company responded to an October 2007 subpoena from the U.S. Department of Health & Human Services Office of Inspector General's regional office in New York. On August 17, 2011, the U.S. District Court for the Southern District of New York unsealed a False Claims Act lawsuit, United States of America ex rel. NPT Associates v. Laboratory Corporation of America Holdings, which alleges that the Company offered UnitedHealthcare kickbacks in the form of discounts in return for Medicare business. The Plaintiff's Third Amended Complaint further alleges that the Company's billing practices violated the False Claims Acts of 14 states and the District of Columbia. The lawsuit seeks actual and treble damages and civil penalties for each alleged false claim, as well as recovery of costs, attorney's fees, and legal expenses.

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

Neither the U.S. government nor any state government has intervened in the lawsuit. The Company's Motion to Dismiss was granted in October 2014 and Plaintiff was granted the right to replead. On January 11, 2016, Plaintiff filed a motion requesting leave to file an amended complaint under seal and to vacate the briefing schedule for the Company's Motion to Dismiss, while the government reviews the amended complaint. The Court granted the motion and vacated the briefing dates. Plaintiff then filed the Amended Complaint under seal. The Company will vigorously defend the lawsuit.

In addition, the Company has received various other subpoenas since 2007 related to Medicaid billing. In October 2009, the Company received a subpoena from the State of Michigan Department of Attorney General seeking documents related to its billing to Michigan Medicaid. The Company cooperated with this request. In October 2013, the Company received a Civil Investigative Demand from the State of Texas Office of the Attorney General requesting documents related to its billing to Texas Medicaid. The Company cooperated with this request. On October 5, 2018, the Company received a second Civil Investigative Demand from the State of Texas Office of the Attorney General requesting documents related to its billing to Texas Medicaid. The Company is cooperating with this request.

On ~~May 2, 2013, the Company was served with a False Claims Act lawsuit,~~ ~~State of Georgia ex rel. Hunter Laboratories, LLC~~ ~~and~~ ~~Chris Riedel v. Quest Diagnostics Incorporated, et al.~~, filed in the State Court of Fulton County, Georgia. The lawsuit, filed by a competitor laboratory, alleges that the Company overcharged Georgia's Medicaid program. The State of Georgia filed a Notice of Declination on August 13, 2012, before the Company was served with the complaint. The case was removed to the U.S. District Court for the Northern District of Georgia. The lawsuit sought actual and treble damages and civil penalties for each alleged false claim, as well as recovery of costs, attorney's fees, and legal expenses. On March 14, 2014, the Company's Motion to Dismiss was granted. The Plaintiffs repled their complaint, and the Company filed a Motion to Dismiss the First Amended Complaint. In May 2015, the Court dismissed the Plaintiffs' anti-kickback claim and remanded the remaining state law claims to the State Court of Fulton County. In July 2015, the Company filed a Motion to Dismiss these remaining claims. The Plaintiffs filed an opposition to the Company's Motion to Dismiss in August 2015. Also, the State of Georgia filed a brief as amicus curiae. In May, 2019, the parties settled the lawsuit.

On August 31, 2015, the Company was served with a putative class action lawsuit, Patty Davis v. Laboratory Corporation of America, et al., filed in the Circuit Court of the Thirteenth Judicial Circuit for Hillsborough County, Florida. The complaint alleges

~~INDEX~~

~~LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(dollars and shares in millions, except per share data)~~

that the Company violated the Florida Consumer Collection Practices Act by billing patients who were collecting benefits under the Workers' Compensation Statutes. The lawsuit seeks injunctive relief and actual and statutory damages, as well as recovery of attorney's fees and legal expenses. In April 2017, the Circuit Court granted the Company’s Motion for Judgment on the Pleadings. The Plaintiff ~~has~~ appealed the Circuit Court’s ruling to the Florida Second District Court of Appeal. On October 16, 2019, the Court of Appeal reversed the Circuit Court’s dismissal, but certified a controlling issue of Florida law to the Florida Supreme Court. On February 17, 2020, the Florida Supreme Court accepted jurisdiction of the lawsuit. The Company will vigorously defend the lawsuit.

In December 2014, the Company received a Civil Investigative Demand issued pursuant to the U.S. False Claims Act from the U.S. Attorney's Office for South Carolina, which requested information regarding alleged remuneration and services provided by the Company to physicians who also received draw and processing/handling fees from competitor laboratories Health Diagnostic Laboratory, Inc. (HDL) and Singulex, Inc. (Singulex). The Company cooperated with the request. On April 4, 2018, the U.S. District Court for the District of South Carolina, Beaufort Division, unsealed a False Claims Act lawsuit, United States of America ex rel. Scarlett Lutz, et al. v. Laboratory Corporation of America Holdings, which alleges that the Company's financial relationships with referring physicians violate federal and state anti-kickback statutes. The Plaintiffs' Fourth Amended Complaint further alleges that the Company conspired with HDL and Singulex in violation of the Federal False Claims Act and the California and Illinois insurance fraud prevention acts by facilitating HDL's and Singulex's offers of illegal inducements to physicians and the referral of patients to HDL and Singulex for laboratory testing. The lawsuit seeks actual and treble damages and civil penalties for each alleged false claim, as well as recovery of costs, attorney's fees, and legal expenses. Neither the U.S. government nor any state government has intervened in the lawsuit. The Company filed a Motion to Dismiss seeking the dismissal of the claims asserted under the California and Illinois insurance fraud prevention statutes, the conspiracy claim, the reverse False Claims Act claim, and all claims based on the theory that the Company performed medically unnecessary testing. On January 16, 2019, the Court entered an order granting in part and denying in part the Motion to Dismiss. The Court dismissed the Plaintiffs' claims based on the theory that the Company performed medically unnecessary testing, the claims asserted under the California and Illinois insurance fraud prevention statutes, and the reverse False Claims Act claim. The Court denied the Motion to Dismiss as to the conspiracy claim. The Company will vigorously defend the lawsuit.

~~On August 3, 2016, the Company was served with a putative class action lawsuit,~~ ~~Daniel L. Bloomquist v. Covance Inc., et al.~~, filed in the Superior Court of California, County of San Diego. The Complaint alleges that Covance Inc. violated the California Labor Code and California Business & Professions Code by failing to provide overtime wages, failing to provide meal and rest periods, failing to pay for all hours worked, failing to pay for all wages owed upon termination, and failing to provide accurate itemized wage statements to Clinical Research Associates and Senior Clinical Research Associates employed by Covance in California. The lawsuit seeks monetary damages, civil penalties, injunctive relief, and recovery of attorney's fees and costs. On October 13, 2016, the case was removed to the U.S. District Court for the Southern District of California. On May 3, 2017, the U.S. District Court for the Southern District of California remanded the case to the Superior Court. The Company will vigorously defend the lawsuit.

Prior to the Company's acquisition of Sequenom, Inc. (Sequenom) between August 15, 2016 and August 24, 2016, six putative class-action lawsuits were filed on behalf of purported Sequenom stockholders (captioned Malkoff v. Sequenom, Inc., et al., No. 16-cv-02054- JAH-BLM, Gupta v. Sequenom, Inc., et al., No. 16-cv-02084-JAH-KSC, Fruchter v. Sequenom, Inc., et al., No. 16-cv-02101- WQH-KSC, Asiatrade Development Ltd. v. Sequenom, Inc., et al., No. 16-cv-02113-AJB-JMA, Nunes v. Sequenom, Inc., et al., No. 16-cv-02128-AJB-MDD, and Cusumano v. Sequenom, Inc., et al., No. 16-cv-02134-LAB-JMA) in the U.S. District Court for the Southern District of California challenging the acquisition transaction. The complaints asserted claims against Sequenom and members of its board of directors (the Individual Defendants). The Nunes action also named the Company and Savoy Acquisition Corp. (Savoy), a wholly owned subsidiary of the Company, as defendants. The complaints alleged that the defendants violated Sections 14(e), 14(d)(4) and 20 of the Securities Exchange Act of 1934 by failing to disclose certain allegedly material information. In addition, the complaints in the Malkoff action, the Asiatrade action, and the Cusumano action alleged that the Individual Defendants breached their fiduciary duties to Sequenom shareholders. The actions sought, among other things, injunctive relief enjoining the merger. On August 30, 2016, the parties entered into a Memorandum of Understanding (MOU) in each of the above-referenced actions. On September 6, 2016, the Court entered an order consolidating for all pre-trial purposes the six individual actions described above under the caption In re Sequenom, Inc.

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

Shareholder Litig., Lead Case No. 16-cv-02054-JAH-BLM, and designating the complaint from the Malkoff action as the operative complaint for the consolidated action. On November 11, 2016, two competing motions were filed by two separate stockholders (James Reilly and Shikha Gupta) seeking appointment as lead plaintiff under the terms of the Private Securities Litigation Reform Act of 1995. On June 7, 2017, the Court entered an order declaring Mr. Reilly as the lead plaintiff and approving Mr. Reilly's selection of lead counsel. The parties agree that the MOU has been terminated. The Plaintiffs filed a Consolidated Amended Class Action Complaint on July 24, 2017, and the Defendants filed a Motion to Dismiss, which remains pending. On March 13, 2019, the Court stayed the action in its entirety pending the U.S. Supreme Court's anticipated decision in Emulex Corp. v. Varjabedian. On April 23, 2019, however, the U.S.

~~INDEX~~

~~LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(dollars and shares in millions, except per share data)~~

Supreme Court dismissed the writ of certiorari in Emulex as improvidently granted. The Company will vigorously defend the lawsuit.

On March 10, 2017, the Company was served with a putative class action lawsuit, Victoria Bouffard, et al. v. Laboratory Corporation of America Holdings, filed in the U.S. District Court for the Middle District of North Carolina. The complaint alleges that the Company's patient list prices unlawfully exceed the rates negotiated for the same services with private and public health insurers in violation of various state consumer protection laws. The lawsuit also alleges breach of implied contract or quasi-contract, unjust enrichment, and fraud. The lawsuit seeks statutory, exemplary, and punitive damages, injunctive relief, and recovery of attorney's fees and costs. In May 2017, the Company filed a Motion to Dismiss Plaintiffs' Complaint and Strike Class Allegations; the Motion to Dismiss was granted in March 2018 without prejudice. On October 10, 2017, a second putative class action lawsuit, Sheryl Anderson, et al. v. Laboratory Corporation of America Holdings, was filed in the U.S. District Court for the Middle District of North Carolina. The complaint contained similar allegations and sought similar relief to the Bouffard complaint, and added additional counts regarding state consumer protection laws. On August 10, 2018, the Plaintiffs filed an Amended Complaint, which consolidated the Bouffard and Anderson actions. On September 10, 2018, the Company filed a Motion to Dismiss Plaintiffs' Amended Complaint and Strike Class ~~Allegations, which remains pending.~~Allegations. On August 16, 2019, the court entered an order granting in part and denying in part the Motion to Dismiss the Amended Complaint, and denying the Motion to Strike the Class Allegations. The Company will vigorously defend the lawsuit.

~~On September 7, 2017, the Company was served with a putative class action lawsuit,~~ ~~John Sealock, et al. v. Covance Market Access Services, Inc~~., filed in the U.S. District Court for the Southern District of New York. The complaint alleged that Covance Market Access Services, Inc. violated the Fair Labor Standards Act and New York labor laws by failing to provide overtime wages, failing to pay for all hours worked, and failing to provide accurate wage statements. The lawsuit sought monetary damages, civil penalties, injunctive relief, and recovery of attorney's fees and costs. In November 2017, the Company filed a Motion to Strike Class Allegations, which was denied. In December 2017, the Plaintiff filed a Motion for Conditional Certification of a Collective Action, which was granted in May 2018. In December 2018, Plaintiff filed, and the Court granted, a second motion to conditionally certify an expanded class to a nationwide class action. This matter has been settled in principle and the settlement is subject to judicial review and approval.

On July 16, 2018, the Company reported that it had detected suspicious activity on its information technology network and was taking steps to respond to and contain the activity. The activity was subsequently determined to be a new variant of ransomware affecting certain LCD information technology systems. As part of its response, the Company took certain systems offline, which temporarily affected test processing and customer access to test results, and also affected certain other information technology systems involved in conducting Company-wide operations. Operations were returned to normal within a few days of the incident. As part of its in-depth investigation into this incident, the Company engaged outside security experts and worked with authorities, including law enforcement. The investigation determined that the ransomware did not and could not transfer patient or client data outside of Company systems and that there was no theft or misuse of patient or client data. The Company cooperated with law enforcement and regulatory authorities with respect to the incident.

The Company has insurance coverage for costs resulting from cyber-attacks and has filed a claim for recovery of its losses resulting from this incident. However, disputes over the extent of insurance coverage for claims are not uncommon and the Company has not recognized any estimated proceeds resulting from this claim. Furthermore, while the Company has not been the subject of any legal proceedings involving this incident, it is possible that the Company could be the subject of claims from persons alleging they suffered damages from the incident, or actions by governmental authorities.

~~On September 10, 2018, the Company was served with a Labor Code Private Attorneys General Act (LCPAGA) lawsuit,~~ ~~Terri Wilson v. Laboratory Corporation of America Holdings~~, which was filed in the U.S. District Court for the Northern District of California. Plaintiff alleged claims for failure to pay meal and rest break premiums, failure to provide compliant wage statements, failure to compensate employees for all hours worked, and failure to pay wages upon termination of employment. Plaintiff asserted these actions violated various California Labor Code provisions and constituted an unfair competition practice under California law. The lawsuit sought monetary damages, civil penalties, injunctive relief, and recovery of attorney's fees and costs. In June, 2019, the parties settled the lawsuit.

~~On September 21, 2018, the Company was served with a putative class action lawsuit,~~ ~~Alma Haro v. Laboratory Corporation of America, et al.~~, which was filed in the Superior Court of California, County of Los Angeles. Plaintiff alleges that employees were not properly paid overtime compensation, minimum wages, meal and rest break premiums, did not receive compliant wage statements, and were not properly paid wages upon termination of employment. Plaintiff asserts these actions violate various California Labor Code provisions and constitute an unfair competition practice under California law. The lawsuit seeks monetary damages, civil penalties, and recovery of attorney's fees and costs. The Company will vigorously defend the lawsuit.

~~On December 20, 2018, the Company was served with a putative class action lawsuit,~~ ~~Feckley v. Covance Inc., et al~~., filed in the Superior Court of California, County of Orange. The complaint alleges that Covance Inc. violated the California Labor Code and California Business & Professions Code by failing to properly pay commissions to employees under a sales incentive

~~INDEX~~

~~LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(dollars and shares in millions, except per share data)~~

compensation plan upon their termination of employment. The lawsuit seeks monetary damages, civil penalties, punitive damages, and recovery of attorney’s fees and costs. On January 22, 2018, the case was removed to the U.S. District Court for the Central District of California. The Company will vigorously defend the lawsuit.

On April 1, 2019, Covance Research Products was served with a Grand Jury Subpoena issued by the Department of Justice (DOJ) in Miami, Florida requiring the production of documents related to the importation into the United States of live non-human primate shipments originating from or transiting through China, Cambodia, and/or Vietnam from April 1, 2014 through March 28, 2019. The Company is cooperating with the DOJ.

On April 4, 2019, Tri-Cities Laboratory (a joint venture that was acquired as part of the Pathology Associates Medical Laboratories transaction in May 2017) was served with a subpoena issued by the DOJ in Newark, New Jersey requiring the production of documents related to test orders and payments to various third party companies and individuals. The Company cooperated with the DOJ.

~~On April 22, 2019, the Company was served with a putative class action lawsuit,~~ ~~Kawa Orthodontics LLP, et al. v. Laboratory Corporation of America Holdings, et al.~~, filed in the U.S. District Court for the Middle District of Florida. The lawsuit alleges that on or about February 6, 2019, the defendants violated the U.S. Telephone Consumer Protection Act (TCPA) by sending unsolicited facsimiles to Plaintiff and at least 40 other recipients without the recipients' prior express invitation or permission. The lawsuit seeks the greater of actual damages or the sum of $0.0005 for each violation, subject to trebling under the TCPA, and injunctive relief. The Company filed a motion to dismiss the case on May 28, 2019. In response to the Motion to Dismiss, the Plaintiff filed an amended complaint, which contains additional allegations, including allegations related to another facsimile. The Company filed a Motion to Dismiss the amended complaint. The Company will vigorously defend the lawsuit.

On May 14, 2019, Retrieval-Masters Creditors Bureau, Inc. d/b/a American Medical Collection Agency (AMCA), an external collection agency, notified the Company about a security incident AMCA experienced that may have involved certain personal information about some of the Company’s patients (the AMCA Incident). The Company referred patient balances to AMCA only when direct collection efforts were unsuccessful. The Company’s systems were not impacted by the AMCA Incident. Upon learning of the AMCA Incident, the Company promptly stopped sending new collection requests to AMCA and stopped AMCA from continuing to work on any pending collection requests from the Company. AMCA informed the Company that it appeared that an unauthorized user had access to AMCA’s system between August 1, 2018 and March 30, 2019, and that AMCA could not rule out the possibility that personal information on AMCA’s system was at risk during that time period. Information on AMCA’s affected system from the Company may have included name, address, and balance information for the patient and person responsible for payment, along with the patient’s phone number, date of birth, referring physician, and date of service. The Company was later informed by AMCA that health insurance information may have been included for some individuals, and because some insurance carriers utilize the Social Security Number as a subscriber identification number, the Social Security Number for someindividuals may also have been affected. No ordered tests, laboratory test results, or diagnostic information from the Company were in the AMCA affected system. The Company notified individuals for whom it had a valid mailing address. For the individuals whose Social Security Number was affected, the notice included an offer to enroll in credit monitoring and identity protection services that will be provided free of charge for 24 months.

~~Eighteen~~Twenty-three putative class action lawsuits were filed against the Company related to the AMCA ~~Incident.~~Incident in various U.S. District Courts. Numerous similar lawsuits have been filed against other health care providers who used AMCA. ~~The~~These lawsuits ~~against~~have been consolidated into a multidistrict litigation in the District of New Jersey. On November 15, 2019, the Plaintiffs filed a Consolidated Class Action Complaint in the U.S. District Court of New Jersey. On January 22, 2020, the Company ~~were~~ filed ~~in various United States District Courts.~~Motions to Dismiss all claims. The ~~lawsuits~~consolidated Complaint generally ~~allege~~alleges that the Company did not adequately protect its patients’ data and ~~assert~~failed to timely notify those patients of the AMCA Incident. The Complaint asserts various causes of action, including but not limited to negligence, breach of implied contract, unjust enrichment, and the violation of state data protection statutes. The ~~lawsuits seek~~Complaint seeks damages on behalf of a class of all affected Company consumers. The attorneys for certain of the Plaintiffs filed a motion with the Judicial Panel on Multi-District Litigation (JPML) seeking to have all cases related to the AMCA Incident consolidated for pre-trial proceedings in a multi-district litigation. The JPML ordered the transfer of the cases to the District of New Jersey.customers. The Company will vigorously defend the multi-district litigation.

Certain governmental entities and individuals have requested information from the Company related to the AMCA Incident. The Company has received requests for information from United States Senators Robert Menendez and Cory A. Booker and from the Attorneys General of Colorado, Connecticut, Illinois, Florida, New York, and Indiana. The request from Indiana includes a Civil Investigative Demand, which requests certain documents from the Company. The Company also provided notice of the AMCA Incident to state and federal regulators where appropriate. The Company is cooperating with these requests.

~~On June 10, 2019, the Company was served with a class action lawsuit,~~ INDEX~~Ignacio v. Laboratory Corporation of America~~, filed in Superior Court of the State of California for the County of Los Angeles. Plaintiff alleges that non-exempt employees based in California were not properly paid overtime compensation, minimum wages, meal and rest break premiums, were not indemnified for business expenses, did not receive compliant wage statements, and were not properly paid wages upon termination of

~~INDEX~~

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

~~employment. Plaintiff~~The Company was served with a shareholder derivative lawsuit, Raymond Eugenio, Derivatively on Behalf of Nominal Defendant, Laboratory Corporation of America Holdings v. Lance Berberian, et al., filed in the Court of Chancery of the State of Delaware on April 23, 2020. The complaint asserts ~~these actions violate various California Labor Code provisions~~derivative claims on the Company’s behalf against the Company’s board of directors and ~~constitute~~certain executive officers. The complaint generally alleges that the defendants failed to ensure that the Company utilized proper cybersecurity safeguards and failed to implement a sufficient response to data security incidents, including the AMCA Incident. The complaint asserts derivative claims for breach of fiduciary duty and seeks relief including damages, certain disclosures, and certain changes to the Company’s internal governance practices. On June 2, 2020, the Company filed a Motion to Stay the lawsuit due to its overlap with the multi-district litigation referenced above. On July 2, 2020, the Company filed a Motion to Dismiss. On July 14, 2020, the court entered an ~~unfair competition practice under California law.~~order staying the lawsuit pending the resolution of the multi-district litigation. The lawsuit ~~seeks monetary damages, liquidated damages, injunctive relief, and recovery of attorney's fees and costs.~~will be vigorously defended.

Certain governmental entities have requested information from the Company related to the AMCA Incident. The Company ~~will vigorously defend~~received a request for information from the ~~lawsuit.~~Office for Civil Rights (OCR) of the Department of Health and Human Services. On April 28, 2020, OCR notified the Company of the closure of its inquiry. The Company has also received requests from a multi-state group of state Attorneys General and is cooperating with these requests for information.

Three putative class action lawsuits related to California wage and hour laws have been served on the Company. On September 21, 2018, the Company was served with a putative class action lawsuit, Alma Haro v. Laboratory Corporation of America, et al., filed in the Superior Court of California, County of Los Angeles. On June ~~26,~~10, 2019, the Company was served with a putative class action lawsuit, Ignacio v. Laboratory Corporation of America, filed in Superior Court of California, County of Los Angeles. On July 1, 2019, the Company was served with a putative class action lawsuit, Jan v. Laboratory Corporation of America, ~~was~~ filed in the Superior Court ~~for the State~~ of California, ~~for the~~ County of Sacramento. ~~Plaintiff alleges~~All three cases were subsequently removed to the U.S. District Court for the Central District of California, and then consolidated for all pre-trial proceedings. In the lawsuits, Plaintiffs allege that ~~non-exempt~~ employees ~~based in California~~ were not properly paid overtime compensation, minimum wages, meal and rest break premiums, did not receive compliant wage statements, and were not properly paid wages upon termination of employment. ~~Plaintiff asserts~~The Plaintiffs assert these actions violate various California Labor Code provisions and constitute an unfair competition practice under California law. The ~~lawsuit seeks~~lawsuits seek monetary damages, ~~liquidated damages, injunctive relief,~~civil penalties, and recovery of attorney's fees and costs. The parties reached a tentative settlement resolving the claims for all three cases. The settlement is subject to Court approval. If the settlement is not approved, the Company will vigorously defend the ~~lawsuit.~~lawsuits.

On July 1,30, 2019, the Company was served with a class action lawsuit, Mitchell v. Covance, Inc. et al., ~~was~~ filed in the ~~United States~~U.S. District Court for the Eastern District of Pennsylvania. Plaintiff alleges that certain individuals employed by Covance Inc. and Chiltern International Inc. were misclassified as exempt employees under the Fair Labor Standards Act and the Pennsylvania Minimum Wage Act and were thereby not properly paid overtime compensation. The lawsuit seeks monetary damages, liquidated damages, and recovery of attorneys’ fees and costs. On February 3, 2020, the Court denied without prejudice the Plaintiff's motion to conditionally certify a putative class action. The Company will vigorously defend the lawsuit.

On January 31, 2020, the Company was served with a putative class action lawsuit, Luke Davis and Julian Vargas, et al. v. Laboratory Corporation of America Holdings, filed in the U.S. District Court for the Central District of California. The lawsuit alleges that visually impaired patients are unable to use the Company's touchscreen kiosks at Company patient service centers in violation of the Americans with Disabilities Act and similar California statutes. The lawsuit seeks statutory damages, injunctive relief, and attorney's fees and costs. On March 20, 2020, the Company filed a Motion to Dismiss Plaintiffs' Complaint and to Strike Class Allegations. The Company will vigorously defend the lawsuit.

On May 14, 2020, the Company was served with a putative class action lawsuit, Jose Bermejo v. Laboratory Corporation of America filed in the Superior Court of California, County of Los Angeles Central District, alleging that certain non-exempt California-based employees were not properly compensated for driving time or properly paid wages upon termination of employment. The Plaintiff asserts these actions violate various California Labor Code provisions and Section 17200 of the Business and Professional Code. The lawsuit seeks monetary damages, civil penalties, and recovery of attorney’s fees and costs. On June 15, 2020, the lawsuit was removed to the U.S. District Court for the Central District of California. On June 16, 2020, the Company was served with a Private Attorney General Act lawsuit by the same plaintiff in Jose Bermejo v. Laboratory Corporation of America, filed in the Superior Court of California, County of Los Angeles Central District, alleging that certain Company practices violated California Labor Code penalty provisions related to unpaid and minimum wages, unpaid overtime, unpaid mean and rest break premiums, untimely payment of wages following separation of employment, failure to maintain accurate pay records, and non-reimbursement of business expenses. The second lawsuit seeks to recover civil penalties and recovery of attorney's fees and costs. The Company will vigorously defend both lawsuits.

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

Under the Company's present insurance programs, coverage is obtained for catastrophic exposure as well as those risks required to be insured by law or contract. The Company is responsible for the uninsured portion of losses related primarily to general, professional and vehicle liability, certain medical costs and workers' compensation. The self-insured retentions are on a per-occurrence basis without any aggregate annual limit. Provisions for losses expected under these programs are recorded based upon the Company's estimates of the aggregated liability of claims incurred.


	~~12. PENSION AND POST-RETIREMENT PLANS~~

~~The Company has two defined contribution retirement plans (401K Plans) which cover substantially all U.S. employees.~~ 11. PENSION AND POSTRETIREMENT PLANS

Retirement Plans

All employees eligible for the ~~LabCorp 401K Plan~~LCD defined-contribution retirement plan (LCD 401(k) Plan) receive a minimum 3% non-elective contribution (NEC) concurrent with each payroll period. Employees are not required to make a contribution to the LCD 401(k) Plan to receive the NEC. The ~~401K~~NEC is non-forfeitable and vests immediately. The LCD 401(k) Plan also permits discretionary contributions by the Company of ~~up to~~ 1% ~~and up~~ to 3% of pay for eligible employees based on ~~years~~service. The Company incurred expense of ~~service with~~$13.9 and $16.2 for the ~~Company. The cost of this plan was $12.9 and $15.8 for~~LCD 401(k) Plan during the three months ended June 30, ~~2019,~~2020 and ~~2018,~~2019 respectively, and ~~was $37.1~~$27.4 and ~~$31.8 for~~$32.2 during the six months ended June 30, 2020 and 2019, ~~and 2018,~~ respectively.

All of the ~~Covance~~CDD U.S. ~~employees, including legacy Chiltern~~ employees are eligible to participate in the ~~Covance 401K plan,~~CDD 401(k) Plan, which is available on a voluntary basis and features a maximum 4.5% Company match, based upon a percentage of the employee’s contributions. Chiltern employees were previously eligible to participate in the Chiltern 401K plan, which featured a maximum 3.0% Company match, based upon a percentage of the employee's contributions. The Chiltern 401K plan merged into the Covance Plan effective January, 7, 2019. The Company incurred expense of ~~$17.9~~$20.3 and ~~$16.5~~$17.9 for the Covance ~~401K~~401(k) plan during the three months ended June 30, ~~2019,~~2020, and ~~2018,~~2019, respectively, and ~~$37.8~~$43.8 and ~~$35.3~~$37.8 during the six months ended June 30, 2020 and 2019, ~~and 2018,~~ respectively.

The Company also maintains several other ~~immaterial~~small 401K plans associated with companies acquired over the last several years.

Pension Plans

The Company ~~also maintains~~has a ~~frozen defined benefit~~defined-benefit retirement plan (Company Plan)~~, which as of~~ and a nonqualified supplemental retirement plan (PEP). Both plans have been closed to new participants since December 31, ~~2009, covered~~2009. Employees participating in the Company Plan and PEP no longer earn service-based credits, but continue to earn investment credits.

The Company Plan covers substantially all ~~employees.~~LCD employees employed prior to December 31, 2009. The benefits to be paid under the Company Plan are based on years of credited service through December 31, 2009, interest credits and ~~ongoing interest credits. Effective January 1, 2010, the Company Plan was closed to new participants.~~average compensation. The ~~Company’s~~Company's policy is to fund the Company Plan with at least the minimum amount required by applicable regulations.

The ~~Company maintains~~PEP covers a ~~second, unfunded, non-contributory, non-qualified defined benefit retirement plan (PEP), which as~~portion of ~~December 31, 2009, covered substantially all of its~~the Company's senior management group. ~~The~~Prior to 2010, the PEP ~~supplements~~provided for the payment of the difference, if any, between the amount of any maximum limitation on annual benefit payments under the Employee Retirement Income Security Act of 1974 and the annual benefit that would be payable under the Company Plan ~~and was closed to new participants effective~~but for such limitation. Effective January 1, ~~2010.~~2010, employees participating in the PEP no longer earn service-based credits. The PEP is an unfunded plan.

The effect on operations for the Company Plan and the PEP is summarized as follows:

Three Months Ended June 30, Six Months Ended June 30,
2019 2018 2019 2018
Service cost for administrative expenses $ 1.0
$ 1.2
$ 2.0
$ 2.6
Interest cost on benefit obligation 3.5
3.2
7.0
6.5
Expected return on plan assets (3.8 ) (4.1 ) (7.6 ) (8.2 )
Net amortization and deferral 2.6
3.1
5.2
5.9
Defined benefit plan costs $ 3.3
$ 3.4
$ 6.6
$ 6.8


	Three Months Ended June 30,						Six Months Ended June 30,
	2020		2019		2020		2019
Service cost for administrative expenses	$	1.3	$	1.0	$	2.6	$	2.0
Interest cost on benefit obligation	2.8		3.5		5.6		7.0
Expected return on plan assets	(3.8)		(3.8)		(7.5)		(7.6)
Net amortization and deferral	2.2		2.6		4.8		5.2
Defined benefit plan costs	$	2.5	$	3.3	$	5.5	$	6.6

The service cost component of net periodic pension cost and net periodic post-retirement benefit cost is included in operating expenses with other employee compensation costs. The other components of net benefit cost, including amortization or prior service cost/credit and settlement and curtailment effects are included in other, net non-operating expenses. During the six months ended June 30, ~~2019~~,2020, the Company made no contributions to the Company Plan. The related net pension obligation for the Company Plan and PEP was $92.7 and $93.4 as of June 30, 2020 and December 31, 2019, respectively.

As a result of the Covance acquisition, the Company sponsors two defined benefit pension plans for the benefit of its employees at two U.K. subsidiaries (U.K. Plans) and one defined benefit pension plan for the benefit of its employees at a German subsidiary (German Plan), all of which are legacy plans of previously acquired companies. The U.K. Plans were closed to future accrual as of December 31, 2019. Benefit amounts for all three plans are based upon years of service and compensation; however, the U.K. Plans were based on service and compensation through December 31, 2019. The German

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

~~(German Plan), all of which are legacy plans of previously acquired companies. Benefit amounts for all three plans are based upon years of service and compensation. The German plan~~Plan is unfunded while the U.K. ~~pension plans~~Plans are funded. The Company’s funding policy has been to contribute annually a fixed percentage of the eligible employee's salary, and additional amounts, at least equal to the local statutory funding requirements.

U.K. Plans
Three Months Ended June 30, Six Months Ended June 30,
2019 2018 2019 2018
Service cost for administrative expenses $ 0.8
$ 0.9
$ 1.6
$ 1.8
Interest cost on benefit obligation 1.9
1.9
3.8
3.8
Expected return on plan assets (2.8 ) (3.2 ) (5.7 ) (6.5 )
Defined benefit plan costs $ (0.1 ) $ (0.4 ) $ (0.3 ) $ (0.9 )

U.K. Plans
Three Months Ended June 30, Six Months Ended June 30,
2019 2018 2019 2018
Assumptions used to determine defined benefit plan cost
Discount rate 2.9 % 2.5 % 2.9 % 2.5 %
Expected return on assets 4.5 % 4.5 % 4.5 % 4.5 %
Salary increases 3.6 % 3.6 % 3.6 % 3.6 %

German Plan
Three Months Ended June 30, Six Months Ended June 30,
2019 2018 2019 2018
Service cost for administrative expenses $ 0.3
$ 0.3
$ 0.6
$ 0.6
Interest cost on benefit obligation 0.2
0.2
0.3
0.3
Defined benefit plan costs $ 0.5
$ 0.5
$ 0.9
$ 0.9

Assumptions used to determine defined benefit plan cost
Discount rate 1.9 % 1.7 % 1.9 % 1.7 %
Expected return on assets N/A
N/A
N/A
N/A
Salary increases 2.0 % 2.0 % 2.0 % 2.0 %

As a result of the Envigo acquisition, the Company assumed a defined benefit pension plan for the benefit of Envigo's U.K. employees (the Envigo ~~plan)~~Plan), which is a legacy plan of a company previously acquired by Envigo. The Envigo ~~plan~~Plan is a funded plan that is closed to future accrual. The related net pension obligation of $56.8, based on the preliminary valuation of acquired assets and assumed liabilities, is reported under Other liabilities in the Condensed Consolidated Balance Sheet as of June 30, 2019. The Company’s funding policy has been to ~~make annual contributions to the plan of~~contribute amounts ~~that are~~ at least equal to the local statutory funding requirements.

The related net pension obligation for these plans inclusive of the U.K. Plans, German Plan, and the Envigo Plan, was $86.0 and $99.1 as of June 30, 2020 and December 31, 2019, respectively.


~~13.~~	~~FAIR VALUE MEASUREMENTS~~

12. FAIR VALUE MEASUREMENTS

The Company’s population of financial assets and liabilities subject to fair value measurements as of June 30, ~~2019~~,2020, and December 31, ~~2018~~,2019, is as follows:


				Fair Value Measurements as of
		Fair Value as of		June 30, 2020
	Balance Sheet					Using Fair Value Hierarchy
	Classification	June 30, 2020		Level 1			Level 2		Level 3
Noncontrolling interest put	Noncontrolling interest	$	15.2	$	—		$	15.2	$	—
Cross currency swaps	Other assets, net	14.3		—			14.3		—
Interest rate swaps	Other assets, net	2.3		—			2.3		—


Cash surrender value of life insurance policies	Other assets, net	78.6		—			78.6		—
Deferred compensation liability	Other liabilities	76.8		—			76.8		—
Contingent consideration	Other liabilities	9.0		—			—		9.0


					Fair Value Measurements as of													Fair Value Measurements as of
		Fair Value as of			June 30, 2019										Fair Value as of			December 31, 2019
	Balance Sheet			Using Fair Value Hierarchy								Balance Sheet						Using Fair Value Hierarchy
	Classification		June 30, 2019			Level 1		Level 2		Level 3				Classification			December 31, 2019			Level 1			Level 2			Level 3
Noncontrolling interest put	Noncontrolling interest	$	15.7		$	—	$	15.7	$	—	Noncontrolling interest put		Noncontrolling interest			$	15.8		$	—		$	15.8		$	—
Cross currency swap asset	Other assets, net	1.2			—		1.2		—
Interest rate swap	Other assets, net	3.7			—		3.7		—
Cross currency swaps											Cross currency swaps		Other assets, net		3.2			—			3.2			—
Interest rate swaps											Interest rate swaps		Other assets, net		1.5			—			1.5			—
Cash surrender value of life insurance policies	Other assets, net	75.3			—		75.3		—		Cash surrender value of life insurance policies		Other assets, net		80.2			—			80.2			—
Deferred compensation liability	Other liabilities	74.3			—		74.3		—		Deferred compensation liability		Other liabilities		76.7			—			76.7			—
Investment in equity securities											Investment in equity securities		Other current assets		9.1			9.1			—			—
Contingent consideration	Other liabilities	20.1			—		—		20.1		Contingent consideration		Other liabilities		9.9			—			—			9.9
Investment in equity securities	Prepaid expenses and other	29.8			29.8		—		—

~~INDEX~~

~~LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(dollars and shares in millions, except per share data)~~

Fair Value Measurements as of

Fair Value
as of
December 31, 2018
Balance Sheet Using Fair Value Hierarchy
Classification December 31, 2018 Level 1 Level 2 Level 3
Noncontrolling interest put Noncontrolling interest $ 15.0
$ —
$ 15.0
$ —
Cross currency swap liability Other liabilities 2.8
—
2.8
—
Interest rate swap Other liabilities 3.1
—
3.1
—
Cash surrender value of life insurance policies Other assets, net 63.5
—
63.5
—
Deferred compensation liability Other liabilities 64.2
—
64.2
—
Contingent consideration Other liabilities 18.6
—
—
18.6

Fair Value Measurement of Level 3 Assets Contingent Consideration
Balance at December 31, 2018 18.6
Addition 1.5
Balance at June 30, 2019 $ 20.1


Fair Value Measurement of Level 3 Liabilities	Contingent Consideration


Balance at December 31, 2019	$	9.9
Payments	(4.8)
Adjustments	(2.1)
Additions	6.0
Balance at June 30, 2020	$	9.0

The Company has a noncontrolling interest put related to its Ontario subsidiary that has been classified as mezzanine equity in the Company’s condensed consolidated balance sheets. The noncontrolling interest put is valued at its contractually determined value, which approximates fair value.

The Company offers certain employees the opportunity to participate in an employee-funded deferred compensation plan (DCP). A participant's deferrals are allocated by the participant to one or more of 2216 measurement funds, which are indexed to externally managed funds. From time to time, to offset the cost of the growth in the participant's investment accounts, the Company purchases life insurance policies, with the Company named as beneficiary of the policies. Changes in the cash surrender value of ~~these~~the life insurance policies are based upon earnings and changes in the value of the underlying investments, which are typically invested in a similar manner ~~similar~~ to the participants' allocations. Changes in the fair value of the DCP obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. The cash

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

surrender value and the DCP obligations are classified within Level 2 because their inputs are derived principally from observable market data by correlation to the hypothetical investments.

~~The Company has contingent accrued earn-out business~~Contingent acquisition consideration liabilities ~~which~~are measured at fair value using Level 3 valuations. These contingent consideration liabilities were recorded at fair value on the acquisition date and are remeasured quarterly based on the then assessed fair value and adjusted if necessary. The increases or decreases in the fair value of contingent consideration payable can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measure is based on significant inputs that are not observable in the market, they are categorized as Level 3.

The carrying amounts of cash and cash equivalents, accounts receivable, income taxes receivable, and accounts payable are considered to be representative of their respective fair values due to their short-term nature. The fair market value of the ~~zero-coupon subordinated notes,~~Senior Notes, based on market pricing, was approximately ~~$1.8~~$6,433.0 and ~~$16.9~~ ~~as of~~ ~~June 30, 2019, and~~ ~~December 31, 2018, respectively. The fair market value of all of the senior notes, based on market pricing, was approximately~~ ~~$5,658.5~~ ~~and~~ ~~$5,318.0~~ ~~as of~~ ~~June 30, 2019, and~~ ~~December 31, 2018, respectively. The fair market value of the floating rate secured note due 2022 received for the sale of CRP was $110.0~~$6,140.6 as of June 30, ~~2019. The effective interest rate on the floating rate secured note receivable was 7.79% as of June 30, 2019.~~2020 and December 31, 2019, respectively. The Company's note and debt instruments are classified as Level 2 instruments, as the fair market values of these instruments are determined using other observable inputs.


~~14.~~	~~DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES~~

13. DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

The Company addresses its exposure to market risks, principally the market risk associated with changes in interest rates and foreign currency exchange rates, through a controlled program of risk management that includes, from time to time, the use of derivative financial instruments such as interest rate and cross currency swap agreements (see Interest Rate Swap and Cross Currency Swap sections below). Although the Company’s zero-coupon subordinated notes contain features that are considered to be embedded derivative instruments (see Embedded Derivatives Related to the Zero-Coupon Subordinated Notes section below), theinstruments. The Company does not hold or issue derivative financial instruments for trading purposes. ~~The derivative financial instrument contracts are with major investment grade financial institutions and the Company does not anticipate any material non-performance by any of the counterparties.~~ The Company does not believe that its exposure to market risk is material to the Company’s financial position or results of operations.

~~INDEX~~

~~LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES~~

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(dollars and shares in millions, except per share data)~~

Interest Rate Swap

The Company is party to ~~two~~a fixed-to-variable interest rate swap ~~agreements~~agreement for its 4.625% senior notes ~~due~~which mature on November 15, 2020, with ~~an aggregate~~a notional amount of ~~$600.0~~$300.0 and variable interest rates based on one-month LIBOR plus 2.298% to hedge against changes in the fair value of a portion of the Company's ~~long term~~ debt. ~~These~~On July 17, 2020, notice was given to holders of the notes that the Company had elected to redeem the outstanding securities on August 17, 2020. The interest rate swap derivative financial ~~instruments are~~instrument is accounted for as fair value ~~hedges~~hedge of the ~~senior notes~~Senior Notes due 2020. These interest rate swaps are included in prepaid and other ~~long-term~~ assets or ~~other long-term~~ liabilities, as applicable, and added to ~~or subtracted from~~ the value of the ~~senior notes, with an aggregate fair value of $3.7 (asset) and $3.1 (liability) at June 30, 2019, and December 31, 2018, respectively.~~Senior Notes. As the specific terms and notional ~~amounts~~amount of the derivative financial ~~instruments match~~instrument matches those of the fixed-rate debt being hedged, the derivative ~~instruments are~~instrument is assumed to be a perfectly effective ~~hedges~~hedge and accordingly, there is no impact to the Company's Condensed Consolidated Statements of Operations. Cash flows from the interest rate swap are included in operating activities.

Carrying amount of hedged liabilities as of Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liabilities as of
June 30, 2019 December 31, 2018 June 30, 2019 December 31, 2018
Balance Sheet Line Item in which Hedged Items are Included
Long-term debt, less current portion $ 603.7
$ 597.0
$ 3.7
$ (3.1 )


	Carrying amount of hedged liabilities as of						Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liabilities as of
	June 30, 2020		December 31, 2019		June 30, 2020		December 31, 2019
Balance Sheet Line Item in which Hedged Items are Included
Current portion, long term debt	$	302.3	$	301.5	$	2.3	$	1.5

Cross Currency Swap

During the fourth quarter of 2018, the Company entered into six U.S. Dollar to Swiss Franc cross-currency swap agreements with an aggregate notional value of $600.0 and which are accounted for as a hedge against the impact of foreign exchange movements on its net investment in a Swiss subsidiary. Of the notional value, $300.0 matures in 2022 and $300.0 matures in 2025. These cross currency swaps maturing in 2022 and 2025 are included in other long-term assets ~~with an aggregate fair value of $0.3 and $0.9, respectively,~~ as of June 30, ~~2019 and are included in other long-term liabilities with an aggregate fair value of $1.0 and $1.8, respectively, as of December 31, 2018.~~2020. Changes in the fair value of the cross-currency swaps are ~~charged or credited through~~recorded as a component of the foreign currency translation adjustment in accumulated other comprehensive income in the Condensed Consolidated Balance Sheet until the hedged item is recognized in earnings. The cumulative amount of the fair value hedging adjustment included in the current value of the cross currency swaps is ~~$(7.8)~~$(8.8) and ~~$4.0, respectively,~~$11.1 for the three and six months ended June 30, ~~2019,~~2020, and was recognized as currency translation within the Condensed Consolidated Statement of Comprehensive Earnings. There were no amounts reclassified from the Condensed Consolidated Statement of Comprehensive Earnings to the Condensed Consolidated Statement of Operations during the three months or six months ended June 30, ~~2019.~~2020.

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)

The table below presents the fair value of derivatives on a gross basis and the balance sheet classification of those instruments:

June 30, 2019 December 31, 2018
Fair Value of Derivative Fair Value of Derivative

Balance Sheet
Caption
Asset Liability U.S. Dollar Notional Asset Liability U.S. Dollar Notional
Derivatives Designated as Hedging Instruments
Interest rate swap Other assets, net or Other liabilities $ 3.7
$ —
$ 600.0
$ —
$ (3.1 ) $ 600.0
Cross currency swaps Other assets, net or Other liabilities $ 1.2
$ —
$ 600.0
$ —
$ (2.8 ) $ 600.0


		June 30, 2020										December 31, 2019
		Fair Value of Derivative										Fair Value of Derivative
	Balance Sheet Caption	Asset		Liability		U.S. Dollar Notional		Asset		Liability		U.S. Dollar Notional
Derivatives Designated as Hedging Instruments

Interest rate swap	Prepaid expenses and other/Other liabilities	$	2.3	$	—	$	300.0	$	1.5	$	—	$	300.0
Cross currency swaps	Other assets, net or Other liabilities	$	14.3	$	—	$	600.0	$	3.2	$	—	$	600.0

The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value hedging relationships:

Amount of pre-tax gain/(loss) included in other comprehensive income
Amounts reclassified to the
Statement of Operations
Amount of pre-tax gain/(loss) included in other comprehensive income Amounts reclassified to the
Statement of Operations
Three Months Ended June 30, Three Months Ended June 30, Six Months Ended June 30, Six Months Ended June 30,
2019 2018 2019 2018 2019 2018 2019 2018
Interest rate swap contracts $ 4.3
$ (10.0 ) $ —
$ —
$ 6.8
$ (9.7 ) $ —
$ —
Cross currency swaps $ (7.8 ) $ (24.3 ) $ —
$ —
$ 4.0
$ (24.2 ) $ —
$ —


	Amount of pre-tax gain/(loss) included in other comprehensive income						Amounts reclassified to the Statement of Operations						Amount of pre-tax gain/(loss) included in other comprehensive income				Amounts reclassified to the Statement of Operations
	Three Months Ended June 30,						Three Months Ended June 30,						Six Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019		2020		2019		2020		2019
Interest rate swap contracts	$	(0.9)	$	4.3	$	—	$	—	$	0.9	$	6.8	$	—	$	—
Cross currency swaps	$	(8.8)	$	(7.8)	$	—	$	—	$	11.1	$	4.0	$	—	$	—

No gains or losses from derivative instruments classified as hedging instruments have been recognized into income for the three and six months ended June 30, ~~2019~~2020 and ~~2018.~~2019.

~~INDEX~~

~~LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES~~14. SUPPLEMENTAL CASH FLOW INFORMATION

~~NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~


	Six Months Ended June 30,
	2020		2019
Supplemental schedule of cash flow information:
Cash paid during period for:
Interest	$	111.5	$	123.8
Income taxes, net of refunds	15.1		119.6
Disclosure of non-cash financing and investing activities:

Conversion of zero-coupon convertible debt	—		7.2

Change in accrued property, plant and equipment	(17.1)		(12.5)
Floating rate secured note receivable due 2022 from the sale of CRP	—		110.0

~~(dollars and shares in millions, except per share data)~~

15. BUSINESS SEGMENT INFORMATION

~~Embedded Derivatives Related to the Zero-Coupon Subordinated Notes~~

The Company’s zero-coupon subordinated notes contain the following two features that are considered to be embedded derivative instruments under authoritative guidance in connection with accounting for derivative instruments and hedging activities:


1)	The Company will pay contingent cash interest on the zero-coupon subordinated notes after September 11, 2006, if the average market price of the notes equals 120% or more of the sum of the issue price, accrued original issue discount and contingent additional principal, if any, for a specified measurement period.


2)	Holders may surrender zero-coupon subordinated notes for conversion during any period in which the rating assigned to the zero-coupon subordinated notes by Standard & Poor’s Ratings Services is BB- or lower.

~~The Company believes these embedded derivatives had~~ no ~~fair value at~~ ~~June 30, 2019, and~~ ~~December 31, 2018. These embedded derivatives also had~~ no ~~impact on the Condensed Consolidated Statements of Operations for the six months ended~~ ~~June 30, 2019, and~~ ~~2018~~.

~~Other Derivative Instruments~~

The Company periodically enters into foreign currency forward contracts, which are recognized as assets or liabilities at their fair value. These contracts do not qualify for hedge accounting and the changes in fair value are recorded directly to earnings. The contracts are short-term in nature and the fair value of these contracts is based on market prices for comparable contracts. The fair value of these contracts is not significant as of June 30, 2019, and December 31, 2018.


~~15.~~	~~SUPPLEMENTAL CASH FLOW INFORMATION~~

Six Months Ended June 30,
2019 2018
Supplemental schedule of cash flow information:
Cash paid during period for:
Interest $ 123.8
$ 188.2
Income taxes, net of refunds 119.6
148.6
Disclosure of non-cash financing and investing activities:

Conversion of zero-coupon convertible debt 7.2
—
Change in accrued property, plant and equipment (12.5 ) 4.8
Floating rate secured note receivable due 2022 from the sale of CRP 110.0
—


~~16.~~	~~BUSINESS SEGMENT INFORMATION~~

The following table is a summary of segment information for the three and six months ended June 30, ~~2019,~~2020 and ~~2018.~~2019. The management approach has been used to present the following segment information. This approach is based upon the way the management of the Company organizes ~~its business unit operations~~segments within an enterprise for making operating decisions and assessing performance. Financial information is reported on the basis that it is used internally by the chief operating decision maker (CODM) for evaluating segment performance and deciding how to allocate resources to segments. The Company’s chief executive officer has been identified as the CODM.

Segment asset information is not presented because it is not used by the CODM at the segment level. Operating earnings of each segment represents ~~net~~ revenues less directly identifiable expenses to arrive at operating income for the segment. General management and administrative corporate expenses are included in general corporate expenses below. ~~The table below represents information about the Company’s reporting segments for the three and six months ended June 30, 2019, and 2018:~~

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(dollars and shares in millions, except per share data)


	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2020		2019		2020		2019
Revenues:
LCD	$	1,692.7	$	1,760.9	$	3,394.7	$	3,482.9
CDD	1,093.7		1,126.3		2,237.5		2,201.0
Intercompany eliminations and other	(17.6)		(5.5)		(39.6)		(11.0)
Revenues	2,768.8		2,881.7		5,592.6		5,672.9

Operating earnings (loss):
LCD	281.3		312.5		486.7		580.8
CDD	65.5		65.8		(273.2)		153.8
General corporate expenses	(49.1)		(42.6)		(108.4)		(80.7)
Total operating income	297.7		335.7		105.1		653.9
Non-operating expenses, net	(0.7)		(65.7)		(75.8)		(129.2)
Earnings before income taxes	297.0		270.0		29.3		524.7
Provision for income taxes	65.4		79.3		114.6		148.1
Net earnings (loss)	231.6		190.7		(85.3)		376.6
Less net income attributable to noncontrolling interests	—		(0.3)		(0.3)		(0.6)
Net income (loss) attributable to Laboratory Corporation of America Holdings	$	231.6	$	190.4	$	(85.6)	$	376.0

16. SUBSEQUENT EVENTS

In July 2020, the Company acquired two businesses and related assets for approximately $200.0 in cash (net of cash acquired). These acquisitions will be included in both the LCD and CDD segments and were made primarily to extend the Company's geographic reach in important market areas, enhance the Company's scientific differentiation and to expand the breadth and scope of the Company's services.

On July 17, 2020, notice was given to holders of $412.2 of the Company’s senior notes, due November 15, 2020, that the Company had elected to redeem the outstanding securities on August 17, 2020 at par. The Company will repay the notes with available cash on hand and borrowings under its revolving credit facility.

INDEX

Three Months Ended Six Months Ended
June 30, June 30,
2019 2018 2019 2018
Revenues:
LCD $ 1,760.9
$ 1,814.0
$ 3,482.9
$ 3,584.2
CDD 1,126.3
1,054.2
2,201.0
2,132.6
Intercompany eliminations (5.5 ) (1.9 ) (11.0 ) (2.2 )
Revenues 2,881.7
2,866.3
5,672.9
5,714.6

Operating earnings:
LCD 312.5
336.3
580.8
639.8
CDD 65.8
68.8
153.8
107.3
Unallocated corporate expenses (42.6 ) (35.9 ) (80.7 ) (72.5 )
Total operating income 335.7
369.2
653.9
674.6
Other income (expense), net (65.7 ) (56.5 ) (129.2 ) (120.4 )
Earnings before income taxes 270.0
312.7
524.7
554.2
Provision for income taxes 79.3
78.6
148.1
147.6
Net earnings 190.7
234.1
376.6
406.6
Less (earnings) loss attributable to noncontrolling interests (0.3 ) (0.3 ) (0.6 ) 0.4
Net income attributable to Laboratory Corporation of America Holdings $ 190.4
$ 233.8
$ 376.0
$ 407.0

~~INDEX~~

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

FORWARD-LOOKING STATEMENTS

Laboratory Corporation of America^® Holdings together with its subsidiaries (the Company) has made in this report, and from time to time may otherwise make in its public filings, press releases and discussions by Company management, forward-looking statements concerning the Company’s operations, performance and financial condition, as well as its strategic objectives. Some of these forward-looking statements relate to future events and expectations and can be identified by the use of forward-looking words such as “believes”, “expects”, “may”, “will”, “should”, “seeks”, “approximately”, ~~“intends”~~“intends��, “plans”, “estimates”, or “anticipates” or the negative of those words or other comparable terminology. Such forward-looking statements speak only as of the time they are made and are subject to various risks and ~~uncertainties and the~~uncertainties. The Company claims the protection afforded by the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those currently anticipated due to a number of factors in addition to those discussed elsewhere herein, including in the "Risk Factors" section of the Annual Report on Form 10-K, and in the Company’s other public filings, press releases, and ~~discussion~~discussions with Company management, including:

changes in government and third-party payer regulations, reimbursement, or coverage policies or other future reforms in the healthcare system (or in the interpretation of current regulations), new insurance or payment systems, including state, regional or private insurance cooperatives (e.g., health insurance exchanges) affecting governmental and third-party coverage or reimbursement for commercial laboratory testing, including the impact of the Protecting Access to Medicare Act of 2014 (PAMA);

significant monetary damages, fines, penalties, assessments, refunds, repayments, damage to the Company’s reputation, unanticipated compliance expenditures, and/or exclusion or debarment from or ineligibility to participate in government programs, among other adverse consequences, arising from enforcement of anti-fraud and abuse laws and other laws applicable to the Company in jurisdictions in which the Company conducts business;

significant fines, penalties, costs, unanticipated compliance expenditures and/or damage to the Company’s reputation arising from the failure to comply with applicable privacy and security laws and regulations, including the Health Insurance Portability and Accountability Act of 1996, the Health Information Technology for Economic and Clinical Health Act, the European Union's General Data Protection Regulation and similar laws and regulations in jurisdictions in which the Company conducts business;

loss or suspension of a license or imposition of a fine or penalties under, or future changes in, or interpretations of applicable licensing laws or regulations regarding the operation of clinical laboratories and the delivery of clinical laboratory test results, including, but not limited to, the U.S. Clinical Laboratory Improvement Act of 1967 and the Clinical Laboratory Improvement Amendments of 1988 and similar laws and regulations in jurisdictions in which the Company conducts business;


5.	penalties or loss of license arising from the failure to comply with applicable occupational and workplace safety laws and regulations, including the U.S. Occupational Safety and Health Administration requirements and the U.S. Needlestick Safety and Prevention Act and similar laws and regulations in jurisdictions in which the Company conducts business;


6.	fines, unanticipated compliance expenditures, suspension of manufacturing, enforcement actions, damage to the Company’s reputation, injunctions, or criminal prosecution arising from failure to maintain compliance with current good manufacturing practice regulations and similar requirements of various regulatory agencies in jurisdictions in which the Company conducts business;


7.	sanctions or other remedies, including fines, unanticipated compliance expenditures, enforcement actions, injunctions or criminal prosecution arising from failure to comply with the Animal Welfare Act or applicable national, state and local laws and regulations in jurisdictions in which the Company conducts business;


8.	~~changes in testing guidelines or recommendations by government agencies, medical specialty societies and other authoritative bodies affecting the utilization of laboratory tests;~~

changes in applicable government regulations or policies affecting the approval, availability of, and the selling and marketing of diagnostic tests, drug development, or the conduct of drug development and medical device and diagnostic studies and trials, including regulations and policies of the U.S. Food and Drug Administration, the U.S. Department of Agriculture, the Medicine and Healthcare products Regulatory Agency in the United Kingdom (U.K.), the State Drug Administration in China (formerly the China Food and Drug Administration), the Pharmaceutical and Medical Devices Agency in Japan, the European Medicines Agency and similar regulations and policies of agencies in jurisdictions in which the Company conducts business;

1. changes in government and third-party payer regulations, reimbursement, or coverage policies or other future reforms in the healthcare system (or in the interpretation of current regulations), new insurance or payment systems, including state, regional or private insurance cooperatives (e.g., health insurance exchanges) affecting governmental and third-party coverage or reimbursement for commercial laboratory testing, including the impact of the U.S. Protecting Access to Medicare Act of 2014 (PAMA);

2. significant monetary damages, fines, penalties, assessments, refunds, repayments, damage to the Company’s reputation, unanticipated compliance expenditures, and/or exclusion or debarment from or ineligibility to participate in government programs, among other adverse consequences, arising from enforcement of anti-fraud and abuse laws and other laws applicable to the Company in jurisdictions in which the Company conducts business;

3. significant fines, penalties, costs, unanticipated compliance expenditures and/or damage to the Company’s reputation arising from the failure to comply with applicable privacy and security laws and regulations, including the U.S. Health Insurance Portability and Accountability Act of 1996, the U.S. Health Information Technology for Economic and Clinical Health Act, the European Union's General Data Protection Regulation and similar laws and regulations in jurisdictions in which the Company conducts business;

4. loss or suspension of a license or imposition of a fine or penalties under, or future changes in, or interpretations of applicable licensing laws or regulations regarding the operation of clinical laboratories and the delivery of clinical laboratory test results, including, but not limited to, the U.S. Clinical Laboratory Improvement Act of 1967 and the U.S. Clinical Laboratory Improvement Amendments of 1988 and similar laws and regulations in jurisdictions in which the Company conducts business;

5. penalties or loss of license arising from the failure to comply with applicable occupational and workplace safety laws and regulations, including the U.S. Occupational Safety and Health Administration requirements and the U.S. Needlestick Safety and Prevention Act and similar laws and regulations in jurisdictions in which the Company conducts business;

6. fines, unanticipated compliance expenditures, suspension of manufacturing, enforcement actions, damage to the Company’s reputation, injunctions, or criminal prosecution arising from failure to maintain compliance with current good manufacturing practice regulations and similar requirements of various regulatory agencies in jurisdictions in which the Company conducts business;

7. sanctions or other remedies, including fines, unanticipated compliance expenditures, enforcement actions, injunctions or criminal prosecution arising from failure to comply with the Animal Welfare Act or applicable national, state and local laws and regulations in jurisdictions in which the Company conducts business;

8. changes in testing guidelines or recommendations by government agencies, medical specialty societies and other authoritative bodies affecting the utilization of laboratory tests;

9. changes in applicable government regulations or policies affecting the approval, availability of, and the selling and marketing of diagnostic tests, drug development, or the conduct of drug development and medical device and diagnostic studies and trials, including regulations and policies of the U.S. Food and Drug Administration, the U.S. Department of Agriculture, the Medicine and Healthcare products Regulatory Agency in the United Kingdom (U.K.), the National Medical Products Administration in China, the Pharmaceutical and Medical Devices Agency in Japan, the

INDEX

European Medicines Agency and similar regulations and policies of agencies in other jurisdictions in which the Company conducts business;


~~10.~~	changes in government regulations or reimbursement pertaining to the biopharmaceutical and medical device and diagnostic industries, changes in reimbursement of biopharmaceutical products or reduced spending on research and development by biopharmaceutical customers;


~~11.~~	~~liabilities that result from the failure to comply with corporate governance requirements;~~


~~12.~~	increased competition, including price competition, potential reduction in rates in response to price transparency and consumerism, competitive bidding and/or changes or reductions to fee schedules and competition from companies that do not comply with existing laws or regulations or otherwise disregard compliance standards in the industry;

~~13.~~

changes in payer mix or payment structure, including insurance carrier participation in health insurance exchanges, an increase in capitated reimbursement mechanisms, the impact of a shift to consumer-driven health plans or plans carrying an increased level of member cost-sharing, and adverse changes in payer reimbursement or payer coverage policies (implemented directly or through a third-party utilization management organization) related to specific diagnostic tests, categories of testing or testing methodologies;


~~14.~~	failure to retain or attract managed care organization (MCO) business as a result of changes in business models, including new risk-based or network approaches, out-sourced Laboratory Network Management or Utilization Management companies, or other changes in strategy or business models by MCOs;


~~15.~~	failure to obtain and retain new customers, an unfavorable change in the mix of testing services ordered, or a reduction in tests ordered, specimens submitted or services requested by existing customers;


~~16.~~	difficulty in maintaining relationships with customers or retaining key employees as a result of uncertainty surrounding the integration of acquisitions and the resulting negative effects on the business of the Company;


~~17.~~	consolidation and convergence of MCOs, biopharmaceutical companies, health systems, large physician organizations and other customers, potentially causing material shifts in insourcing, utilization, pricing and reimbursement, including full and partial risk-based models;


~~18.~~	~~failure to effectively develop and deploy new systems, system modifications or enhancements required in response to evolving market and business needs;~~


~~19.~~	~~customers choosing to insource services that are or could be purchased from the Company;~~


~~20.~~	~~failure to identify, successfully close and effectively integrate and/or manage acquisitions of new businesses;~~


~~21.~~	inability to achieve the expected benefits and synergies of newly-acquired businesses, including due to items not discovered in the due-diligence process, and the impact on the Company's cash position, levels of indebtedness and stock price;


~~22.~~	~~termination, loss, delay, reduction in scope or increased costs of contracts, including large contracts and multiple contracts;~~


~~23.~~	~~liability arising from errors or omissions in the performance of testing services, contract research services or other contractual arrangements;~~


~~24.~~	changes or disruption in the provision or transportation of services or supplies provided by third parties, or their termination for failure to follow the Company's performance standards and requirements;


~~25.~~	~~damage or disruption to the Company's facilities;~~


~~26.~~	~~damage to the Company's reputation, loss of business, or other harm from acts of animal rights activists or potential harm and/or liability arising from animal research activities;~~


~~27.~~	~~adverse results in litigation matters;~~


~~28.~~	~~inability to attract and retain experienced and qualified personnel;~~


~~29.~~	failure to develop or acquire licenses for new or improved technologies, such as point-of-care testing, mobile health technologies, and digital pathology, or potential use of new technologies by customers and/or consumers to perform their own tests;


~~30.~~	~~substantial costs arising from the inability to commercialize newly licensed tests or technologies or to obtain appropriate coverage or reimbursement for such tests;~~


~~31.~~	~~failure to obtain, maintain and enforce intellectual property rights for protection of the Company's products and services and defend against challenges to those rights;~~


~~32.~~	scope, validity and enforceability of patents and other proprietary rights held by third parties that may impact the Company's ability to develop, perform, or market the Company's products or services or operate its business;

10. changes in government regulations or reimbursement pertaining to the biopharmaceutical and medical device and diagnostic industries, changes in reimbursement of biopharmaceutical products or reduced spending on research and development by biopharmaceutical customers;

11. liabilities that result from the failure to comply with corporate governance requirements;

12. increased competition, including price competition, potential reduction in rates in response to price transparency and consumerism, competitive bidding and/or changes or reductions to fee schedules and competition from companies that do not comply with existing laws or regulations or otherwise disregard compliance standards in the industry;

13. changes in payer mix or payment structure, including insurance carrier participation in health insurance exchanges, an increase in capitated reimbursement mechanisms, the impact of a shift to consumer-driven health plans or plans carrying an increased level of member cost-sharing, and adverse changes in payer reimbursement or payer coverage policies (implemented directly or through a third-party utilization management organization) related to specific diagnostic tests, categories of testing or testing methodologies;

14. failure to retain or attract managed care organization (MCO) business as a result of changes in business models, including new risk-based or network approaches, out-sourced laboratory network management or utilization management companies, or other changes in strategy or business models by MCOs;

15. failure to obtain and retain new customers, an unfavorable change in the mix of testing services ordered, or a reduction in tests ordered, specimens submitted or services requested by existing customers, and delays in payment from customers;

16. difficulty in maintaining relationships with customers or retaining key employees as a result of uncertainty surrounding the integration of acquisitions and the resulting negative effects on the business of the Company;

17. consolidation and convergence of MCOs, biopharmaceutical companies, health systems, large physician organizations and other customers, potentially causing material shifts in insourcing, utilization, pricing and reimbursement, including full and partial risk-based models;

18. failure to effectively develop and deploy new systems, system modifications or enhancements required in response to evolving market and business needs;

19. customers choosing to insource services that are or could be purchased from the Company;

20. failure to identify, successfully close, and effectively integrate and/or manage acquisitions of new businesses;

21. inability to achieve the expected benefits and synergies of newly-acquired businesses, including due to items not discovered in the due-diligence process, and the impact on the Company's cash position, levels of indebtedness and stock price;

22. termination, loss, delay, reduction in scope or increased costs of contracts, including large contracts and multiple contracts;

23. liability arising from errors or omissions in the performance of testing services, contract research services, or other contractual arrangements;

24. changes or disruption in the provision or transportation of services or supplies provided by third parties; or their termination for failure to follow the Company's performance standards and requirements;

25. damage or disruption to the Company's facilities;

26. damage to the Company's reputation, loss of business, or other harm from acts of animal rights activists or potential harm and/or liability arising from animal research activities;

27. adverse results in litigation matters;

28. inability to attract and retain experienced and qualified personnel or the loss of significant personnel as a result of illness or otherwise;

29. failure to develop or acquire licenses for new or improved technologies, such as point-of-care testing, mobile health technologies, and digital pathology, or potential use of new technologies by customers and/or consumers to perform their own tests;

INDEX

30. substantial costs arising from the inability to commercialize newly licensed tests or technologies or to obtain appropriate coverage or reimbursement for such tests;

31. failure to obtain, maintain and enforce intellectual property rights for protection of the Company's products and services and defend against challenges to those rights;

32. scope, validity and enforceability of patents and other proprietary rights held by third parties that may impact the Company's ability to develop, perform, or market the Company's products or services or operate its business;

33. business interruption, receivable impairment, delays in cash collection impacting days sales outstanding, supply chain disruptions, increases in operating costs, or other impacts on the business due to natural disasters, including adverse weather, fires and earthquakes, political crises, including terrorism and war, public health crises and disease epidemics and pandemics, and other events outside of the Company's control;

34. discontinuation or recalls of existing testing products;

35. a failure in the Company's information technology systems, including with respect to testing turnaround time and billing processes, or the failure of the Company or its third-party suppliers and vendors to maintain the security of business information or systems or to protect against cybersecurity attacks such as denial of service attacks, malware, ransomware and computer viruses, or delays or failures in the development and implementation of the Company’s automation platforms, any of which could result in a negative effect on the Company’s performance of services, a loss of business or increased costs, damages to the Company’s reputation, significant litigation exposure, an inability to meet required financial reporting deadlines, or the failure to meet future regulatory or customer information technology, data security and connectivity requirements;

36. business interruption, increased costs, and other adverse effects on the Company's operations due to the unionization of employees, union strikes, work stoppages, general labor unrest or failure to comply with labor or employment laws;

37. failure to maintain the Company's days sales outstanding levels, cash collections (in light of increasing levels of patient responsibility), profitability and/or reimbursement arising from unfavorable changes in third-party payer policies, payment delays introduced by third party utilization management organizations and increasing levels of patient payment responsibility;

38. impact on the Company's revenues, cash collections and the availability of credit for general liquidity or other financing needs arising from a significant deterioration in the economy or financial markets or in the Company's credit ratings by Standard & Poor's and/or Moody's;

39. failure to maintain the expected capital structure for the Company, including failure to maintain the Company's investment grade rating, or leverage ratio covenants under its term loan facility and revolving credit facility;

40. changes in reimbursement by foreign governments and foreign currency fluctuations;

41. inability to obtain certain billing information from physicians, resulting in increased costs and complexity, a temporary disruption in receipts and ongoing reductions in reimbursements and revenues;

42. expenses and risks associated with international operations, including, but not limited to, compliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, other applicable anti-corruption laws and regulations, trade sanction laws and regulations, and economic, political, legal and other operational risks associated with foreign jurisdictions;

43. failure to achieve expected efficiencies and savings in connection with the Company's business process improvement initiatives;

44. changes in tax laws and regulations or changes in their interpretation, including the U.S. Tax Cuts and Jobs Act (TCJA);

45. global economic conditions and government and regulatory changes, including, but not limited to the U.K.'s exit from the European Union; and

46. effects, duration, and severity of the ongoing COVID-19 pandemic, including the impact on operations, personnel, and liquidity, and the actions the Company, or governments, have taken or may take in response, and damage to the Company's reputation or loss of business resulting from the perception of the Company's response to the COVID-19 pandemic, including the availability and accuracy and timeliness of delivery of any tests that the Company develops, collaborates on or provides for the detection of COVID-19.

INDEX


~~33.~~	business interruption or other impact on the business due to adverse weather, fires and/or other natural disasters, acts of war, terrorism or other criminal acts, and/or widespread outbreak of influenza or other pandemic illness;


~~34.~~	~~discontinuation or recalls of existing testing products;~~

~~35.~~

a failure in the Company's information technology systems, including with respect to testing turnaround time and billing processes, or the failure of the Company or its third-party suppliers and vendors to maintain the security of business information or systems or to protect against cybersecurity attacks such as denial of service attacks, malware, ransomware and computer viruses, or delays or failures in the development and implementation of the Company’s automation platforms, any of which could result in a negative effect on the Company’s performance of services, a loss of business or increased costs, damages to the Company’s reputation, significant litigation exposure, an inability to meet required financial reporting deadlines, or the failure to meet future regulatory or customer information technology, data security and connectivity requirements;


~~36.~~	business interruption, increased costs, and other adverse effects on the Company's operations due to the unionization of employees, union strikes, work stoppages, general labor unrest or failure to comply with labor or employment laws;


~~37.~~	failure to maintain the Company's days sales outstanding levels, cash collections (in light of increasing levels of patient responsibility), profitability and/or reimbursement arising from unfavorable changes in third-party payer policies, payment delays introduced by third party benefit management organizations and increasing levels of patient payment responsibility;


~~38.~~	impact on the Company's revenues, cash collections and the availability of credit for general liquidity or other financing needs arising from a significant deterioration in the economy or financial markets or in the Company's credit ratings by Standard &Poor's and/or Moody's;


~~39.~~	~~failure to maintain the expected capital structure for the Company, including failure to maintain the Company's investment grade rating;~~


~~40.~~	~~changes in reimbursement by foreign governments and foreign currency fluctuations;~~


~~41.~~	inability to obtain certain billing information from physicians, resulting in increased costs and complexity, a temporary disruption in receipts and ongoing reductions in reimbursements and net revenues;


~~42.~~	expenses and risks associated with international operations, including, but not limited to, compliance with the U.S. Foreign Corrupt Practices Act, the U.K. Bribery Act, other applicable anti-corruption laws and regulations, trade sanction laws and regulations, and economic, political, legal and other operational risks associated with foreign jurisdictions;


~~43.~~	~~failure to achieve expected efficiencies and savings in connection with the Company's business process improvement initiatives;~~


~~44.~~	~~changes in tax laws and regulations or changes in their interpretation, including the Tax Cuts and Jobs Act (TCJA); and~~


~~45.~~	~~global economic conditions and government and regulatory changes, including, but not limited to the U.K.'s announced intention to exit from the European Union.~~

Except as may be required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Given these uncertainties, one should not put undue reliance on any forward-looking statements.

GENERAL (dollars in millions, except per share data)

~~During~~

Revenues for the six months ended June 30, ~~2019, revenues~~2020 were ~~$5,672.9,~~$5,592.6, a decrease of ~~0.7%~~(1.4)% from ~~$5,714.6~~$5,672.9 during the six months ended June 30, 2019. The decrease in revenues was due to a 3.6% decline of organic revenue, 0.4% from the ~~first half~~disposition of ~~2018.~~a business, and 0.1% from unfavorable foreign currency translation, partially offset by 2.6% from acquisitions. The 3.6% decline inof organic revenue was ~~primarily~~ due to the ~~disposition of businesses of 1.9% and foreign currency translation of 0.8%~~pandemic, which reduced the Company's organic Base Business by 11.7%, partially offset by ~~acquisitions of 1.0%~~8.1% from COVID-19 related business. Base Business includes the Company's business operations except for molecular and serology COVID-19 testing (COVID-19 Testing). The decline in the organic ~~growth of 1.0% (which~~Base Business includes the negative impact from PAMA of ~~1.0%)~~0.6%.

~~Effective January 1, 2019,~~In March 2020, COVID-19 was declared a pandemic. COVID-19 has had and continues to have an extensive impact on the global health and economic environments. Given the continued unpredictability of the COVID-19 pandemic and the corresponding government restrictions and customer behavior, there are a wide-range of feasible financial results for 2020. While the Company's Base Business continues to be negatively impacted by the COVID-19 pandemic, the Company's outlook has improved across the enterprise.

In LCD, demand for its Base Business continues to be below the Company's historical levels; however, the Company's Base Business has been steadily recovering from its trough in April, while at the same time COVID-19 Testing continues to grow. To date, the Company ~~adopted Accounting Standards Codification (ASC) 842~~ ~~Leases~~ ~~using the effective date method.~~has performed more than 9.2 million molecular and 2.2 million antibody COVID-19 tests and has a current capacity of 180,000 molecular and 300,000 antibody tests per day. The Company ~~elected~~continues to increase capacity across multiple platforms for its COVID-19 Testing subject to the ~~package~~availability of ~~practical expedients,~~equipment and testing supplies and key personnel.

In CDD, while the pandemic is expected to continue to negatively impact its business, this impact is expected to subside throughout the year as CDD continues to work on projects supporting global vaccine and treatment development, with additional support from COVID-19 Testing.

As a result of the impact of COVID-19, during the six months ended June 30, 2020, the Company recorded goodwill and other asset impairment charges of $437.4, $426.4 within CDD and $11.0 within LCD, all of which ~~includes not reassessing whether existing contracts contain leases under~~were recorded in the ~~new definition~~three months ended March 31, 2020. See Note 6 Goodwill and Intangible Assets for discussion of ~~a lease, reassessing~~goodwill and intangible asset impairments and Note 2 Revenue for the ~~classification~~discussion of ~~existing leases,~~credit losses and ~~reassessing whether previously capitalized initial direct costs qualify for capitalization under the new standard.~~additional price concessions. The Company also ~~elected not~~wrote-off or wrote down certain of the Company's investments by $25.4 due to ~~separate lease and non-lease components. The adoption~~the impact of ~~this standard resulted~~COVID-19, $7.1 included in Equity method earnings (loss), net (recorded in the ~~recording of $770.0 of additional operating lease liabilities as of~~three months ended March 31, ~~2019.~~

On2020), and $18.3 included in Other, net ($13.1 recorded during the three months ended March 31, 2020 and $5.2 recorded during the three months ended June 3, 2019, the Company's CDD segment completed the acquisition of Envigo's nonclinical contract research services business, expanding CDD's global nonclinical drug development capabilities with additional locations and resources. Envigo also completed the acquisition of the Covance Research Products (CRP) business, which was part of the CDD segment. The two companies will continue to collaborate through a multi-year, renewable supply agreement. The Company paid cash consideration of $601.0, received a floating rate secured note of $110.0, and recorded a loss on sale of CRP of $8.8. The Company funded the transaction through a new term loan facility.30, 2020).

The Company ~~remains on track~~instituted numerous actions to ~~deliver $150.0~~help mitigate the financial impact from the COVID-19 pandemic, which included furloughs, reduced hours, and the suspension of discretionary merit adjustments and 401(k) plan contributions in the United States (U.S.). In response to its improved outlook, the Company has been rapidly resuming regular work schedules and is proceeding with merit adjustments and will retroactively reinstate 401(k) plan contributions in the U.S.

In April 2020, the Company received cash payments of approximately $55.9 from the Public Health and Social Services Emergency Fund for provider relief (Relief Fund) that was appropriated by Congress to the Department of Health and Human Services (HHS) in the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). Upon receiving and satisfying the terms and conditions associated with the distributed funds, the Company accounted for the transaction by applying the guidance in ASC 450-30 Gain Contingencies, and recorded these funds in Other, net ~~savings from CDD's three-year LaunchPad initiative by~~non-operating income in the ~~end~~Consolidated Statement of Operations as of June 30, 2020.

On July 30, the Company announced plans to create a program to offer total antibody testing at no charge through the patient’s doctor in support of increased blood plasma donations for use as a possible COVID-19 treatment. The Company ~~expects phase II of LCD’s LaunchPad initiative to deliver approximately $200.0 in net savings over~~is working with public health authorities and the ~~next~~

~~INDEX~~

~~three years, while incurring approximately $40.0 in one-time implementation costs. Approximately one-third~~provider community on the details of the ~~total savings are expected to be realized each year.~~three-month program and is evaluating the impact this program will have on the consolidated financial statements.

~~On May 14, 2019, Retrieval-Masters Creditors Bureau, Inc. d/b/a American Medical Collection Agency (AMCA), an external collection agency, notified~~There remains significant uncertainty regarding the ~~Company about a security incident AMCA experienced that may have involved certain personal information about some~~duration and severity of the pandemic and its impact on the Company’s patients (the AMCA Incident). The Company referred patient balances to AMCA only when direct collection efforts were unsuccessful. The Company’s systems were not impacted by the AMCA Incident. Upon learningbusiness, results of ~~the AMCA Incident, the Company promptly stopped sending new collection requests to AMCA~~operations and stopped AMCA from continuing to work on any pending collection requests from the Company. AMCA informed the Company that it appeared that an unauthorized user had access to AMCA’s system between August 1, 2018 and March 30, 2019, and that AMCA could not rule out the possibility that personal information on AMCA’s system was at risk during that time period. Information on AMCA’s affected system from the Company may have included name, address, and balance informationfinancial position for the ~~patient~~balance of 2020 and ~~person responsible for payment, along~~beyond. For more information regarding the risks associated with COVID-19 and its impact on the patient’s phone number, date of birth, referring physician, and date of service. The Company was later informed by AMCA that health insurance information may have been included for some individuals, and because some insurance carriers utilize the Social Security Number as a subscriber identification number, the Social Security Number for some individuals may also have been affected. No ordered tests, laboratory test results, or diagnostic information from the Company wereCompany’s business, see Risk Factors in the AMCA affected system. The Company notified individuals for whom it had a valid mailing address. For the individuals whose Social Security Number was affected, the notice included an offer to enroll in credit monitoring and identity protection services that will be provided free of charge for 24 months.Part II - Item 1A.

PAMA, which went into effect on January 1, 2018, resulted in a net reduction of revenue of approximately $70.0 in 2018 from all payers affected by the Clinical Lab Fee Schedule. A reduction of approximately $54.0 has been incurred through the first half of 2019. Unless further implementation of PAMA is delayed or changed, an additional reduction of approximately $61.0 is expected for 2019.

INDEX

RESULTS OF OPERATIONS (dollars in millions)

Three months ended June 30, ~~2019~~,2020, compared with three months ended June 30, ~~2018~~2019

Revenues


	Three Months Ended June 30,									Three Months Ended June 30,
	2019			2018			Change			2020		2019		Change
LCD	$	1,760.9		$	1,814.0		(2.9	)%	LCD	$	1,692.7	$	1,760.9	(3.9)	%
CDD	1,126.3			1,054.2			6.8	%	CDD	1,093.7		1,126.3		(2.9)	%
Intercompany eliminations	(5.5		)	(1.9		)	189.5	%
Intercompany eliminations and other									Intercompany eliminations and other	(17.6)		(5.5)		220.0	%
Total	$	2,881.7		$	2,866.3		0.5	%	Total	$	2,768.8	$	2,881.7	(3.9)	%

The ~~increase~~decrease in revenues for the three months ended June 30, ~~2019,~~2020, as compared with the corresponding period in ~~2018~~2019 was ~~0.5%~~3.9%. The ~~increase~~decrease in revenue was due to a 5.4% decline of organic revenue, 0.3% from the disposition of a business, and 0.1% from unfavorable foreign currency translation, partially offset by 1.9% from acquisitions. The 5.4% decline of organic revenue was due to the pandemic, which reduced the Company's organic Base Business by 20.9%, partially offset by COVID-19 Testing of 15.4%. The decline in organic Base Business includes the lower Medicare and Medicaid pricing as a result of PAMA of 0.5%.

LCD revenues for the quarter were $1,692.7, a decrease of 3.9% compared to revenues of $1,760.9 in the second quarter of 2019. The decrease in revenues was primarily due to ~~acquisitions~~a 4.9% decline in organic revenue and 0.1% from unfavorable foreign currency translation, partially offset by 1.1% from acquisitions. The 4.9% organic revenue decline includes a 30.1% decline of ~~1.4%~~the organic Base Business (due to the pandemic), partially offset by 25.2% from COVID-19 Testing. The 30.1% decline of the organic Base Business includes a 0.8% negative impact from PAMA and a 1.2% reduction due to the September 2019 nonrenewal of the BeaconLBS - UnitedHealthcare contract pertaining to the Florida market.

Total volume (measured by requisitions) decreased by 19.5% as organic ~~growth~~volume declined by 20.7%, partially offset by acquisition volume of ~~1.7% (which~~1.2%. The decline in organic volume includes a 35.3% reduction of organic Base Business (due to the pandemic), partially offset by increased demand for COVID-19 Testing of 14.6%. The organic Base Business volumes continued to improve throughout the quarter with daily volume in June averaging approximately 17.0% below June volume in 2019. At the same time, demand for COVID-19 Testing continues to increase, contributing approximately 23.0% to total volume in June. While total volume declined 19.5%, price/mix increased by 15.6% due to COVID-19 Testing of 10.7% and the Base Business of 4.9%. The Base Business price includes the negative impact from PAMA of ~~(0.9%)), partially offset by~~0.8% and the ~~disposition~~non-renewal of ~~businesses~~the BeaconLBS contract of ~~1.9% and negative foreign currency translation of 0.7%.~~

LCD revenues for the quarter were $1,760.9, a decrease of 2.9% compared to revenues of $1,814.0 in the second quarter of 2018. The decrease in revenues was due to the negative impact from disposition of businesses of 2.8%, negative foreign currency translation of 0.2% and a decline in organic revenues versus prior year of 0.3%, partially offset by acquisitions of 0.4%. Organic revenue growth in constant currency of negative 0.3% includes the impact from PAMA of 1.5% and fewer revenue days of 0.6%.

~~Total LCD volume (measured by requisitions) excluding the disposition of businesses, decreased by 0.9%, as acquisition volume contributed 0.2% and organic volume declined by~~ 1.2%. Organic volume was negatively impacted by approximately 2.5% from the combination of lower consumer genetics, managed care contract changes, and fewer revenue days. Excluding the disposition of businesses, revenue per requisition increased by 1.0%, despite the negative impact from PAMA of 1.5%.

CDD revenues for the second quarter were ~~$1,126.3, an increase~~$1,093.7, a decrease of ~~6.8%~~2.9% over revenues of ~~$1,054.2~~$1,126.3 in the second quarter of ~~2018.~~2019. The ~~increase~~decrease in revenues was primarily due to a 5.2% decline in organic ~~growth~~revenue, 0.7% from the disposition of ~~5.5%~~a business, and ~~acquisitions of 3.3%,~~0.1% from unfavorable foreign currency translation, partially offset by 3.1% benefit from an acquisition. The decline in organic revenue was primarily due to the negative ~~foreign currency translation of 1.6%~~impact from the pandemic, partially offset by a 1.1% increase from COVID-19 molecular testing through its Central Laboratories business. The pandemic continues to cause delays in clinical trial progression and aassociated testing, reductions in investigator site access, as well as interruptions to the supply chain particularly impacting the nonclinical business ~~disposition of 0.3%.~~

~~INDEX~~

unit.

Cost of Revenues


	Three Months Ended June 30,									Three Months Ended June 30,
	2019			2018			Change			2020			2019			Change
Cost of revenues	$	2,056.9		$	2,031.2		1.3	%	Cost of revenues	$	2,008.3		$	2,056.9		(2.4)	%
Cost of revenues as a % of revenues	71.4		%	70.9		%			Cost of revenues as a % of revenues	72.5		%	71.4		%

Cost of revenues ~~increased 1.3%~~decreased 2.4% during the three months ended June 30, ~~2019,~~2020, as compared with the corresponding period in ~~2018.~~2019. Cost of revenues as a percentage of revenues during the three months ended June 30, ~~2019,~~2020, increased to ~~71.4%~~72.5% as compared to ~~70.9%~~71.4% in the corresponding period in ~~2018. The~~2019. This increase iswas primarily due to the impact of COVID-19, higher personnel costs (primarily driven by merit increases), and ~~rent expense to support the Company's global growth initiatives.~~PAMA, partially offset by LaunchPad savings.

Selling, General and Administrative Expenses


	Three Months Ended June 30,
	2020			2019			Change
Selling, general and administrative expenses	$	396.3		$	415.3		(4.6)	%
Selling, general and administrative expenses as a % of revenues	14.3		%	14.4		%

INDEX

Three Months Ended June 30,
2019 2018 Change
Selling, general and administrative expenses $ 415.3
$ 395.2
5.1 %
Selling, general and administrative expenses as a % of revenues 14.4 % 13.8 %
During the three months ended June 30, 2020, the Company incurred $4.6 of acquisition and divestiture related costs and $7.8 in management transition costs. In addition, the Company recorded $0.2 of non-capitalized costs associated with the implementation of a major system as part of its LaunchPad business process improvement initiative and $1.8 related to miscellaneous other items. These charges were offset by insurance proceeds of $10.0 related to the 2018 ransomware attack. These items increased selling, general and administrative expenses by $7.7.

During the three months ended June 30, 2019, the Company incurred $33.2 ofin acquisition and divestiture ~~related~~ costs, $1.5 in management transition ~~cost~~costs and $0.1 in costs related to the ~~previous~~2018 ransomware attack. In addition, the Company recorded $2.6 of non-capitalized costs associated with the implementation of a major system as part of its LaunchPad business process improvement initiative. These items increased selling, general and administrative expenses by $37.4.

During the three months ended June 30, 2018, the Company incurred integration and other related costs of $19.6 primarily relating to the Chiltern acquisition and the planned sale of the Covance Food Solutions business. In addition, the Company incurred $1.4 in consulting expenses relating to fees incurred as part of its integration and management transition costs, $0.1 in costs related to a ransomware attack and $2.5 of non-capitalized costs associated with the implementation of a major system as part of its LaunchPad business process improvement initiative. These items increased selling, general and administrative expenses by $23.6.

Excluding these charges, selling, general and administrative expenses as a percentage of revenues were 14.0% and 13.1% ~~and 13.0%~~ during each of the three months ended June 30, 2020, and 2019, ~~and 2018, respectively, due to the decreased revenue from the implementation of PAMA.~~respectively.

Amortization of Intangibles and Other Assets


	Three Months Ended June 30,							Three Months Ended June 30,
	2019		2018		Change			2020		2019		Change
LCD	$	25.6	$	26.2	(2.3	)%	LCD	$	25.3	$	25.6	(1.2)	%
CDD	34.6		32.3		7.1	%	CDD	34.8		34.6		0.6	%
Total amortization of intangibles and other assets	$	60.2	$	58.5	2.9	%	Total amortization of intangibles and other assets	$	60.1	$	60.2	(0.2)	%

The decrease in amortization of intangibles and other assets within ~~the~~ LCD ~~segment~~ primarily reflects the impact of acquisitions occurring after June 30, ~~2018, offset by the reduction~~2019, net of ~~amortizable intangible assets pursuant to the divestiture of three LCD businesses in 2018.~~ Amortization of intangible assets within ~~the~~ CDD ~~segment~~ increased primarily due to the impact of acquisitions occurring after June 30, ~~2018, offset by the reduction of amortizable intangible assets pursuant to the divestiture of one CDD business during the second quarter of~~ 2019.

Restructuring and Other Special Charges


	Three Months Ended June 30,
	2020		2019		Change
Restructuring and other charges	$	6.4	$	13.6	(52.9)	%

Three Months Ended June 30,
2019 2018 Change
Restructuring and other special charges $ 13.6
$ 12.2
11.5 %
During the three months ended June 30, 2020, the Company recorded net restructuring and other charges of $6.4: $3.7 within LCD and $2.7 within CDD. The charges were comprised of $5.4 related to severance and other personnel costs, $3.3 for a CDD lab facility and equipment impairment, and $4.2 in facility closures, impairment of operating lease right-of use assets and general integration activities. The charges were offset by the reversal of previously established liability of $1.0 and $5.5 in unused severance costs and facility-related costs, respectively.

During the three months ended June 30, 2019, the Company recorded net restructuring and other special charges of $13.6: $3.0 within LCD and $10.6 within CDD. The charges were comprised of $3.5 related to severance and other personnel costs along with $10.2 in costs associated with facility closures, impairment of operating lease right-of-use assets and general integration initiatives. The charges were offset by the reversal of previously established reserves of $0.1 in unused facility reserves.

During the three months ended June 30, 2018, the Company recorded net restructuring and other special charges of $12.2: $5.5 within LCD and $6.7 within CDD. The charges were comprised of $11.8 related to severance and other personnel costs along with $1.3 in costs associated with facility closures and general integration initiatives. The charges were offset by the reversal of previously established reserves of $0.7 and $0.2 in unused facility reserves and unused severance reserves, respectively.

~~INDEX~~

Interest Expense

Three Months Ended June 30,
2019 2018 Change
Interest expense $ (59.1 ) (63.1 ) (6.3 )%


	Three Months Ended June 30,
	2020		2019		Change
Interest expense	$	(52.7)	$	(59.1)	(10.8)	%

The decrease in interest expense for the three months ended June 30, ~~2019,~~2020, as compared with the corresponding period in ~~2018,~~2019, is primarily due to a lower outstanding balance on term loans, lower variable interest rates, the repayment of the ~~2.50%~~2.625% senior notes and a portion of the 4.625% senior notes in ~~2018, the repayment of the 2014 term loan and partial repayment of the 2017 term loan,~~2019, partially offset by ~~an increased level~~the issuance of ~~borrowing on the revolving credit facility and the new 2019 term loan.~~$1,050.0 in debt securities in November 2019.

Equity Method Income

Three Months Ended June 30,
2019 2018 Change
Equity method income $ 2.5
$ 3.0
(16.7 )%


	Three Months Ended June 30,
	2020		2019		Change
Equity method income, net	$	1.8	$	2.5	(28.0)	%

INDEX

decrease in income for the three months ended June 30, ~~2019,~~2020, as compared with the corresponding period in ~~2018,~~2019, was primarily due to decreased profitability of the Company's joint ventures.

Other, net

Three Months Ended June 30,
2019 2018 Change
Other, net $ (10.5 ) $ 2.8
(475.0 )%


	Three Months Ended June 30,
	2020		2019		Change
Other, net	$	47.7	$	(10.5)	(554.3)	%

The change in other, net for the three months ended June 30, ~~2019, is primarily due~~2020, as compared to ~~the $8.8 loss on disposition of a business incurred during~~ the three months ended June 30, 2019, ~~and~~is primarily due to $55.9 of funding from the ~~$5.3~~Relief Fund that was appropriated by Congress to the HHS in the CARES Act. This funding was partially offset by the $5.2 write-off or write down of ~~two~~certain of the Company's ~~cost method~~ investments ~~partially offset by a net increase in other investment gains~~primarily due to the negative impact of ~~$3.1.~~the COVID-19 global pandemic. In addition, foreign currency transaction losses of ~~$3.2~~$1.7 were recognized for the three months ended June 30, ~~2019~~2020 and ~~gains~~losses of ~~$0.9~~$3.2 were recognized in the corresponding period of ~~2018.~~2019.

Income Tax Expense


	Three Months Ended June 30,
	2020			2019			Change
Income tax expense	$	65.4		$	79.3		(17.5)	%
Income tax expense as a % of earnings before income taxes	22.0		%	29.4		%

Three Months Ended June 30,
2019 2018 Change
Income tax expense $ 79.3
$ 78.6
0.9 %
Income tax expense as a % of earnings before income taxes 29.4 % 25.1 %

The 2020 tax rate was favorable to the 2019 tax rate ~~was unfavorable to 2018 primarily~~ due to ~~acquisitions~~the mix of earnings inclusive of federal, state, and ~~divestitures. While both 2019 and 2018 were favorably impacted by~~ foreign ~~earnings taxed at lower rates than the U.S. statutory rate, the benefit was greater in 2018 than 2019.~~changes.

Operating Income by Segment


	Three Months Ended June 30,									Three Months Ended June 30,
	2019			2018			Change			2020			2019			Change
LCD operating income	$	312.5		$	336.3		(7.1	)%	LCD operating income	$	281.3		$	312.5		(10.0)	%
LCD operating margin	17.7		%	18.3		%	(0.6	)%	LCD operating margin	16.6		%	17.7		%	(1.1)	%
CDD operating income	65.8			68.8			(4.4	)%	CDD operating income	65.5			65.8			(0.5)	%
CDD operating margin	5.9		%	6.5		%	(0.6	)%	CDD operating margin	6.0		%	5.9		%	0.1	%
General corporate expenses	(42.6		)	(35.9		)	18.7	%	General corporate expenses	(49.1)			(42.6)			15.3	%
Total operating income	$	335.7		$	369.2		(9.1	)%	Total operating income	$	297.7		$	335.7		(11.3)	%

LCD operating income was ~~$312.5~~$281.3 for the three months ended June 30, ~~2019,~~2020, a decrease of ~~7.1%~~10.0% over operating income of ~~$336.3~~$312.5 in the corresponding period of ~~2018,~~2019, and LCD operating margin decreased 601.1% basis points ~~year-over-year. The~~year-over-year.The decrease ~~in operating income and margin were~~was primarily due to the ~~impact from PAMA of approximately $27.0, disposition of businesses,~~reduction in the Base Business (primarily due to the pandemic) and higher personnel costs, ~~and cybersecurity expenses,~~ partially offset by the increase in COVID-19 Testing and LaunchPad ~~initiatives.~~savings. The Company remains on track to deliver approximately $200.0 of net savings from its three-year ~~phase II of LabCorp Diagnostics’~~LCD's LaunchPad initiative by the end of 2021.

CDD operating income was ~~$65.8~~$65.5 for the three months ended June 30, ~~2019,~~2020, a decrease ~~of 4.4%~~ over operating income of ~~$68.8~~$65.8 in the corresponding period of ~~2018, and CDD operating margin decreased 60 basis points year-over-year.~~2019. The decrease ~~in operating income and margin~~ was primarily due to ~~acquisition-related expenses,~~the negative impact from the pandemic and higher personnel costs, ~~cybersecurity investments~~

~~INDEX~~

~~and rent expense to support the Company's global growth initiatives,~~ partially offset by ~~organic demand,~~molecular COVID-19 testing and LaunchPad ~~savings, acquisitions and currency translation.~~savings. The Company isremains on track to deliver approximately $150.0 of net savings from its three-year ~~CDD~~CDD's LaunchPad initiative by the end of ~~2020, and $30.0 of cost synergies from the integration of Chiltern by the end of 2019.~~2020.

General corporate expenses are comprised primarily of administrative services such as executive management, human resources, legal, finance, corporate affairs, and information technology. Corporate expenses were ~~$42.6~~$49.1 for the three months ended June 30, ~~2019,~~2020, an increase of ~~18.7%~~15.3% over corporate expenses of ~~$35.9~~$42.6 in the corresponding period of ~~2018.~~2019. The increase in corporate expenses in ~~2019~~2020 is primarily due to ~~the benefit of a favorable legal settlement in 2018 offsetting normal corporate expenses.~~higher personnel costs, including executive transition costs.

Six months ended June 30, ~~2019,~~2020, compared with six months ended June 30, ~~2018~~2019

Revenues


	Six Months Ended June 30,
	2020		2019		Change
LCD	$	3,394.7	$	3,482.9	(2.5)	%
CDD	2,237.5		2,201.0		1.7	%
Intercompany eliminations and other	(39.6)		(11.0)		260.0	%
Total	$	5,592.6	$	5,672.9	(1.4)	%

INDEX

Six Months Ended June 30,
2019 2018 Change
LCD $ 3,482.9
$ 3,584.2
(2.8 )%
CDD 2,201.0
2,132.6
3.2 %
Intercompany eliminations (11.0 ) (2.2 ) 400.0 %
Total $ 5,672.9
$ 5,714.6
(0.7 )%

~~The decrease in revenues~~Revenues for the six months ended June 30, ~~2019, as compared with~~2020 were $5,592.6, a decrease of (1.4)% from $5,672.9 during the ~~corresponding period in 2018 was 0.7%.~~six months ended June 30, 2019. The ~~decline~~decrease in revenues was ~~primarily~~ due to a 3.6% decline of organic revenue, 0.4% from the disposition of ~~businesses of 1.9%~~a business, and ~~negative~~0.1% from unfavorable foreign currency translation, partially offset by 2.6% from acquisitions. The 3.6% decline of ~~0.8%~~organic revenue was due to a 11.7% decline in the Company's organic Base Business (as a result of the pandemic), partially offset by ~~acquisitions of 1.0% and~~8.1% from COVID-19 related business. The decline in the organic ~~growth of 1.0% (which~~Base Business includes the negative impact from PAMA of ~~1.0%)~~0.6%.

LCD revenues for the six months ended June 30, ~~2019,~~2020 were ~~$3.48 billion,~~$3,394.7, a decrease of ~~2.8% over~~2.5% compared to revenues of ~~$3.58 billion~~$3,482.9 for the six months ended June 30, ~~2018.~~2019. The decrease in revenue was due to a 3.9% decline in organic revenue, partially offset by 1.4% from acquisitions. The 3.9% decline in organic revenue,was due to a 17.1% decline of the organic Base Business (due to the pandemic), partially offset by 13.2% from COVID-19 Testing. The 17.1% decline of organic Base Business includes a 1.0% negative impact from PAMA and a 1.2% reduction due to the September 2019 nonrenewal of the BeaconLBS - UnitedHealthcare contract pertaining to the Florida market.

Total volume (measured by requisitions) decreased by 12.0% as organic volume declined by 13.4%, partially offset by acquisition volume of 1.4%. The decline in organic volume includes a 21.0% reduction of organic Base Business (due to the pandemic), partially offset by increased demand for COVID-19 Testing of 7.6%. The organic Base Business volumes continued to improve throughout the second quarter with daily volume in June averaging approximately 17.0% below June volume in 2019. At the same time, demand for COVID-19 Testing continues to increase, contributing approximately 23.0% to total volume in June. While total volume declined 12.0%, price/mix increased by 9.4% due to COVID-19 Testing of 5.5% and Base Business of 3.9%. The Base Business price includes the negative impact from PAMA of 1.0% and the non-renewal of the BeaconLBS contract of 1.2%.

CDD revenues for six months ended June 30, 2020 were $2,237.5, an increase of 1.7% over revenues of $2,201.0 for the six months ended June 30, 2019. The increase in revenue was primarily due to the benefit of acquisitions of 4.6%, partially offset by a decline in organic revenue 1.9% and disposition of a business of 1.0%. The decline in organic revenue was primarily due to the negative impact from the ~~disposition of businesses of 2.9% and negative currency translation of 0.2%,~~pandemic, partially offset by ~~acquisitions of 0.2%. Organic revenues growth was flat~~a 0.6% increase from COVID-19 molecular testing through its Central Laboratories business. The pandemic continues to cause delays in clinical trial progression and ~~included~~associated testing, reductions in investigator site access, as well as interruptions to the ~~negative impact of 1.5% from PAMA and 0.8% due to fewer revenue days.~~

~~Total volume (measured by requisitions) excluding~~supply chain particularly impacting the disposition of businesses was flat as acquisition volume contributed 0.1% and organic volume declined by 0.2%. Organic volume was negatively impacted by approximately 2.0% from the combination of lower consumer genetics, managed care contract changes, and fewer revenue days. Excluding the disposition of businesses, revenue per requisition increased by 0.3%, including the negative impact from PAMA of 1.5%.

CDD revenues for the six months ended June 30, 2019 were $2,201.0, an increase of 3.2% over revenues of $2,132.6 in the six months ended June 30, 2018. The increase was primarily due to organic growth of 3.0% and acquisitions of 2.3%, partially offset by negative foreign currency translation of 1.8% and anonclinical business ~~disposition of 0.1%.~~unit.

Cost of Revenues


	Six Months Ended June 30,									Six Months Ended June 30,
	2019			2018			Change			2020			2019			Change
Cost of revenues	$	4,058.4		$	4,100.5		(1.0	)%	Cost of revenues	$	4,104.1		$	4,058.4		1.1	%
Cost of revenues as a % of revenues	71.5		%	71.8		%			Cost of revenues as a % of revenues	73.4		%	71.5		%

Cost of revenues ~~decreased 1.0%~~increased 1.1% during the six months ended June 30, ~~2019,~~2020, as compared with the corresponding period in ~~2018.~~2019. Cost of revenues as a percentage of revenues ~~remained relatively consistent~~ during the six months ended June 30, ~~2019, decreasing slightly~~2020, increased to ~~71.5%~~73.4% as compared to ~~71.8%~~71.5% in the corresponding period in ~~2018.~~2019. This increase was primarily due to the impact of COVID-19, higher personnel costs (primarily driven by merit increases and one additional payroll day that predominantly impacted LCD), and PAMA, partially offset by LaunchPad savings.

Selling, General and Administrative Expenses


	Six Months Ended June 30,
	2020			2019			Change
Selling, general and administrative expenses	$	791.8		$	809.1		(2.1)	%
Selling, general and administrative expenses as a % of revenues	14.2		%	14.3		%

Six Months Ended June 30,
2019 2018 Change
Selling, general and administrative expenses $ 809.1
$ 792.2
2.1 %
Selling, general and administrative expenses as a % of revenues 14.3 % 13.9 %
During the six months ended June 30, 2020, the Company incurred $13.0 of acquisition and divestiture related costs and $10.6 in management transition costs. In addition, the Company recorded $1.1 of non-capitalized costs associated with the implementation of a major system as part of its LaunchPad business process improvement initiative and $1.2 related to miscellaneous other items.These charges were offset by insurance proceeds of $10.0 related to the 2018 ransomware attack. These items increased selling, general and administrative expenses by $19.6.

During the six months ended June 30, 2019, the Company incurred $44.3 ofin acquisition and divestiture ~~related~~ costs, $2.9 in consulting expenses relating to fees incurred as part of its integration and management transition ~~cost~~costs and $0.7 in costs related to athe 2018 ransomware attack. In addition, the Company recorded $5.0 of non-capitalized costs associated with the implementation of a major system as part of its LaunchPad business process improvement initiative. These items increased selling, general and administrative expenses by $52.9.

INDEX

During the six months ended June 30, 2018, the Company incurred integration and other related costs of $37.6 primarily relating to the Chiltern acquisition and planned sale of the Company's Covance Food Solutions business. In addition, the Company incurred $4.5 in consulting expenses relating to fees incurred as part of its integration and management transition costs. During the quarter, the Company paid a special one-time bonus of $31.1 ($6.3 of which was recorded in selling, general and administrative expenses) to non-bonus eligible employees in recognition of the benefits the Company received from the passage of the TCJA. In addition, the Company incurred $4.2 of non-capitalized costs associated with the implementation of a major system as part of its LaunchPad business process improvement initiative. These items increased selling, general and administrative expenses by $50.4 and cost of sales by $26.9.

Excluding these charges, selling, general and administrative expenses as a percentage of revenues were 13.8% and 13.3% ~~and 13.0%~~ during each of the six months ended June 30, 2020, and 2019, ~~and 2018, respectively, primarily due to due to the decreased revenue from the implementation of PAMA.~~respectively.

Amortization of Intangibles and Other Assets


	Six Months Ended June 30,							Six Months Ended June 30,
	2019		2018		Change			2020		2019		Change
LCD	$	50.3	$	56.4	(10.8	)%	LCD	$	51.4	$	50.3	2.2	%
CDD	67.0		64.4		4.0	%	CDD	71.0		67.0		6.0	%
Total amortization of intangibles and other assets	$	117.3	$	120.8	(2.9	)%	Total amortization of intangibles and other assets	$	122.4	$	117.3	4.3	%

The ~~decrease~~increase in amortization of intangibles and other assets within LCD primarily reflects the impact of acquisitions occurring after June 30, ~~2018, offset by the reduction~~2019. Amortization of ~~amortizable~~ intangible assets ~~pursuant~~within CDD increased primarily due to the ~~divestiture~~impact of ~~three~~acquisitions occurring after June 30, 2019.

Goodwill and Other Asset Impairments


	Six Months Ended June 30,
	2020		2019		Change
Goodwill and other asset impairments	$	437.4	$	—	N/A

During the six months ended June 30, 2020 , the Company recorded goodwill and other asset impairment charges of $437.4, $426.4 within CDD and $11.0 within LCD, ~~businesses~~representing 3.9% of the Company's total goodwill and intangible assets. The Company concluded that the fair value was less than carrying value for two of its reporting units and recorded goodwill impairment of $418.7 in ~~2018.~~the CDD segment and $3.7 in the LCD segment. The Company also recorded a charge of $2.7 for the impairment of a CDD tradename, $7.3 for LCD software, and $5.0 for the impairment of the CDD floating rate secured note receivable due 2022.

Restructuring and Other Special Charges


	Six Months Ended June 30,
	2020		2019		Change
Restructuring and other charges	$	31.8	$	34.2	(7.0)	%

Six Months Ended June 30,
2019 2018 Change
Restructuring and other special charges $ 34.2
$ 26.5
29.1 %
During the six months ended June 30, 2020, the Company recorded net restructuring and other charges of $31.8: $11.8 within LCD and $20.0 within CDD. The charges were comprised of $10.5 related to severance and other personnel costs, $8.0 for a CDD lab facility impairment, and $20.0 in facility closures, impairment of operating lease right-of use assets and general integration activities. The charges were offset by the reversal of previously established liability of $1.0 and $5.7 in unused severance costs and facility-related costs, respectively.

During the six months ended June 30, 2019, the Company recorded net restructuring and other special charges of $34.2: $16.1 within LCD and $18.1 within CDD. The charges were comprised of $20.3 related to severance and other personnel costs along with $13.5 in costs associated with facility closures, impairment of operating lease right-of-use assets and general integration initiatives. The charges were increased by the adjustment of previously established reserves of $0.4 in facility reserves.

Interest Expense

Six Months Ended June 30,
2019 2018 Change
Interest expense $ (115.8 ) (126.6 ) (8.5 )%


	Six Months Ended June 30,
	2020		2019	Change
Interest expense	$	(107.7)	(115.8)	(7.0)	%

The decrease in interest expense for the six months ended June 30, ~~2019,~~2020, as compared with the corresponding period in ~~2018,~~2019, is primarily due to a lower outstanding balance on term loans, lower variable interest rates, the repayment of the ~~2.50%~~2.625% senior notes and a portion of the 4.625% senior notes in ~~2018, the repayment of the 2014 term loan, partial repayment of the 2017 term loan and a reduced level of borrowing on the revolving credit facility,~~2019, partially offset by the ~~new 2019 term loan.~~issuance of $1,050.0 in debt securities in November 2019.

Equity Method Income


	Six Months Ended June 30,
	2020		2019		Change
Equity method income, net	$	(4.8)	$	5.5	(187.3)	%

Six Months Ended June 30,
2019 2018 Change
Equity method income $ 5.5
$ 5.5
— %

INDEX

Equity method income represents the Company's ownership share in joint venture partnerships along with equity investments in other companies in the health care industry. All of these partnerships and investments reside within LCD. ~~Equity~~The decrease in income for the six months ended June 30, ~~2019, was consistent~~2020, as compared with the corresponding period in ~~2018.~~

~~INDEX~~

2019, was primarily due to the impairment of an equity method investment and decreased profitability of the Company's joint ventures.

Other, net

Six Months Ended June 30,
2019 2018 Change
Other, net $ (20.9 ) $ (0.7 ) 2,885.7 %


	Six Months Ended June 30,
	2020		2019		Change
Other, net	$	31.6	$	(20.9)	(251.2)	%

The change in other, net for the six months ended June 30, 2020, as compared to the six months ended June 30, 2019, is primarily due to the ~~$8.8 loss on disposition of a business,~~$55.9 funding from the ~~$5.3 write-off of two of~~Relief Fund that was appropriated by Congress to the ~~Company's cost method investments (as compared to $3.5 of investment write-offs during~~HHS in the ~~six months ended June 30, 2018) and net investment losses of $2.8. Foreign currency transaction losses were $7.8 and $1.0, respectively for the 2019 and 2018 periods presented.~~

~~Income Tax Expense~~

Six Months Ended June 30,
2019 2018 Change
Income tax expense $ 148.1
$ 147.6
0.3 %
Income tax expense as a % of earnings before income taxes 28.2 % 26.6 %

~~The 2019 tax rate was unfavorable to 2018 primarily due to acquisitions, divestitures and a lower stock-based compensation benefit.~~CARES Act. This funding was partially offset by ~~TCJA taxes for~~ the ~~repatriation tax that only impacted 2018. While both 2019 and 2018~~$18.3 write-off or write down of certain of the Company's investments primarily due to the negative impact of the COVID-19 global pandemic. In addition, foreign currency transaction losses of $4.5 were ~~favorably impacted by foreign earnings taxed at lower rates than the U.S. statutory rate, the benefit was greater in 2018 than 2019.~~

~~Operating Income by Segment~~

Six Months Ended June 30,
2019 2018 Change
LCD operating income $ 580.8
$ 639.8
(9.2 )%
LCD operating margin 16.7 % 17.9 % (1.2 )%
CDD operating income 153.8
107.3
43.3 %
CDD operating margin 7.0 % 5.0 % 2.0 %
General corporate expenses (80.7 ) (72.5 ) 11.3 %
Total operating income $ 653.9
$ 674.6
(3.1 )%

~~LCD operating income was $580.8~~recognized for the six months ended June 30, ~~2019, a decrease~~2020 and losses of ~~9.2% over operating income of $639.8~~$7.8 were recognized in the corresponding period of ~~2018,~~2019.

Income Tax Expense


	Six Months Ended June 30,
	2020			2019			Change
Income tax expense	$	114.6		$	148.1		(22.6)	%
Income tax expense as a % of earnings before income taxes	391.1		%	28.2		%

The 2020 tax rate was unfavorable to the 2019 tax rate due to impairment charges for which either no tax benefit was recorded (as they were not deductible) or the associated tax assets required a full valuation allowance.


	Six Months Ended June 30,
	2020			2019			Change
LCD operating income	$	486.7		$	580.8		(16.2)	%
LCD operating margin	14.3		%	16.7		%	(2.4)	%
CDD operating income	(273.2)			153.8			(277.6)	%
CDD operating margin	(12.2)		%	7.0		%	(19.2)	%
General corporate expenses	(108.4)			(80.7)			34.3	%
Total operating income	$	105.1		$	653.9		(83.9)	%

LCD operating income was $486.7 for the six months ended June 30, 2020, a decrease of 16.2% over operating income of $580.8 in the corresponding period of 2019, and LCD operating margin decreased ~~120~~(2.4)% basis points year-over-year. The ~~decline~~decrease in operating income and margin were primarily due to the ~~impact from PAMA of approximately $54.0, disposition of businesses,~~reduction in Base Business (primarily due to the pandemic) and higher personnel costs, ~~and cybersecurity expenses,~~ partially offset by the increase in COVID-19 Testing and LaunchPad ~~initiatives.~~savings. The Company remains on track to deliver approximately $200.0 of net savings from its three-year, phase II of ~~LabCorp Diagnostics’~~LCD's LaunchPad initiative by the end of 2021.

CDD operating ~~income~~loss was ~~$153.8~~$(273.2) for the six months ended June 30, ~~2019, an increase of 43.3%~~2020, a decrease over operating income of ~~$107.3~~$153.8 in the corresponding period of ~~2018, and CDD operating margin increased 200 basis points year-over-year.~~2019. The ~~increase~~decrease in operating income and margin ~~were~~was primarily due to ~~organic demand, LaunchPad savings, acquisitions~~the negative impact of COVID-19, specifically goodwill and ~~currency translation,~~other asset impairments of $426.4, and higher personnel costs, partially offset by ~~personnel costs, cybersecurity investments,~~organic demand, acquisitions, and ~~rent expense to support the Company's global expansion.~~LaunchPad savings. The Company is on track to deliver $150.0 of net savings from its three-year CDD LaunchPad initiative by the end of ~~2020, and $30.0 of cost synergies from the integration of Chiltern by the end of 2019.~~2020.

General corporate expenses are comprised primarily of administrative services such as executive management, human resources, legal, finance, corporate affairs, and information technology. Corporate expenses were ~~$80.7~~$108.4 for the six months ended June 30, ~~2019,~~2020, an increase of ~~11.3%~~34.3% over corporate expenses of ~~$72.5~~$80.7 in the corresponding period of ~~2018.~~2019. The increase in corporate expenses in ~~2019~~2020 is primarily due to higher personnel costs, including executive transition costs, and ~~the benefit of a favorable legal settlement in 2018 offsetting normal corporate~~COVID-19 related expenses.

LIQUIDITY AND CAPITAL RESOURCES (dollars and shares in millions)

The Company's strong cash-generating ability ~~to generate cash~~ and ~~its~~ financial condition typically have provided ready access to capital markets. The Company's principal source of liquidity is operating cash flow, supplemented by proceeds from debt ~~offerings and availability under its senior unsecured revolving credit facility.~~offerings. The Company's senior unsecured revolving credit facility is further discussed in Note ~~8 (Debt)~~7 Debt to the Company's ~~Unaudited~~ Condensed Consolidated Financial Statements.

INDEX

~~INDEX~~

~~During~~In summary, the Company's cash flows were as follows for the six months ended June 30, 2020 and 2019, ~~and 2018, respectively, the Company's cash flows were as follows:~~respectively:

Six Months Ended June 30,
2019 2018
Net cash provided by operating activities $ 419.3
$ 567.1
Net cash used for investing activities (891.3 ) (196.3 )
Net cash provided by (used for) financing activities 311.7
(458.1 )
Effect of exchange rate on changes in cash and cash equivalents (1.1 ) (7.9 )
Net change in cash and cash equivalents $ (161.4 ) $ (95.2 )


	Six Months Ended June 30,
	2020		2019
Net cash provided by operating activities	$	574.5	$	419.3
Net cash used for investing activities	(230.0)		(891.3)
Net cash used for financing activities	(119.7)		311.7
Effect of exchange rate changes on cash and cash equivalents	(5.3)		(1.1)
Net (decrease) increase in cash and cash equivalents	$	219.5	$	(161.4)

Cash and Cash Equivalents

Cash and cash equivalents at June 30, 2020 and 2019, totaled $557.0 and ~~2018, totaled~~ $265.4, ~~and $221.4,~~ respectively. Cash and cash equivalents consist of highly liquid instruments, such as time deposits, commercial paper, and other money market investments, substantially all of which have original maturities of three months or less.

Operating Activities

During the six months ended June 30, ~~2019,~~2020, the Company's operations provided ~~$419.3~~$574.5 of cash as compared to ~~$567.1~~$419.3 during the same period in ~~2018.~~2019. The ~~$147.8 decrease~~$155.2 increase in cash provided from operations in ~~2019~~2020 as compared with the corresponding ~~2018~~2019 period is primarily due to ~~lower~~higher cash earnings partially offset by higher working capital. For the first six months of 2020, cash earnings included the $55.9 CARES Act funding and ~~increased~~benefited from income and payroll tax deferrals, while working capital ~~needs.~~was negatively impacted by an increase in COVID-19 related testing supplies inventory and accounts receivable. The COVID-19 pandemic has created uncertainty about the Company's near-term operating cash flows. Based on current expectations of the impact of COVID-19, the Company expects to continue to generate positive cash flows from operating activities, however, should the COVID-19 impact worsen or last longer than anticipated, the Company may see a significant decline in cash flows from operating activities. For more information regarding the risks associated with the COVID-19 and its impact on the Company's business, see Risk Factors in Part II - Item IA.

Investing Activities

Net cash used for investing activities for the six months ended June 30, ~~2019,~~2020, was ~~$891.3~~$230.0 as compared to net cash used for investing activities of ~~$196.3~~$891.3 for the six months ended June 30, ~~2018.~~2019. The change in cash used for investing activities was primarily due to ~~more~~a decrease in business acquisitions during the six months ended June 30, ~~2019.~~2020. Capital expenditures were ~~$179.4~~$205.1 and ~~$159.7~~$179.4 for the six months ended June 30, 2020, and 2019, ~~and 2018,~~ respectively. The Company expects capital expenditures in 2019 to be approximately 4.0% of revenues primarily in connection with projects to support growth in the Company's core businesses, including projects related to LaunchPad. The Company intends to continue to pursue acquisitions to fund growth and make important investments in its business, including in information technology, to improve efficiency and enable the execution of the Company's strategic vision. Such expenditures are expected to be funded by cash flow from operations, as well as borrowings under the Company's revolving credit facility or any successor facility, as needed.

Financing Activities

Net cash ~~provided by~~used for financing activities for the six months ended June 30, ~~2019,~~2020, was ~~$311.7~~$119.7 compared to net cash ~~used for~~provided by financing activities of ~~$458.1~~$311.7 for the six months ended June 30, ~~2018.~~2019. The change in cash flows from financing activities for the six months ended June 30, 2020, as compared to the six months ended June 30, 2019, ~~as compared~~were primarily due to ~~2018, was primarily~~net financing proceeds from the ~~result~~term loan and revolving credit facilities in 2019 of ~~debt proceeds greater than payments during the period partially~~$635.0 offset by ~~increased~~$200.0 more in share repurchases ~~during the first half of~~in 2019.

~~On June 3, 2019, the Company entered into a new $850.0 term loan facility in addition to its $750.02017 term loan facility.~~The 2019 term loan facility will mature on June 3, 2021. Proceeds of the 2019 term loan facility were used for general corporate purposes, including to repay approximately $250.0 of the 2017 term loan facility and in connection with the acquisition of Envigo's nonclinical research services business.

~~The 2019 term facility accrues interest at a per annum rate equal toat the~~ Company's election, either a LIBOR rate plus a margin ranging from 0.55% to 1.175%, or a base rate determined according to a prime rate or federal funds rate plus a margin ranging from 0.0% to 0.175%. The 2019 term loan balance at June 30, 2019, was $850.0. As of June 30, 2019, the effective interest rate on the 2019 term loan was 3.24%.

On September 15, 2017, the Company entered into a $750.0 term loan. The 2017 term loan facility will mature on September 15, 2022. The 2017 term loan balance was $277.0 and $527.0 at June 30, 2019, and December 31, 2018, respectively.

~~As of June 30, 2019, the effective interest rate on the 2017 term loan was 3.56%.~~

On September 15, 2017, the Company also entered into an amendment and restatement of its existing senior unsecured revolving credit facility, which was originally entered into on December 21, 2011, amended and restated December 19, 2014, and further amended on July 13, 2016. The senior revolving credit facility consists of a five-year revolving facility in the principal amount of up to $1,000.0, with the option of increasing the facility by up to an additional $350.0, subject to the agreement of one or more new or existing lenders to provide such additional amounts and certain other customary conditions. The revolving credit facility also provides for a subfacility of up to $100.0 for swing line borrowings and a subfacility of up to $150.0 for issuances of letters of credit. The revolving credit facility is permitted to be used for general corporate purposes, including working capital, capital expenditures, funding of share repurchases and certain other payments, and acquisitions and other investments.The Company had $35.0 outstanding on its revolving credit facility at June 30, 2019, and no outstanding balance on December 31, 2018.

~~INDEX~~

Under the Company's term loan credit ~~facilities~~facility and the revolving credit facility, the Company is subject to negative covenants limiting subsidiary indebtedness and certain other covenants typical for investment grade-rated borrowers and the Company is required to maintain certain leverage ratios. The Company was in compliance with all covenants under the term loan credit ~~facilities~~facility and the revolving credit facility at June 30, ~~2019. As~~2020 and expects that it will remain in compliance with its existing debt covenants for the next twelve months.

During the fourth quarter of 2020, $412.2 of the Company's senior notes mature. The Company has elected to redeem these notes in August 2020 at par using available cash on hand and borrowings under its revolving credit facility.

At June 30, ~~2019, the ratio of total debt to consolidated proforma trailing 12 month EBITDA was 3.4 to 1.0.~~

~~As of June 30, 2019,~~2020 the Company ~~provided letters~~had $557.0 of ~~credit aggregating $72.2, primarily in connection with certain insurance programs. Letters~~cash and $997.0 of ~~credit provided by the Company are issued~~available borrowings under ~~the Company's~~its revolving credit facility, which does not mature until 2022. In May 2020, in order to obtain increased financial covenant flexibility, the Company and ~~are renewed annually.~~its lenders entered into amendments to the term loan facility and the revolving credit facility to increase the maximum leverage ratio to 5.0x debt to last twelve months EBITDA for the three month periods ending June 30, September 30 and December 31, 2020, 4.5x for period ended March 31, 2021 and then reverts back to 4.0x. The amendments also provide that during any period in which the Company's leverage ratio exceeds 4.5x debt to last twelve months EBITDA (i) the company will be prohibited from consummating share repurchases, subject to limited exceptions, (ii) borrowings under the revolving credit facility will accrue interest at a per annum rate equal to, at the Company's election, either a LIBOR rate plus a margin of 1.25% or a base

INDEX

rate plus a margin of 0.25%, (iii) the facility fee that the Company is required to pay on the aggregate commitments under the revolving credit facility will be 0.25% per annum, and (iv) borrowings under the term loan facility will accrue interest at a per annum rate equal to, at the Company's election, either a LIBOR rate plus a margin of 1.175% or a base rate plus a margin of 0.175%.

The Company instituted numerous actions to help mitigate the financial impact from the COVID-19 pandemic, which included furloughs, reduced hours, and the suspension of discretionary merit adjustments and 401(k) plan contributions in the United States (U.S.). In response to its improved outlook, the Company has been rapidly resuming regular work schedules and is proceeding with merit adjustments and will retroactively reinstate 401(k) plan contributions in the U.S.

At the end of 2018, the Company had outstanding authorization from the board of directors to purchase up to $443.5 of Company common stock. During January 2019, the Company purchased 0.8 shares of its common stock at an average price of $131.71 for a total cost of $100.1 under this plan. On February 6, 2019, the board of directors replaced the Company's existing share repurchase plan with a new plan authorizing repurchase of up to $1.25 billion of the Company's common stock. The repurchase authorization has no expiration. During the three months ended June 30, 2019, the Company purchased 1.3 shares of its common stock at an average price of $159.13 for a total cost of $199.9. As of June 30, 2019, the Company had outstanding authorization from the board of directors to purchase up to ~~$1.05 billion~~$900.0 of Company common stock. As of June 30, 2020, the Company had outstanding authorization from the board of directors to purchase up to $800.0 of the Company's common stock.

The Company had a $35.9 and $26.7 reserve for unrecognized income tax benefits, including interest and penalties, as of June 30, 2019, and December 31, 2018, respectively. Approximately $5.1 and $6.0 is classified in accrued expenses and other, and approximately $30.8 and $20.7 is classified in deferred income taxes and other tax liabilities in the Company's Condensed Consolidated Balance Sheets.

~~Zero-coupon Subordinated Notes~~

~~On March 11, 2019,~~repurchase authorization has no expiration date; however, the Company ~~announced that for the period from~~temporarily suspended stock repurchases beginning in March ~~11, 2019,~~2020 due to ~~September 10, 2019, the zero-coupon subordinated notes will accrue contingent cash interest at a rate of no less than 0.125%~~impact of the ~~average market price of a zero-coupon subordinated note for the five trading days ended August 27, 2019, in addition to the continued accrual of the original issue discount.~~

Credit Ratings

The Company’s investment grade debt ratings from Moody’s and from Standard and Poor’s (S&P) contribute to its ability to access capital markets.

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk

Market risk is the potential loss arising from adverse changes in market rates and prices, such as foreign currency exchange rates, interest rates, and other relevant market rate or price changes. In the ordinary course of business, the Company is exposed to various market risks, including changes in foreign currency exchange and interest rates, and the Company regularly evaluates its exposure to such changes. The Company addresses its exposure to market risks, principally the market risks associated with changes in foreign currency exchange rates and interest rates, through a controlled program of risk management that includes, from time to time, the use of derivative financial instruments such as foreign currency forward contracts, and interest rate and cross currency swap agreements. Although, as set forth below, the Company’s zero-coupon subordinated notes contain features that are considered to be embedded derivative instruments, the Company does not hold or issue derivative financial instruments for trading purposes.

Foreign Currency Exchange Rates

Approximately ~~12.5%~~12.0% of the Company's revenues for the six months ended June 30, ~~2019,~~2020, and approximately ~~15.3%~~12.5% of ~~those~~the Company's revenue for the six months ended June 30, ~~2018,~~2019, were denominated in currencies other than the U.S. dollar. The Company's financial

~~INDEX~~

statements are reported in U.S. dollars and, accordingly, fluctuations in exchange rates will affect the translation of revenues and expenses denominated in foreign currencies into U.S. dollars for purposes of reporting the Company's consolidated financial results. In the ~~first~~second quarter of ~~2019~~2020 and the year ended December 31, ~~2018,~~2019, the most significant currency exchange rate exposures were to the Canadian dollar, Swiss Franc, Euro and British Pound. Excluding the impacts from any outstanding or future hedging transactions, a hypothetical change of 10% in average exchange rates used to translate all foreign currencies to U.S. dollars would have impacted income before income taxes for the six months ended June 30, ~~2019,~~2020 by approximately ~~$2.2.~~$2.6. Gross accumulated currency translation adjustments recorded as a separate component of shareholders’ equity were ~~$47.2~~$(80.5) and ~~$(82.6)~~$47.2 at June 30, ~~2019,~~2020 and ~~2018,~~2019, respectively. The Company does not have significant operations in countries in which the economy is considered to be highly-inflationary.

The Company earns revenue from service contracts over a period of several months and, in some cases, over a period of several years. Accordingly, exchange rate fluctuations during this period may affect the Company's profitability with respect to such contracts. The Company is also subject to foreign currency transaction risk for fluctuations in exchange rates during the period of time between the consummation and cash settlement of transactions. The Company limits its foreign currency transaction risk through exchange rate fluctuation provisions stated in some of its contracts with customers, or it may hedge transaction risk with foreign currency forward contracts. At June 30, ~~2019,~~2020, the Company had 2738 open foreign exchange forward contracts relating to service contracts with various amounts maturing monthly through July ~~2019~~2020 with a notional value totaling approximately ~~$328.1.~~$612.5. At December 31, ~~2018,~~2019, the Company had 34 open foreign exchange forward contracts relating to service contracts with various amounts maturing monthly through January ~~2019~~2020 with a notional value totaling approximately ~~$487.9.~~$369.2.

The Company is party to ~~six~~ U.S. Dollar to Swiss Franc ~~cross currency~~cross-currency swap agreements with an aggregate notional amount of $600.0, maturing in 2022 and 2025, as a hedge against the impact of foreign exchange movements on its net investment in a Swiss Franc functional currency subsidiary.

Interest Rates

Some of the Company's debt is subject to interest at variable rates. As a result, fluctuations in interest rates affect the business. The Company attempts to manage interest rate risk and overall borrowing costs through an appropriate mix of fixed and variable rate debt including by the utilization of derivative financial instruments, primarily interest rate swaps.

INDEX

Borrowings under the Company's term loan credit facility and revolving credit facility are subject to variable interest rates, unless fixed through interest rate swaps or other agreements. As of June 30, 2020 and December 31, 2019, the Company had ~~$277.0 of unhedged variable rate debt from the 2017 term loan credit facility, $850.0~~$375.0 and $375.0, respectively, of unhedged variable debt from the 2019 term loan credit facility and ~~$35.0 outstanding on its revolving credit facility. As of December 31, 2018, the Company had $527.0 of unhedged variable rate debt from the 2017 term loan credit facility~~$0.0 and $0.0, respectively, outstanding on its revolving credit facility.

To hedge against changes in the fair value of a portion of the Company's long-term debt, the Company is party to ~~two~~a fixed-to-variable interest rate swap ~~agreements~~agreement for a portion of the 4.625% senior notes due 2020 with an aggregate notional amount of ~~$600.0~~$300.0 and variable interest rates based on one-month LIBOR plus 2.298%.


1)	The Company will pay contingent cash interest on the zero-coupon subordinated notes after September 11, 2006, if the average market price of the notes equals 120% or more of the sum of the issue price, accrued original issue discount and contingent additional principal, if any, for a specified measurement period.


2)	Holders may surrender zero-coupon subordinated notes for conversion during any period in which the rating assigned to the zero-coupon subordinated notes by Standard & Poor’s Ratings Services is BB- or lower.

Each quarter-point increase or decrease in the variable rate would result in the Company's interest expense changing by approximately ~~$2.9~~$0.9 per year for the Company's unhedged variable rate debt.

ITEM 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, the Company carried out, under the supervision and with the participation of the Company’s management, including the Company’s principal executive officer and principal financial officer, an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Based upon this evaluation, the Company’s principal executive officer and principal financial officer concluded that the Company’s disclosure controls and procedures were effective as of June 30, ~~2019~~.

~~INDEX~~

2020.

Changes in Internal Control Over Financial Reporting

On June 3, 2019, the Company completed the acquisition of Envigo's nonclinical contract research services business. The Company’s management has extended its oversight and monitoring processes that support internal control over financial reporting to include the acquired Envigo operations. The Company’s management is continuing to integrate the acquired operations of Envigo's nonclinical contract research services business into the Company’s overall internal control over financial reporting process. However, management plans to exclude these operations from its annual assessment of internal controls over financial reporting for the year ending December 31, 2019.

There were no ~~other~~ changes in the Company’s internal control over financial reporting (as defined in Rules13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) that occurred during the quarter ended June 30, ~~2019,~~2020, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

~~INDEX~~39

INDEX

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

See Note 1110 (Commitments and Contingencies) to the Company’s unaudited condensed consolidated financial statements, above, which is incorporated herein by reference.

Item 1A. Risk Factors

~~There~~The risk factors set forth below revise and supplement the corresponding risk factors set forth in Part I - Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as amended. With the exception of the following, there have been no material changes in the risk factors that appear in Part I - Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, ~~2018.~~2019.

The effects of the outbreak of the COVID-19 pandemic have had and could continue to have material adverse impacts on the Company’s business, results of operations, cash flows, and financial position.

The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business. In the second half of March, daily volume for routine tests started to decline as a result of decreased consumer demand driven by a significant reduction in physician office visits, the cancellation of elective medical procedures, and the negative impacts on discretionary spending resulting from the economic downturn, among other factors. In addition, the performance of the Company’s drug development business was challenged by COVID-19 due to actions that clients have taken and are taking that slowed clinical trial progress and the associated testing as well as restrictions in trial site access in certain countries and interruptions in the supply chain. Given the continued unpredictability pertaining to the COVID-19 pandemic and the corresponding government restrictions and customer behavior, the impact on the Company's business is not yet certain and depends on the number of evolving factors that the Company may not be able to predict or effectively respond to.

The further spread of COVID-19, and the Company’s initiatives to help limit the spread of the illness, will impact the Company’s ability to carry out its business as usual, which could materially adversely impact its business and financial condition. The Company has incurred additional costs for the safety of its employees and the continuity of its operations, including increased frequency of deep cleaning and sanitation at each of its physical locations, additional safety training and processes, enhanced hygiene practices and materials, flexible and remote working where possible, and allowing for greater social distancing for the Company’s employees who must work on-site. Additionally, the Company has made a number of changes at the Company’s patient service centers for the comfort and safety of the patients, many of which have also increased costs for the Company. For example, the Company has set aside the first business hour of every day for vulnerable patients, launched a mobile check-in process that allows patients to wait for their appointment from within their car or other nearby location, and increased sanitation and disinfection in check-in areas, waiting rooms, bathrooms, and hallways with Centers for Disease Control and Prevention (CDC)-approved disinfectants.

The Company faces increased cybersecurity risks due to the number of employees that are working remotely in regions impacted by stay-at-home orders. Increased levels of remote access create additional opportunities for cybercriminals to exploit vulnerabilities, and employees may be more susceptible to phishing and social engineering attempts. The Company may also be subject to increased cyber-attacks, such as phishing attacks by threat actors using the attention placed on the pandemic as a method for targeting the Company's personnel. In addition, technological resources may be strained due to the number of remote users.

Adverse changes in government and third-party payer regulations, reimbursement, or coverage policies (or in the interpretation of current regulations) relating to COVID-19 testing could materially impact the Company's results of operations, cash flows and financial position.

The Company expects to continue to incur additional costs, which may be significant, as it continues to implement operational changes in response to this pandemic. Further, the COVID-19 outbreak has disrupted and could continue to disrupt the Company’s supply chain, including by impacting its ability to secure test collection supplies, equipment and testing supplies for its facilities, personal protective equipment for its employees in its testing locations, patient service centers, and drug development clinics. For similar reasons, the COVID-19 pandemic has also adversely impacted, and may continue to adversely impact, third parties that are critical to the Company’s business, including vendors, suppliers, and business partners. These developments, and others that are difficult or impossible to predict, could impact materially the Company’s business, financial results, cash flows, and financial position.

The Company has diverted resources to developing and enhancing the accessibility of COVID-19 testing, while at the same time taking certain steps with respect to its business strategy in order to increase cash flexibility. For example, the Company

INDEX

temporarily suspended its share repurchase program, applied a heightened threshold to acquisition activity, delayed some of its capital expenditures, and temporarily suspended merit pay increases and 401(k) contributions for U.S. employees for 2020. In response to its improved outlook, the Company has been rapidly resuming regular work schedules and is proceeding with merit adjustments and will retroactively reinstate 401(k) plan contributions in the U.S. These measures, and any other measures the Company has taken and will continue to take to mitigate COVID-19, may be insufficient to ensure the financial stability of the Company, or may have other adverse impacts on the Company’s business, results of operations, cash flows, and financial position. Additionally, if the pandemic continues for an extended period of time, the Company may be forced to prioritize its application of resources to the continued mitigation of COVID-19, at the expense of other potentially profitable opportunities or initiatives, such as through the development of new products or selected business acquisitions.

If the Company does not respond appropriately to the COVID-19 pandemic, or if the Company’s customers do not perceive its response to be adequate, the Company could suffer damage to its reputation, which could adversely affect its business.

On March 11, 2020, the outbreak of COVID-19 was declared a global pandemic and containment and mitigation measures were recommended; six days prior to this characterization, the Company announced the availability of its LabCorp 2019 Novel Coronavirus (COVID-19) NAA test, which detects the presence of the underlying virus that causes COVID-19, for use with patients who meet current guidance for evaluation of infection with COVID-19. On April 9, 2020, the Company announced an agreement to collaborate on a comprehensive U.S.-based COVID-19 patient data registry. The Company has performed more than 9.2 million molecular tests since making its first COVID-19 test available. The Company also launched a self-collection kit for its COVID-19 NAA test under an emergency use authorization from the FDA, as well as expanded availability of serology tests to detect antibodies to the virus that causes COVID-19. The Company has performed more than 2.2 million antibody tests as of July 30, 2020. The Company continues to increase capacity for COVID-19 molecular testing but the Company's testing capacity is dependent on access to multiple testing platforms and the availability of equipment and testing supplies and key personnel. Despite the Company's efforts to expand capacity and access to COVID-19 testing, the Company may not be successful in meeting expectations, and the Company’s customers and other stakeholders may perceive the Company’s responses to the pandemic as insufficient, inadequate or not equivalent to or better than competitors, including with respect to the availability of testing and the amount of time it takes for delivery of test results. Factors that may be out of the Company’s control, such as the availability of equipment, supplies, and key personnel and geographical changes in demand, may impact the Company’s ability to maintain testing capacity and timely delivery of test results and the Company's other responses to the COVID-19 pandemic, and may have an adverse effect on the Company’s operations. Any such disruptions could result in negative publicity, and the Company could suffer damage to its reputation, which could adversely affect its business, results of operations, cash flows, and financial position.

The success of the Company is dependent in part on the efforts of its management team and employees, and the COVID-19 pandemic could divert or hinder the Company’s human capital resources, which may adversely affect the Company’s operations.

The Company’s management team and employees have been acutely focused on efforts to respond to and mitigate COVID-19, including developing the LabCorp 2019 Novel Coronavirus (COVID-19) NAA test. Since that time, the Company has been continuously working to increase the number of tests that can be performed and improve the time for delivering test results. The Company’s management team is also working closely with federal and state authorities, health officials, and other key constituencies to make testing available to patients who meet the CDC criteria for who should be tested, and Department of Health and Human Services (HHS) guidance for prioritization of testing. These response efforts have required, and will continue to require, a large investment of time and resources that would otherwise be focused on the development and growth of the Company. Further, the Company's ability to maintain and expand testing capacity depend upon maintaining and expanding its employee population. If the Company’s management team or employees become unavailable due to illness or from other related factors, its operations could be materially adversely affected.

The ongoing COVID-19 pandemic has created significant volatility, uncertainty, and economic disruption that could have an adverse impact on the Company’s financial position, including with respect to the Company’s ability to repay its senior notes due in the fourth quarter of 2020 and maintain its maximum leverage ratio covenant under its term loan facility and revolving credit facility.

While the Company believes that it maintains a solid financial position, including a strong balance sheet, investment grade ratings, and significant access to credit, the sweeping nature of the rapidly-evolving COVID-19 pandemic has created cascading effects, all of which are difficult to predict. As the pandemic continues to create disruptions or turmoil in the credit and financial markets, the Company’s ability to access capital on favorable terms and continue to meet its liquidity needs in the future could be adversely impacted. The Company may also experience greater than normal impact due to fluctuations in foreign exchange rates and interest rates, decreased sales volumes, changes in employment rates and health insurance coverage, the speed of the anticipated recovery, the ability of its customers to pay for its services, and governmental and business reactions to the pandemic, all of which are highly uncertain and cannot be predicted. The Company implemented several measures in order to

INDEX

increase cash flexibility in light of these economic uncertainties, including temporarily suspending its share repurchase program, applying a heightened threshold to acquisition activity, delaying some of its capital expenditures, and suspending merit pay increases and U.S. employee 401(k) contributions for 2020. As the Company's business performance has improved, the Company will proceed with merit adjustments and will retroactively reinstate 401(k) contributions for 2020. These measures, and any other measures the Company may take to mitigate COVID-19, may be insufficient to ensure the financial stability of the Company, and may have other adverse impacts on the Company’s business, results of operations, cash flows, and financial position.

In May 2020, the Company and its lenders entered into amendments to the term loan facility and the revolving credit facility to increase the maximum leverage ratio covenant to 5.0x debt to last twelve months EBITDA for each of the three month periods ending June 30, September 30, and December 31, 2020 and 4.5x debt to last twelve months EBITDA for the three month period ending March 31, 2021. Violation of that covenant could preclude the Company from borrowing on the revolving credit facility and require repayment of its term loan of $375.0, if demanded by a majority of the Company's bank group. There can be no assurance that the Company will be able to maintain compliance with this modified covenant due to the uncertainties of the Company's financial performance as a result of the COVID-19 pandemic. If the Company were not able to do so, any future covenant amendment or waiver that the Company may need or seek in the future may lead to increased costs, increased interest rates, additional restrictive covenants and other available lender protections. There can be no assurance that the Company would be able to obtain additional amendments or waivers in a timely manner, on acceptable terms, or at all.

During the fourth quarter of 2020, $412.2 of the Company's senior notes mature. The Company has elected to redeem these notes in the third quarter from available cash on hand and borrowings under its revolving credit facility. However, any failure to pay the senior notes prior to or at maturity, or a violation of its term loan and revolving credit facility leverage ratio covenants or other covenants, a failure to obtain any additional covenant amendments or waivers, or a failure to obtain alternative financing, if required, could result in a default, which would result in defaults under the Company’s other debt agreements and have material adverse consequences for the Company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds (dollars in ~~millions)~~millions, except per share data)

The following table sets forth information with respect to purchases of shares of the Company’s common stock based on settled trades made during the three months ended June 30, ~~2019,~~2020, by or on behalf of the Company:


	Total Number of Shares Repurchased	Average Price Paid Per Share		Total Number of Shares Repurchased as Part of Publicly Announced Program	Maximum Dollar Value of Shares that May Yet Be Repurchased Under the Program
April 1 - April 30	—	$	—	—	$	800.0
May 1 - May 31	—	—		—	800.0
June 1 - June 30	—	—		—	800.0
	—	$	—	—	$	800.0

Total Number of Shares Repurchased Average Price Paid Per Share Total Number of Shares Repurchased as Part of Publicly Announced Program Maximum Dollar Value of Shares that May Yet Be Repurchased Under the Program
April 1 - April 30 0.7
$ 154.49
0.7
$ 1,151.0
May 1 - May 31 0.6
163.95
0.6
1,050.0
June 1 - June 30 —
—
—
1,050.0
1.3
$ 159.13
1.3
$ 1,050.0

On February 6, 2019, the board of directors replaced the Company's existing share repurchase plan with a new plan authorizing repurchase of up to $1.25 billion of the Company's common stock. The repurchase authorization has no expiration. During the three months ended June 30, 2019, the Company purchased 1.3 shares of its common stock at at an average price of $159.13 for a total cost of $199.9. As of June 30, ~~2019,~~2020, the Company had outstanding authorization from the board of directors to purchase up to ~~$1.05 billion~~$800.0 of the Company's common stock. The repurchase authorization has no expiration date; however the Company temporarily suspended stock repurchases beginning in March 2020 due to impact of the COVID-19 pandemic.

Item 5. Other Information

On August 6, 2019, the Company and David P. King, Chairman, President and Chief Executive Officer of the Company, entered into a Transition Agreement effective June 30, 2019 (the Transition Agreement), as contemplated by the Term Sheet dated June 4, 2019 (the Term Sheet), which was previously described in the Company’s Form 8-K filed on June 5, 2019. The Transition Agreement supersedes the Term Sheet and confirms that Mr. King will (i) transition from the positions of President and Chief Executive Officer effective November 1, 2019 (the Transition Date); (ii) continue to serve on the Board as Chairman of the Board from the Transition Date until a date mutually agreed with the Board and no later than December 31, 2020; and (iii) serve as Senior Advisor to the Company’s Chief Executive Officer (Senior Advisor) from the Transition Date through at least December 31, 2020.None.

Pursuant to the Transition Agreement, Mr. King’s current annual base salary of $1,200,000, subject to any ordinary course increases by the Compensation Committee of the Board, will continue until December 31, 2019, after which he will be entitled to a base salary of $1,000,000 per year for the period beginning January 1, 2020 until he ceases serving as Chairman of the Board or as a Senior Advisor to the CEO. Mr. King will continue to be eligible to receive an annual bonus pursuant to LabCorp’s Management Incentive Bonus Plan (the MIB Plan) for fiscal year 2019 reflective of his full 2019 MIB Plan opportunity, with achievement to be based on specific performance objectives determined by the Compensation Committee of the Board. For fiscal year 2020, Mr. King will not be eligible to receive an annual bonus pursuant to the MIB Plan.

In accordance with the terms of the Transition Agreement, all of Mr. King’s equity awards outstanding as of the date of the Transition Agreement will be subject to the Company’s Senior Executive Transition Policy and will continue to be eligible for vesting and continue to become exercisable, payable or eligible for the termination of restrictions, as applicable, on the same terms and conditions as if Mr. King were to remain employed by the Company during the original exercise or vesting period, subject to modifications if necessary to comply with applicable law. On January 1, 2020, Mr. King will receive a grant of restricted stock units with an aggregate grant date fair value of $6,500,000 and a one-year vesting period, which shall be subject to LabCorp’s

INDEX

Senior Executive Transition Policy and the terms of the Company’s 2016 Omnibus Incentive Plan (the 2020 Grant). The 2020 Grant will continue to be eligible for vesting and continue to become payable on the same terms and conditions as if Mr. King were to have remained employed by the Company during the one-year vesting period.

Mr. King will continue to receive the perquisites he currently receives and will remain eligible to participate generally in the employee benefit plans in which he currently participates through the period he serves as Senior Advisor. Mr. King will be subject to indefinite confidentiality and non-disparagement restrictions, two-year post-termination non-competition and non-solicitation covenants, and three-year standstill covenants under the Transition Agreement.

~~The foregoing description does not purport to be complete and is qualified by reference to the full text of the Transition Agreement, a copy of which is filed as Exhibit 10.1 hereto.~~

Item 6. Exhibits



(a)		Exhibits
10.13.1		~~Transition Agreement David P. King~~
~~10..2~~	~~Executive Employment Agreement, dated June 4, 2019, by~~Amended and ~~between~~Restated By-laws of Laboratory Corporation of America Holdings (adopted and ~~Adam H. Schechter (incorporated by reference to Exhibit~~ effective July 7, 2020).
10.1		Amendment No. 1, dated as of May 7, 2020, to the ~~Company's Current Report on Form 8-K filed on June 5, 2019)~~
~~10.3~~	Term Loan Credit Agreement, dated June 3, 2019, ~~by and~~ among ~~Laboratory Corporation of America Holdings,~~the Company, Bank of America, N.A. as administrative agent, and the lenders party thereto. (incorporated herein by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on May 8, 2020).
10.2		Amendment No. 1, dated as of May 7, 2020, to the Second Amended and Restated Credit Agreement, dated September 15, 2017 (originally dated as of December 21, 2011), among the Company, Bank of America, N.A. as administrative agent, and the lenders party thereto (incorporated herein by reference to Exhibit ~~10.1~~10.2 to the ~~Company's Current~~Company’s Quarterly Report on Form ~~8-K~~10-Q filed on ~~June 3, 2019)~~May 8, 2020).
31.1*		Certification by the Chief Executive Certification by Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) pursuant to Rule 13a-14(a) or Rule 15d-14(a)
31.2*		Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a)
32**		Written Statement of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)
101.INS*		Inline XBRL Instance Document - The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*		Inline XBRL Taxonomy Extension Schema
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)



*						filed herewith
**						furnished herewith

INDEX

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

Registrant


		By:	/s/ ADAM H. SCHECHTER
			Adam H. Schechter
			Chief Executive Officer

~~By:~~	~~/s/ DAVID P. KING~~
	~~David P. King~~
	~~Chairman of the Board, President~~
	~~and Chief Executive Officer~~



			By:			/s/ GLENN A. EISENBERG
						Glenn A. Eisenberg
						Executive Vice President and
						Chief Financial Officer

July 31, 2020

~~August 8, 2019~~

4445



	June 30, 2019			December 31, 2018
ASSETS
Current assets:
Cash and cash equivalents	$	265.4		$	426.8
Accounts receivable	1,576.1			1,467.9
Unbilled services	488.8			394.4
Supplies inventories	219.7			237.3
Prepaid expenses and other	298.6			309.0
Total current assets	2,848.6			2,835.4
Property, plant and equipment, net	2,544.2			1,740.3
Goodwill, net	7,843.7			7,360.3
Intangible assets, net	4,015.9			3,911.1
Joint venture partnerships and equity method investments	86.7			60.5
Deferred income tax assets	1.7			1.7
Other assets, net	403.6			276.0
Total assets	$	17,744.4		$	16,185.3

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	531.6		$	634.6
Accrued expenses and other	820.3			870.0
Unearned revenue	404.2			356.4
Short-term operating lease liabilities	229.2			—
Short-term finance lease liabilities	8.2			7.9
Short-term borrowings and current portion of long-term debt	502.3			10.0
Total current liabilities	2,495.8			1,878.9
Long-term debt, less current portion	6,135.0			5,990.9
Operating lease liabilities	586.1			—
Financing lease liabilities	46.2			51.0
Deferred income taxes and other tax liabilities	948.3			940.0
Other liabilities	368.6			334.0
Total liabilities	10,580.0			9,194.8
Commitments and contingent liabilities
Noncontrolling interest	20.0			19.1
Shareholders’ equity:
Common stock, 97.8 and 98.9 shares outstanding at June 30, 2019 and December 31, 2018, respectively	9.1			11.7
Additional paid-in capital	91.4			1,451.1
Retained earnings	7,455.8			7,079.8
Less common stock held in treasury	—			(1,108.1		)
Accumulated other comprehensive loss	(411.9		)	(463.1		)
Total shareholders’ equity	7,144.4			6,971.4
Total liabilities and shareholders’ equity	$	17,744.4		$	16,185.3



	For the Six Months Ended June 30, 2018
	U.S.		Canada		U.K.		Switzerland		Other Europe		Other		Total
Payer/Customer
LCD
Clients	18	%	1	%	—	%	—	%	—	%	—	%	19	%
Patients	7	%	—	%	—	%	—	%	—	%	—	%	7	%
Medicare and Medicaid	9	%	—	%	—	%	—	%	—	%	—	%	9	%
Third-party	25	%	2	%	—	%	—	%	—	%	—	%	27	%
Total LCD revenues by payer	59	%	3	%	—	%	—	%	—	%	—	%	62	%

CDD
Biopharmaceutical and medical device companies	20	%	—	%	2	%	5	%	4	%	7	%	38	%

Total revenues	79	%	3	%	2	%	5	%	4	%	7	%	100	%



	June 30, 2019		December 31, 2018
Sales commission assets	$	27.4	$	24.2
Deferred contract fulfillment costs	14.2		12.9
Total	$	41.6	$	37.1



	LCD						CDD
	Severance and Other Employee Costs			Facility Costs			Severance and Other Employee Costs			Facility Costs			Total
Balance as of December 31, 2018	$	2.1		$	7.4		$	6.5		$	27.6		$	43.6
Reclassification for ASC 842 adoption	—			(5.7		)	—			(27.1		)	(32.8		)
Restructuring charges	11.9			1.0			8.4			1.7			23.0
Adjustments to prior restructuring accruals	(0.1		)	—			0.5			—			0.4
Impairment of operating lease right-of-use asset	—			3.3			—			7.5			10.8
Cash payments and other adjustments	(13.6		)	(3.1		)	(8.5		)	(7.2		)	(32.4		)
Balance as of June 30, 2019	$	0.3		$	2.9		$	6.9		$	2.5		$	12.6
Current													$	10.4
Non-current													2.2
													$	12.6



	LCD		CDD			Total
Balance as of January 1, 2019	$	3,638.8	$	3,721.5		$	7,360.3
Goodwill acquired during the period	22.3		468.2			490.5
Dispositions	—		(12.6		)	(12.6		)
Adjustments to goodwill	1.9		3.6			5.5
Balance at June 30, 2019	$	3,663.0	$	4,180.7		$	7,843.7



	June 30, 2019							December 31, 2018
	Gross Carrying Amount		Accumulated Amortization			Net		Gross Carrying Amount		Accumulated Amortization			Net
Customer relationships	$	4,307.9	$	(1,233.0	)	$	3,074.9	$	4,119.4	$	(1,146.7	)	$	2,972.7
Patents, licenses and technology	452.3		(224.1		)	228.2		447.3		(211.2		)	236.1
Non-compete agreements	82.5		(57.2		)	25.3		76.8		(53.7		)	23.1
Trade names	407.7		(202.9		)	204.8		404.0		(189.1		)	214.9
Land use right	11.1		(4.9		)	6.2		10.8		(4.1		)	6.7
Canadian licenses	476.5		—			476.5		457.6		—			457.6
	$	5,738.0	$	(1,722.1	)	$	4,015.9	$	5,515.9	$	(1,604.8	)	$	3,911.1



	Three Months Ended June 30, 2019		Six Months Ended June 30, 2019
Operating lease cost	$	59.9	$	110.8

Finance lease cost:
Amortization of ROU assets	$	1.5	$	2.9
Interest on lease liabilities	0.4		1.2
Total finance lease cost	$	1.9	$	4.1



	Six Months Ended June 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	(115.2	)
Operating cash flows from finance leases	(0.9		)
Financing cash flows from finance leases	(4.8		)

ROU assets obtained in exchange for lease obligations:
Operating leases	$	43.7
Finance leases	0.2



	June 30, 2019
Operating Leases
Operating lease ROU assets (included in Property, plant and equipment, net)	$	770.3

Short-term operating lease liabilities	229.2
Operating lease liabilities	586.1
Total operating lease liabilities	$	815.3



	June 30, 2019
Finance Leases
Finance lease ROU assets (included in Other assets)	$	85.4

Short-term finance lease liabilities	$	8.2
Finance lease liabilities	46.2
Total finance lease liabilities	$	54.4

Weighted Average Remaining Lease Term
Operating leases	5.8
Finance leases	6.5

Weighted Average Discount Rate
Operating leases	4.2		%
Finance leases	4.8		%



Year Ended December 31,	Operating Leases		Finance Leases

2019	$	191.1	$	8.6
2020	145.4		8.0
2021	107.0		6.7
2022	80.9		6.0
2023	61.5		6.5
Thereafter	155.6		23.1



	June 30, 2019			December 31, 2018
Zero-coupon convertible subordinated notes	$	1.4		$	8.7
2.625% senior notes due 2020	500.0			—
Debt issuance costs	(1.0		)	(0.5		)
Current portion of note payable	1.9			1.8
Total short-term borrowings and current portion of long-term debt	$	502.3		$	10.0



	Issued		Held in Treasury		Outstanding
Common shares at December 31, 2018	122.4		(23.5	)	98.9
Common stock issued under employee stock plans	1.0		—		1.0
Surrender of restricted stock and performance share awards	—		(0.1	)	(0.1	)
Retirement of common stock	(2.0	)	—		(2.0	)
Retirement of treasury stock	(23.6	)	23.6		—
Common shares at June 30, 2019	97.8		—		97.8



	Foreign Currency Translation Adjustments			Net Benefit Plan Adjustments			Accumulated Other Comprehensive Earnings (Loss)
Balance at December 31, 2018	$	(389.8	)	$	(73.3	)	$	(463.1	)
Other comprehensive earnings before reclassifications	47.2			5.5			52.7
Tax effect of adjustments	—			(1.5		)	(1.5		)
Balance at June 30, 2019	$	(342.6	)	$	(69.3	)	$	(411.9	)



	U.K. Plans
	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Service cost for administrative expenses	$	0.8		$	0.9		$	1.6		$	1.8
Interest cost on benefit obligation	1.9			1.9			3.8			3.8
Expected return on plan assets	(2.8		)	(3.2		)	(5.7		)	(6.5		)
Defined benefit plan costs	$	(0.1	)	$	(0.4	)	$	(0.3	)	$	(0.9	)



	German Plan
	Three Months Ended June 30,						Six Months Ended June 30,
	2019			2018			2019			2018
Service cost for administrative expenses	$	0.3		$	0.3		$	0.6		$	0.6
Interest cost on benefit obligation	0.2			0.2			0.3			0.3
Defined benefit plan costs	$	0.5		$	0.5		$	0.9		$	0.9

Assumptions used to determine defined benefit plan cost
Discount rate	1.9		%	1.7		%	1.9		%	1.7		%
Expected return on assets	N/A			N/A			N/A			N/A
Salary increases	2.0		%	2.0		%	2.0		%	2.0		%